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Summary 
 
Summary 
Receptors with tyrosine-based signaling motifs control essential functions of hematopoietic 
cells, including lymphocytes and platelets. Downstream of the platelet receptor glycoprotein 
(GP) VI and the T cell receptor (TCR) the immunoreceptor tyrosine-based activation motif 
(ITAM) initiates a signaling cascade that involves kinases, adapter and effector proteins and 
finally leads to cellular activation. This thesis summarizes the results of three studies 
investigating different aspects of receptor signaling and regulation in platelets and T cells. 
In the first part, the impact of constitutive Ca2+ influx on TCR signaling and T cell physiology 
was investigated using a transgenic mouse line with a mutation in the Ca2+ sensor stromal 
interaction molecule 1 (STIM1). The elevated cytoplasmic Ca2+ level resulted in an altered 
phosphorylation pattern of the key enzyme phospholipase (PL) Cγ1 in response to TCR 
stimulation, but without affecting its enzymatic activity. Withdrawal of extracellular Ca2+ or 
inhibition of the phosphatase calcineurin restored the normal phosphorylation pattern. In 
addition, there was a decrease in the release of Th2-type cytokines interleukin 4, 5 and 13 
upon stimulation in vitro. 
The second part of the thesis deals with the role of the adapter protein growth factor 
receptor-bound protein 2 (Grb2) in platelets using a megakaryocyte/platelet-specific knockout 
mouse line. Loss of Grb2 severely impaired signaling of GPVI and C-type lectin-like 
receptor 2 (CLEC-2), a related hemITAM receptor. This was attributed to defective 
stabilization of the linker for activation of T cells (LAT) signalosome and resulted in reduced 
adhesion, aggregation, Ca2+ mobilization and procoagulant activity downstream of 
(hem)ITAM-coupled receptors in vitro. In contrast, the signaling pathways of G protein-
coupled receptors (GPCRs) and the integrin αIIbβ3, which do not utilize the LAT 
signalosome, were unaffected. In vivo, the defective (hem)ITAM signaling caused prolonged 
bleeding times, however, thrombus formation was only affected under conditions where 
GPCR signaling was impaired (upon acetylsalicylic acid treatment). These results establish 
Grb2 as an important adapter protein in the propagation of GPVI- and CLEC-2-induced 
signals. 
Finally, the proteolytic regulation of the immunoreceptor tyrosine-based switch motif (ITSM)-
bearing receptor CD84 in platelets was investigated. This study demonstrated that in mice 
CD84 is cleaved by two distinct and independent proteolytic mechanisms upon platelet 
activation: shedding of the extracellular part, which is exclusively mediated by a disintegrin 
and metalloproteinase (ADAM) 10 and cleavage of the intracellular C-terminus by the 
protease calpain. Finally, the analysis of soluble CD84 levels in the plasma of transgenic 
mice revealed that shedding of CD84 by ADAM10 occurs constitutively in vivo. 
 
I 
Zusammenfassung 
 
Zusammenfassung 
Rezeptoren mit Tyrosin-basierten Signaltransduktionsmotiven sind von fundamentaler 
Bedeutung für die Funktion hematopoietischer Zellen wie Lymphozyten und Thrombozyten. 
Unterhalb des Glykoproteins (GP) VI auf Thrombozyten und des T-Zell Rezeptors (TZR) auf 
T-Zellen initiiert das immunoreceptor tyrosine-based activation motif (ITAM) eine 
Signalkaskade, die Kinasen, Adapter- und Effektorproteine mit einbezieht und schlussendlich 
zur Aktivierung der Zelle führt. Die hier vorgelegte Arbeit fasst die Ergebnisse dreier Studien 
zusammen, die sich mit verschiedenen Aspekten der Signaltransduktion und Regulation von 
Rezeptoren in Thrombozyten und T-Zellen befasst. 
Im ersten Teil wurde der Einfluss eines konstitutiven Ca2+-Einstroms auf die TZR 
Signalkaskade und T-Zell Funktion untersucht. Hierzu wurde eine transgene Mauslinie mit 
einer Mutation im Ca2+-Sensor stromal interaction molecule 1 (STIM1) verwendet. Die 
erhöhte zytoplasmatische Ca2+-Konzentration veränderte das Phosphorylierungsmuster der 
Phospholipase (PL) Cγ1, ein Schlüsselenzym der Signalkaskade, nach Stimulation des 
TZRs. Die enzymatische Aktivität der PLCγ1 blieb hierbei jedoch unverändert. In der 
Abwesenheit von extrazellulärem Ca2+ oder bei Inhibition der Phosphatase Calcineurin war 
das Phosphorylierungsmuster hingegen wieder normal. Darüber hinaus zeigten die T-Zellen 
nach Stimulation in vitro eine verringerte Produktion von Interleukinen des Th2-Typs 
(Interleukin-4, 5 und 13). 
Der zweite Teil der Arbeit befasst sich mit der Funktion des Adapterproteins growth factor 
receptor-bound protein 2 (Grb2) in Thrombozyten, die unter Zuhilfenahme einer 
Megakaryozyten- und Thrombozyten-spezifischen Knockout Mauslinie untersucht wurde. 
Hierbei zeigte es sich, dass der Verlust von Grb2 die Signaltransduktion von GPVI und des 
verwandten hemITAM-Rezeptors C-type lectin-like receptor 2 (CLEC-2) schwer 
beeinträchtigt. Dies konnte auf eine mangelnde Stabilisierung des linker for activation of 
T cells (LAT) Signalosoms zurückgeführt werden und resultierte in einer verminderten 
Adhäsion, Aggregation, Ca2+-Mobilisierung und prokoagulatorischen Aktivität nach 
Aktivierung (hem)ITAM gekoppelter Rezeptoren in vitro. Im Gegensatz hierzu blieben die 
Signaltransduktionswege G-protein-gekoppelter Rezeptoren (GPCRs) und des Integrins 
αIIbβ3, die das LAT Signalosom nicht nutzen, unbeeinflusst. In in vivo Studien verursachte 
die beeinträchtigte (hem)ITAM Signaltransduktion eine verlängerte Blutungszeit der Mäuse, 
während die Entstehung von Thromben nur bei gleichzeitiger Hemmung von GPCR-
Signalwegen (durch Acetylsalicylsäuregabe) vermindert war. Diese Ergebnisse etablieren 
Grb2 als ein wichtiges Adapterprotein in der Signaltransduktionskaskade von GPVI und 
CLEC-2. 
 
II 
Zusammenfassung 
 
Schließlich wurde im dritten Teil dieser Arbeit die proteolytische Regulation des Rezeptors 
CD84, der ein immunoreceptor tyrosine-based switch motif (ITSM) enthält, untersucht. In 
dieser Studie konnte gezeigt werden, dass CD84 in Mausthrombozyten durch zwei 
verschiedene und unabhängige proteolytische Mechanismen geschnitten wird: Zum einen 
durch Shedding des extrazellulären Teils, was ausschließlich durch die a disintegrin and 
metalloproteinase (ADAM) 10 bewerkstelligt wird, und zum anderen durch das Schneiden 
des intrazellulären C-Terminus durch die Protease Calpain. Des Weiteren zeigte eine 
Untersuchung von Plasmaproben transgener Mäuse, dass das Shedding von CD84 durch 
ADAM10 konstitutiv in vivo erfolgt. 
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Introduction 
 
1 Introduction 
1.1 Platelets 
Platelets are small anucleated blood cells which originate from the cytoplasm of 
megakaryocytes (MKs) in the bone marrow. The platelet count in the blood of healthy 
humans ranges from 150,000 – 450,000 platelets/µl and averages at about 250,000 
platelets/µl. Mice, which represent an important model system in thrombosis research, exhibit 
a platelet count of approximately 1,000,000 platelets/µl. The lifespan of platelets is about 10 
days in humans and about 5 days in mice. 
Since platelets lack a nucleus, their protein de novo synthesis is limited. However, several 
other cell organelles and structures are present in platelets like mitochondria, the open 
canalicular and dense tubular system, glycogen stores and three major types of granules (α-
granules, dense granules and lysosomes) which have different contents. 
Platelets play an essential role in hemostasis, as they survey the vascular integrity while 
circulating through the blood stream. In an intact vasculature, most platelets never undergo 
firm adhesion to the vessel wall and are cleared by the reticuloendothelial system in the 
spleen and liver at the end of their life time. Upon disruption of the endothelial cell layer, 
however, platelets rapidly adhere to the exposed components of the subendothelial 
extracellular matrix (ECM). This leads to subsequent platelet activation and initiates a self-
amplifying loop that results in the recruitment of additional platelets that interact with each 
other to form a plug that seals the wound. This process, called primary hemostasis, is a 
prerequisite to limit blood loss after injury. On the other hand, under pathological conditions, 
such as rupture of an atherosclerotic plaque, thrombus formation may result in irreversible 
occlusion of the vessel. In the worst case, the obstruction of blood flow with the 
accompanying loss of oxygen supply results in irreversible damage of vital organs.1,2 
Myocardial infarction, triggered by occlusion of coronary arteries, and stroke, elicited by 
thrombus embolization to the brain, are two of the leading causes of disability and mortality 
worldwide.3 Therefore, a detailed understanding of platelet physiology and the mechanisms 
underlying thrombus formation is essential to develop novel therapeutic strategies.2,4 
 
1.1.1 Platelets and thrombus formation 
Platelet activation and subsequent thrombus formation at sites of vascular injury involve 
multiple interactions of platelet receptors with immobilized ligands and soluble agonists and 
can be divided into three major steps (Figure 1-1): (i) tethering and adhesion of platelets, (ii) 
platelet activation and finally (iii) platelet aggregation and thrombus growth.  
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Figure 1-1 Simplified model of platelet adhesion and aggregation on the ECM. Platelet tethering 
on the wounded vessel wall is mediated by GPIb-vWF interaction, which mediates platelet 
deceleration and enables the platelet to stay in close contact with the ECM. In the next step, GPVI-
collagen interactions initiate cellular activation, followed by a shift of integrins from a low to a high 
affinity state. The release of second wave mediators like ADP and TxA2 by activated platelets, as well 
as the locally produced thrombin further enhance platelet activation and mediate thrombus growth. 
Finally, the thrombus is stabilized by signaling through CLEC-2; the underlying mechanism remains to 
be identified. Activated integrins mediate firm adhesion of platelets to the ECM as well as platelet-
platelet interactions via binding to vWF and fibrinogen. (Picture is taken from: Stegner and Nieswandt, 
J Mol Med, 2011)5 
In the first step, platelets are tethered to ECM components, like collagen, laminin or 
fibronectin, and “roll” along the side of injury in a stop-and-go manner. Under high shear 
conditions, such as those prevailing in arteriols or stenosed arteries, this initial adhesion is 
mediated by the interaction of platelet receptor complex glycoprotein (GP) Ib/V/IX with von 
Willebrand factor (vWF), which becomes immobilized on collagen.6 This interaction is 
characterized by a fast dissociation rate and therefore does not allow firm platelet adhesion 
by itself, but induces the rapid deceleration of the platelets, thereby enabling the interaction 
of collagen with the immunoglobulin-like receptor GPVI, the major platelet collagen 
receptor.7,8 Through an immunoreceptor tyrosine-based activation motif (ITAM) in the 
associated Fc receptor (FcR) γ-chain, GPVI induces intracellular signaling processes. These 
lead to cellular activation and the release of second wave mediators, most notably adenosine 
diphosphate (ADP), secreted by dense granules, and thromboxane A2 (TxA2), synthesized by 
cyclooxygenase-1. Additionally, platelet activation results in scramblase-mediated exposure 
of negatively charged phosphatidylserine (PS) on the platelet surface, providing a platform 
for the assembly of two major coagulation factor complexes and subsequent thrombin 
production.9 In parallel, exposed tissue factor (TF) triggers local thrombin generation. ADP, 
thrombin and TxA2 further reinforce and sustain cellular activation by initiating different 
pathways via G protein-coupled receptors (GPCRs),10 and recruit additional platelets from 
the blood stream into the growing thrombus. In addition, platelet activation can also be 
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triggered through the hemITAM receptor C-type lectin-like receptor 2 (CLEC-2),11 but the 
receptor ligand in this process remains to be identified. 
All these signaling pathways finally converge in the “final common pathway” of platelet 
activation: the functional upregulaton of adhesion receptors of the integrin class which shift 
from a low to a high affinity state, allowing firm ligand binding. Platelets express three β1 
integrins, α2β1, α5β1 and α6β1, which mediate binding to collagen, fibronectin and laminin, 
respectively, and two β3 integrins, αvβ3 (binds to vitronectin) and αIIbβ3. The latter one is 
the most abundantly expressed integrin in platelets and plays an essential role in 
aggregation, since its binding of multiple ligands, most notably fibrinogen, fibrin and vWF, 
bridges adjacent platelets and also mediates stable platelet adhesion to the ECM.2,12 Ligand 
occupied integrins in turn transduce “outside-in” signals, which promote platelet cytoskeletal 
rearrangements, spreading and clot retraction.12,13 
 
1.2 Signaling events during thrombus formation 
Platelets express a variety of receptors that induce or contribute to platelet activation. Based 
on the underlying signaling pathways, two major routes can be distinguished.5 Both 
culminate in the activation of phospholipase C (PLC) isoforms and subsequent elevation of 
intracellular calcium (Ca2+) levels ([Ca2+]i), a central step in platelet activation, and a 
prerequisite for granule release, integrin activation and procoagulant activity.14 
One pathway is initiated by engagement of the GPVI-FcR γ-chain complex or CLEC-2 and 
requires the phosphorylation of critical tyrosine residues in the ITAM or (hem)ITAM, 
respectively, and is similar to signaling cascades used by immunoreceptors. Signal 
propagation is mediated by tyrosine kinases of the spleen tyrosine kinase (Syk) and Src 
families, as well as downstream adapter proteins and effector proteins and finally culminates 
in activation of PLCγ2.12,15 Details of this signaling pathway are discussed in the next capter.  
The other major pathway is triggered by GPCRs which are stimulated by soluble platelet 
agonists, such as thrombin, ADP and TxA2. Three different types of heterotrimeric G proteins 
are found downstream of GPCRs in platelets: Gq, G12/13 and Gi. The G proteins induce 
multiple signaling events, like stimulation of Rho-GTPases (via G12/13), phosphoinositide-3-
kinase (PI3K)/Akt (via Gi) signaling and activation of PLCβ (via Gq).10  
In GPCR as well as in (hem)ITAM signaling, the activated PLC isoforms hydrolyze the 
membrane phospholipid phosphatidylinositol-4,5-biphosphate (PIP2) to inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). DAG activates protein kinase C (PKC) and 
induces moderate Ca2+ influx via transient receptor potential channel (TRPC) 6.16 IP3 binds to 
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IP3 sensitive Ca2+ channels in the membrane of intracellular Ca2+ stores, thereby inducing 
store depletion. The decrease in the Ca2+ store content subsequently triggers the opening of 
Ca2+ channels in the plasma membrane, resulting in pronounced elevations of [Ca2+]i. This 
process is known as store-operated Ca2+ entry (SOCE) and represents the main Ca2+ influx 
mechanism in non-excitable cells, including platelets (see chapter 1.7).14,17,18 
 
1.3 (hem)ITAM receptor signaling in platelets 
The ITAM is a conserved sequence motif involved in the signaling of a number of 
hematopoietic immunoglobulin receptors, like the T and B cell receptor (TCR and BCR), Fc 
receptors and activating natural killer cell receptors. The ITAM was described in the late 
1980’s19 and consists of two copies of the sequence YxxL/I separated by 6-12 amino acids 
(aa) (YxxL/I(x)6-12YxxL/I; in which x is an unspecified aa). The two tyrosine residues within 
the motif become phosphorylated upon receptor engagement and are the starting point for 
complex downstream signaling cascades. 
Platelets express three receptors that signal via ITAM or hemITAM: GPVI, CLEC-2 and 
FcγRIIa. Since the latter one is present in human, but not in mouse platelets, and the 
experiments presented in this thesis were almost entirely performed with mouse platelets, 
only GPVI and CLEC-2 will be discussed here. ITAM-signaling of the TCR is described in 
chapter 1.5. 
 
1.3.1 GPVI 
Two receptors capable of binding collagens are expressed in platelets: GPVI and integrin 
α2β1.8 While α2β1 has been considered to be the main collagen receptor in platelets for long 
time, it is now well established that this role applies to GPVI7,8,20 and that α2β1 has a 
supportive role for the initial collagen-platelet interaction.21 
GPVI is a 62 kDa type transmembrane protein belonging to the immunoglobulin (Ig) 
superfamily of surface receptors. It has a structure similar to the natural killer cell receptor 
and to the Fcα receptor22 and is exclusively expressed in platelets and MKs. GPVI consists 
of two IgG domains bearing the collagen binding site, followed by a mucin-rich stalk, 
containing O-glycosylation sites, a transmembrane domain and a cytoplasmic tail.8,23 The 
cytoplasmic tail is short, comprising only 27 aa in mice (51 aa in humans),8 and contains a 
basic and a proline-rich region which allow binding of calmodulin24 and Src-family tyrosine 
kinases,25 respectively. 
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The most important ligand for GPVI is fibrillar collagen, with type I and III representing the 
major components of the ECM in blood vessels. The glycine-proline-hydroxyproline (GPO) 
repeats within the collagen represents the specific GPVI recognition motif.8 Powerful platelet 
activation via GPVI can also be induced by the GPVI specific agonists collagen-related 
peptide (CRP), made up of GPO repeats, and the snake venom toxin convulxin (CVX). CVX 
is a powerful activator of GPVI,26 since it is tetrameric and therefore capable of clustering 4 
GPVI proteins.27  
The GPVI receptor is noncovalently associated with an FcR γ-chain homodimer which 
represents the signaling subunit of GPVI.28,29 Each FcR γ-chain contains one ITAM and 
functionally resembles the CD3 and ζ chains in T cells and Igα and Igβ in B cells (see below 
and Figure 1-3).  
Crosslinking of GPVI by ligand binding leads to the activation of the Src-kinase family 
members Fyn and Lyn which are associated to the cytoplasmic tail of GPVI (Figure 1-2; 
reviewed in 12). How GPVI clustering activates Fyn and Lyn is not established, but a favoured 
model suggests that their activity is regulated by GPVI translocation to lipid rafts, tyrosine 
phosphatases and immunoreceptor tyrosine-based inhibition motif (ITIM) receptors.30 Src 
kinases phosphorylate the conserved tyrosine residues within the ITAMs of the FcR γ-chain, 
leading to recruitment of the tyrosine kinase Syk which binds these phosphorylated tyrosine 
residues by its tandem Src homology 2 (SH2) domain. Subsequently, Syk undergoes 
autophosphorylation and phosphorylation by Src kinases and becomes activated. In the next 
step, Syk initiates a signaling cascade that resembles the one of the TCR (see chapter 1.5). 
A central step is the phosphorylation of the adapter protein linker for activation of T cells 
(LAT) that builds the core for the formation of a signalosome. This LAT signalosome is 
composed of a series of adapter and effector proteins. To the first group belong, besides 
LAT, Grb2-related adapter downstream of Shc (Gads) and SH2 domain-containing leukocyte 
protein of 76 kDa (SLP-76),12 but also the adapter growth factor receptor-bound protein 2 
(Grb2) has been reported to associate to LAT upon platelet stimulation of human platelets 
with GPVI agonists.26,31 These proteins form a scaffold for the binding of numerous signaling 
molecules that are targeted to the cell plasma membrane close to their molecular substrates. 
Among these signaling molecules are the Tec family kinases Tec and Btk, the guanine 
nucleotide exchange factors (GEFs) Vav1 and Vav3, PI3K and the small GTPase Rac1.12 All 
these complex interactions orchestrate the regulation of the major effector enzyme in the 
GPVI signaling pathway, PLCγ2 (see above and chapter 1.7.2). 
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Figure 1-2 Signaling of the GPVI/FcR γ-chain complex. Crosslinking of GPVI results in the 
activation of the Src-kinases Fyn and Lyn initiating a Syk-dependent signaling pathway. For details 
see text. Src, Syk and Tec kinases are depicted in dark red, adapter proteins in orange. Grey circles 
denote additional proteins involved in the LAT signalosome. For overview reason, not every 
phosphorylation event and interaction is highlighted herein. (Image modified from Dütting et al., 
Trends Pharmacol Sci, 2012)23  
This signaling pathway is of great importance for platelet physiology. The absence or 
inhibition of components of this signaling pathway like Rac1,32 the GEFs Vav1 and Vav3,33 
Syk34 and the Src kinases Fyn and Lyn35 has been reported to impair or to abolish platelet 
responses to collagen and to interfere with thrombus formation in vivo.32,36 The importance of 
adapter proteins in GPVI signaling is separately discussed in chapter 1.6. In addition, GPVI 
can be cleaved from the cell surface by metalloproteinases, generating a soluble GPVI 
fragment and a small transmembrane remnant.37 This process is called ectodomain-shedding 
and is supposed to downregulate platelet reactivity (see chapter 1.9).38  
GPVI is a promising antithrombotic target as in mice, GPVI deficiency, either by antibody-
mediated depletion or genetic approaches, results in protection from arterial thrombosis 
accompanied by only mildly prolonged tail bleeding times. Similarly, human patients with 
GPVI deficiency show no major bleeding diathesis (reviewed in 23). 
 
1.3.2 CLEC-2 
In 2006, CLEC-2 was identified as a novel platelet receptor that mediates strong cellular 
activation in response to the snake venom toxin rhodocytin.39 CLEC-2 is a type II 
transmembrane protein with one extracellular C-type lectin-like domain (CLTD) mediating 
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binding to non-carbohydrate ligands, and a cytoplasmic tail of 31 amino acids. CLEC-2 is one 
of the most megakaryocyte-specific and most abundantly expressed genes in MKs,40 but is 
also expressed in liver sinusoidal cells and some immune cells.15 
Within its intracellular N-terminus CLEC-2 contains a conserved YXXL sequence which 
mediates downstream signaling.15 This motif is similar to the ITAM with the important 
difference, that only one copy of this sequence is present within the protein. Hence, this motif 
is called hemITAM. This feature requires CLEC-2 dimerization to induce platelet 
activation,41,42 thereby bringing together two hemITAMs, which serve as a binding site for the 
two SH2 domains of the kinase Syk upon phosphorylation. The signaling pathways 
downstream of the CLEC-2 receptor strongly resemble the pathway downstream of GPVI,15,43 
involving Syk and the Src-family kinases, the adapters LAT and SLP-76, Vav1, the Tec 
kinase Btk, PI3K and Rac1.32,39,44 Strikingly, the sequence of phosphorylation at the proximal 
end differs between CLEC-2 and the ITAM-coupled receptor GPVI: while the ITAM becomes 
phosphorylated by the Src-family kinases Fyn and Lyn, followed by the recruitment of Syk, 
the hemITAM within CLEC-2 is phosphorylated by Syk itself, while Src-family kinases are 
important for downstream signaling.45,46 
So far the only known physiological CLEC-2 ligand is podoplanin which is expressed in 
various tissues, including lymphatic endothelial cells, alveolar cells and kidney podocytes, 
but is also present on tumor cells.39,47 Importantly, the interaction of CLEC-2 with podoplanin 
and the subsequent platelet activation are essential for proper separation of lymphatic and 
blood vessels during development, as demonstrated by the appearance of blood filled 
lymphatics and edema in various mouse models deficient in one of those proteins (reviewed 
in 47). More recently, it has been shown that the interaction of podoplanin with platelet 
CLEC-2 maintains the integrity of high endothelial venules.48 
In addition, CLEC-2 plays an important role in the stabilization of platelet thrombi: CLEC-2-
deficient platelets exhibit impaired stable aggregate formation in whole blood perfusion 
assays in vitro, and thrombus formation in CLEC-2 depleted or CLEC-2-deficient bone 
marrow chimeric (BMc) mice was abolished in vivo.11,49 Since podoplanin is not expressed in 
blood vessels and hematopoietic cells, the mechanism by which CLEC-2 contributes to 
thrombus stabilization may involve a novel, yet not identifed CLEC-2 ligand, or alternatively 
homophilic interactions of CLEC-2 receptors.49 Similar to the outcome of GPVI deficiency, 
mice lacking CLEC-2 in the hematopoietic system show no49-51 or only moderately prolonged 
tail bleeding times,11 and therefore CLEC-2 has been proposed to be a promising 
antithrombotic target. Of note, the combined deficiency of CLEC-2 and GPVI resulted in a 
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dramatic hemostatic defect, indicating a functional redundancy of these two (hem)ITAM 
receptors.50 
 
1.3.3 Attenuation of ITAM signaling by ITIM receptors 
Platelet activation by the (hem)ITAM receptors GPVI and CLEC-2 can be attenuated by 
receptors bearing an ITAM variant termed  ITIM (consensus sequence: (S/I/V/L)xYxx(I/V/L)). 
Phosphorylated ITIMs serve as docking site for SH2 domain-containing protein-tyrosine 
phosphatases (SHP) 1 and 2 and the SH2 domain-containing inositol-5-phosphatase-1 
(SHIP-1) which dephosphorylate key components of activation pathways.52 Platelets express 
four ITIM-containing receptors: platelet-endothelial cell adhesion molecule-1 (PECAM-1), 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), triggering receptor 
expressed on myeloid cell-like transcript-1 (TLT-1) and G6b-B.30 PECAM-1 has been 
reported to mediate weak inhibition of platelet activation by GPVI and CLEC-2, similar 
observations were made for CEACAM1 against platelet activation by GPVI.53,54 The 
physiological significance of this inhibition for platelet physiology remains to be established.30 
Strikingly, mice deficient in G6b-B exhibited a severe macrothrombocytopenia and increased 
platelet turnover, clearly establishing this ITIM receptor as an essential mediator of platelet 
function and production.55 
Receptors bearing a second variant of the ITAM, the immunoreceptor tyrosine based switch 
motif (ITSM), are discussed in chapter 1.8. 
 
1.4 T cells  
Lymphocytes are the effector cells of the adaptive immune system which specifically 
recognizes and responds to foreign antigens. B lymphocytes are responsible for antibody 
production and hence form the humoral part of the adaptive immune response, while T 
lymphocytes (also termed T cells) are the mediators of cellular immune response. The 
characteristic feature of T cells is the expression of a TCR which is encoded by a somatically 
rearranged gene and clonally distributed among T cells, thus enabling them to detect a very 
large spectrum of antigens. Most T cells express a TCR that constitutes of an α and β chain 
(αβ receptor), while only a small portion expresses a γδ TCR. T cells with an αβ TCR can be 
further divided in two major T cell subsets, depending on which co-receptor they express. 
CD8+ T cells can recognize peptides associated with class I major histocompatibility 
complexes (MHC) and subsequently kill infected cells or tumor cells that display foreign 
antigens; hence they are also called cytotoxic T cells. CD4+ T cells are restricted to class II 
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MHC complexes present on antigen-presenting cells, such as dendritic cells and 
macrophages. This T cell subset has been termed T helper cells, since their support of B cell 
differentiation is essential for proper antibody production. 
T cells originate from precursors that arise in the bone marrow and migrate to the thymus. 
These cells are called thymocytes and undergo various stages of maturation within the 
thymus to give rise to CD4+ or CD8+ T cells. Central steps of this maturation are positive and 
negative selection processes. Positive selection ensures the expression of a functional TCR 
that is capable of interacting with peptide/MHC complexes and also finally assigns the 
thymocytes to the CD4+ or CD8+ lineage. During negative selection, potentially harmful cells 
recognizing self antigens with high affinity are eliminated to prevent autoimmune reaction. 
This process is called central tolerance. Of note, proper receptor signaling is required for T 
cell maturation, since absence of critical signaling molecules can result in the absence of 
mature T cells.56 
Because of their central role in adaptive immunity, CD4+ T cells are extensively studied. 
CD4+ T cells are a heterogeneous cell population in which different subsets or lineages can 
be distinguished. Regulatory T cells (Tregs) make up about 10 - 20% of the CD4+ T cells in 
mouse lymph nodes and spleen. This cell population is characterized by strong expression of 
the α-chain of the high-affinity IL-2 receptor (CD25) and the transcription factor 
forkhead box P3 (Foxp3), which is critical for their development and function.57 Tregs are 
produced in the thymus (natural Tregs; nTregs), but can also be induced from naïve T cells 
in the periphery (inducible Tregs, iTregs). Tregs play an essential role in maintaining 
immunological unresponsiveness to self-antigens (peripheral tolerance) and in suppressing 
excessive immune responses. This is illustrated by mouse models with mutated Foxp3 gene 
which lack regulatory T cells and develop an aggressive lymphoproliferative autoimmune 
syndrome.57 
Upon TCR activation, naïve CD4 T cells may differentiate into one of several lineages of T 
helper (Th) cells, as defined by their pattern of cytokine production and function.58 Th1 cells 
secrete interferon (IFN)γ and stimulate the phagocyte-mediated immunity by promoting the 
intracellular destruction of phagocytosed bacteria. The signature cytokines of Th2 cells are 
interleukin (IL) 4, 5 and 13. These cells contribute to the defence against extracellular 
parasites, including helminthes, by promoting IgE- and eosinophil/mast cell-mediated 
immune reactions. This polarization into distinct Th subsets is primarily controlled by the 
particular cytokine milieu,58 and also the strength of TCR signaling, with weak signaling 
favoring Th2 differentiation and stronger signals promoting Th1 differentiation. 59 A third type 
of effector Th cells, Th17, was identified in 2003, and is characterized by secretion of IL-17. 
 
9 
Introduction 
 
The principal role of Th17 cells appears to be the protection against bacterial and fungal 
infections, but the lineage came into the focus of intense research due to their participation in 
inflammatory and autoimmune diseases.60 As mentioned above, naïve T cells can also 
differentiate into iTregs. This process is controlled by transforming growth factor (TGF)-β, 
IL-2 and retinoic acid.57 
 
1.5 T cell receptor signaling of CD4+ T cells 
The TCR of CD4+ T cells consists of a heterodimer of two transmembrane polypeptide 
chains, termed α and β, covalently linked by a disulfide bridge. Like GPVI, the α and β chain 
of the TCR belong to the Ig superfamily and comprise one N-terminal variable and one 
constant Ig-like domain in their extracellular part, a hydrophobic transmembrane region and a 
short cytoplasmic region.61 The TCR is accompanied by a CD4 co-receptor, which is involved 
in the binding of the TCR to peptide/class II MHC complexes. 
Signaling through the TCR controls key events in T cell physiology: It is required during T cell 
development in the thymus (see above), the survival of naïve T cells in the periphery,62 and, 
of course, for the clonal expansion and activation of T cells after encountering their specific 
antigen. The proximal signaling events downstream of the TCR have many similarities to the 
signaling pathway of the BCR and the platelet collagen receptor GPVI, involving ITAM-
bearing receptor subunits, kinases of the Src, Tec and Syk/ZAP-70 families, PLCγ and 
adapter proteins (Figure 1-3).12,63,64 
 
Figure 1-3 Comparison of BCR, TCR and GPVI signaling. Please note: This is a simplified overview 
of the complex signaling pathways of B cells, T cells and platelets, emphasizing general similarities in 
the signaling cascades. Therefore, biochemical details may not apply to the individual signaling 
pathways. 
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Like GPVI, the TCR itself does not have intrinsic enzymatic activity, but is associated with 
multiple signaling subunits: the CD3 γ,δ and ε proteins and ζ chains. Each αβ dimer forms a 
complex with one CD3 γβ heterodimer, one CD3 δε heterodimer and one covalent ζζ 
homodimer. Like the FcR γ-chain, these molecules contain ITAMs in their cytoplasmic tails 
which initiate downstream signaling pathways. One ITAM is present in each CD3 protein, 
and three in each ζ chain, adding up to 10 ITAMs per TCR complex.61 Of note, antibodies 
directed against CD3ε can trigger T cell activation. 
Physiological TCR signaling in CD4+ T cells is induced by binding of the TCR to its specific 
peptide antigen presented on class II MHC complexes. The first proximal event is the 
activation of the Src family kinase tyrosine kinase Lck which is associated with the 
cytoplasmic tail of CD4. The active Lck subsequently phosphorylates the ITAM within the 
CD3 and ζ chains. This is followed by the recruitment of ZAP-70, which binds to 
phosphotyrosines and becomes phosphorylated by Lck (Figure 1-4). As a result, ZAP-70 
acquires its own kinase activity and, similarly to its family member Syk in platelets, 
orchestrates the following signaling steps by phosphorylation of numerous downstream 
targets. Among the most important ZAP-70 substrates are the adapter proteins LAT and 
SLP-76 that form the backbone of a multiprotein complex which organizes adapter and 
effector molecules to allow the activation of multiple signaling pathways. The composition of 
this T cell LAT signalosome shares many similarities to the LAT signalosome present in the 
GPVI signaling pathway, including the adapters SLP-76, Gads and Grb2- the GEF Vav1, 
PI3K and the Tec kinase IL-2-induced tyrosine kinase (Itk). It is thought, that the complex 
interactions of different molecules stabilize the signalosome to facilitate optimal activation of 
the key enzyme PLCγ1.64  
These proximal signaling events finally lead to cytoskeletal changes with Vav1 as an 
important mediator of actin remodeling,65 and the induction of transcriptional activity. There 
are three major transcription factors in T cells which are activated by distinct signaling 
pathways: nuclear factor of activated T cells (NFAT), activator protein 1 (AP-1, a dimer of 
Fos/Jun) and NF-κB (Figure 1-4; reviewed in 63,64). 
The two metabolites generated from PLCγ1 activity, IP3 and DAG, have essential roles in the 
activation of these pathways. DAG recruits the GEF Ras guanyl nucleotide-releasing protein 
(RasGRP) to the plasma membrane where it becomes activated. RasGRP catalyzes the 
GTP for GDP exchange on the guanine nucleotide-binding protein Ras, thereby converting 
the protein into its activated form. This process of Ras activation is further enhanced by a 
second GEF, son of sevenless homolog 1 (Sos1), which is recruited to the LAT signalosome 
by the adapter protein Grb2. Ras in turn initiates a phosphorylation cascade that results in 
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the activation of the mitogen-activated protein (MAP) kinase extracellular-signal-regulated 
kinase (ERK). ERK translocates into the nucleus where it triggers the transcription of AP-1. 
Two other members of the MAP kinase family, c-Jun N-terminal kinase (JNK) and p38, are 
activated in a similar manner by a pathway involving the GEF Vav1, as well as Rac and 
Cdc42 (Figure 1-4).63,64 The second important signaling pathway regulated by DAG is 
mediated by its activation of PKCθ. PKCθ induces a signaling pathway that finally liberates 
the transcription factor NF-kB from its inhibitory subunits allowing its translocation into the 
nucleus where it activates different genes required for T cell function (Figure 1-4).64,66 
 
 
Figure 1-4 Summary of the TCR-induced signaling pathways. Ligand binding of the TCR induces a 
signaling cascade involving the formation of a LAT signalosome which is the origin of the three major 
signaling pathways: the MAP-kinase pathway (blue), resulting in the transcription of AP-1 (Fos and 
Jun), the NF-κB pathway (red) and the calcineurin-NFAT pathway (green), triggered by elevation of 
[Ca2+]i. For details, see text. Please note: In this simplified overview not all signaling events and 
interactions are depicted. 
IP3, the second metabolite generated by PLCγ1, induces a robust Ca2+ influx by a 
mechanism termed SOCE (see chapter 1.7). Ca2+ is a universal second messenger essential 
for activation of T cells.67 TCR-induced elevation of [Ca2+]i results in binding of Ca2+ to 
calmodulin which in turn binds to and activates the phosphatase calcineurin. This protein 
dephosphorylates the NFAT protein, thereby unmasking the nuclear localization sequence 
resulting in the translocation of NFAT into the nucleus (Figure 1-4). The activity of calcineurin 
is counterbalanced by the nucleus-resident glycogen synthase kinase 3 (GSK3) which 
promotes the extracellular export of NFAT. In the nucleus, NFAT can form cooperative 
complexes with a variety of other transcription factors, most notably AP-1, thereby integrating 
signaling pathways, resulting in distinct specific gene expression patterns. The importance of 
the calcineurin-NFAT pathway for T cell activation is illustrated by the fact that the most 
potent immunosuppressants FK506 and cyclosporin A directly target this pathway68,69 Of 
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note, transcriptional activity of NFAT in the absence of AP-1 activation has been reported to 
induce a pattern of gene expression that results in T cell anergy, a state of unresponsiveness 
to re-stimulation of the TCR that can be induced e.g. by TCR stimulation in the absence of 
ligation of the CD28 co-receptor.70,71  
In addition to NFAT, Ca2+ influx also regulates other signaling pathways including the 
transcription factors myocyte-enhancing factor 2 (MEF2) and downstream regulatory element 
antagonist modulatror (DREAM), as well as Ca2+-calmodulin-dependent kinase II 
(CamKII).69,72 In addition, Ca2+ also participates in the regulation of NF-κb.73 
 
1.6 Adapter proteins in platelet and T cell receptor signaling 
Adapters are proteins that lack enzymatic activity, but contain multiple protein-interaction 
sites and serve as intracellular scaffolds that organize effector molecules and their substrates 
in the correct spatiotemporal manner, thereby allowing the activation of multiple signaling 
pathways.74 The most prominent adapter molecules in platelets and T cells include LAT, 
SLP-76, Grb2 and Gads. 
 
1.6.1 LAT, SLP-76 and Gads 
LAT and SLP-76 are among the most important targets of ZAP-70/Syk kinases in T cells and 
platelets 75-78 and form the backbone of a multimolecular signaling complex in close proximity 
to the plasma membrane, referred to as the LAT signalosome (see above and 12,79).  
Upon receptor stimulation, the transmembrane protein LAT is phosphorylated at five tyrosine 
residues which subsequently serve as binding sites for several SH2 domain containing 
proteins, e.g. PLCγ, Grb2 and Gads.79 SLP-76 becomes phosphorylated at three tyrosine 
residues which facilitate binding of Vav and Nck.80 Of note, LAT and SLP-76 do not directly 
bind to each other, but are linked to each other by a third adapter protein, Gads. Gads, like 
PLCγ, is constitutively bound to the proline rich region of SLP-76, and, upon receptor 
stimulation, recruits SLP-76 to LAT by way of the interaction of its SH2 domain with phospho-
LAT.81 An additional adapter protein within this complex is Grb2, which is discussed below. 
Although LAT and SLP-76 nucleate the signalosome, several other effector and adapter 
proteins are required to stabilize this protein complex and a current model proposes that the 
numerous interactions cooperatively regulate the optimal recruitment and activation of the 
key enzyme PLCγ.64,79 
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The T cell and platelet phenotypes of mice lacking LAT, SLP-76 and Gads have been 
described. Strikingly, the absence of LAT or SLP-76 results in a complete inhibition of pre-
TCR signaling of thymocytes and subsequently in a block in T cell development and the lack 
of peripheral T cells.56,82-84 Platelets from Slp76-/- and Lat-/- mice exhibit defective responses 
to agonists of the (hem)ITAM receptors GPVI and CLEC-2, however, to a different extent: 
SLP76-/- platelets show severe defects in aggregation and Ca2+ mobilization, even in 
response to high doses of CVX and CRP. Phosphorylation of PLCγ2 is dramatically reduced 
and only detectable at residual levels at high agonist concentrations, clearly demonstrating 
that SLP-76 is essential to couple GPVI to PLCγ2 activation.76,85,86 In contrast, the GPVI 
signaling defect of LAT-deficient platelets can be overcome at high agonist concentrations as 
demonstrated by the full aggregation response and robust PLCγ2 phosphorylation.31,77,86 
Nevertheless, LAT-deficient platelets fail to form three-dimensional thrombi under flow,31 
show decreased PS exposure87 and Lat-/- mice are protected in a thrombosis model of laser 
induced injury.88 Absence of SLP-76 also impairs CLEC-2 signaling: mice with a platelet-
specific deletion of SLP-76 show a defect in lymphatic/blood vessel separation, similar to 
mice deficient in CLEC-2 or its ligand podoplanin.47,89 Distinct from GPVI, however, CLEC-2 
is able to induce a partial activation of PLCγ2 and platelet aggregation at high rhodocytin 
concentrations in the absence of SLP-76 in vitro.39,44 LAT deficiency also results in 
aggregation defects in response to rhodocytin,31,39 but Lat-/- mice, in contrast to Slp76-/- mice, 
are born at normal Mendelian ratios and neither show fetal hemorrhage nor blood filled 
lymphatics,56,85,90 indicating that LAT function downstream of CLEC-2 can be bypassed in 
vivo. Of note, SLP-76 is also involved in the activation of PLCγ2 downstream of integrin 
αIIbβ3 and is required for platelet spreading, while LAT is dispensable for this process.31,86,91 
In addition, Gads-/- mice have been described. Studies with these animals revealed a less 
prominent role of this adapter protein in TCR and GPVI signaling as compared to LAT and 
SLP-76. Gads-/- thymocytes show several developmental defects, but still differentiated into 
mature T cells, indicative of residual signaling activity of the pre-TCR.92 Platelets lacking 
Gads are grossly normal and only exhibit mild aggregation defects in response to weak 
activation of GPVI or CLEC-2.31 
 
1.6.2 Grb2 
Grb2 was the first adapter protein to be described93 and is the prototype of the Grb2 family of 
adapters which also comprises Gads and Grb2-related adapter protein (Grap). The Grb2 
protein is composed of a central SH2 domain flanked by two SH3 domains and has 
molecular weight of about 25 kDa (Figure 1-5).93,94 SH3 domains bind to prolin-rich 
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recognition sites with a PxxP core, SH2 domains bind to short consensus motifs bearing 
phosphorylated tyrosine residues.95,96 Grb2 was initially identified as an essential mediator of 
Ras activation downstream of growth factor receptors.94 A number of seminal publications in 
1993 ultimately unraveled the underlying mechanism how Grb2 couples receptor signaling to 
Ras activation (summarized in 97): Ligand induced crosslinking of the surface receptor 
induces kinase activity and trans-phosphorylation of tyrosine residues in the cytoplasmic 
receptor domains leading to the recruitment of Grb2 which binds to these residues with its 
SH2 domain. Grb2 itself is constitutively bound to Sos1, a GEF, which becomes localized 
into the vicinity of its substrate Ras. Sos1 provokes a GTP/GDP exchange in Ras, triggering 
a signaling cascade of serine-threonine kinases. 
 
Figure 1-5 Domain structure of the mouse 
Grb2 protein. The ruler designates the amino 
acids.  
(Source: http://smart.embl-heidelberg.de) 
 
 
Grb2 is ubiquitously expressed and therefore also found in lymphocytes, where it can interact 
with several components involved in antigen receptor signaling,74,96,98 and platelets (see 
below). One of the most prominent Grb2 interaction partners present in T cells and platelets 
is LAT.78 This interaction has been extensively studied79 and it is now established that Grb2, 
via its SH2 domain, binds to phosphorylated LAT at the distal three tyrosines.99,100 Similar to 
its recruitment to growth factor receptors, Sos1 is also recruited via Grb2 to LAT upon TCR 
stimulation.78,101 Importantly, it has been shown that Grb2 and Sos1 form 2:1 complexes in 
Jurkat cells which oligomerize with LAT into large signaling clusters to enhance TCR 
signaling.102 In contrast, the role of Sos1 in Ras activation and downstream ERK activation 
upon TCR stimulation seems to be of minor importance, since Ras activation is mainly 
triggered by the GEF Ras-GRP.64 Similar to Gads, it has been shown that Grb2 is also able 
to couple Lat and SLP-76 in DT40 B cells, but it has lower binding affinity to SLP-76 and thus 
does this coupling less efficiently.103,104  
Because of the pivotal role of Grb2 in growth factor receptor signaling, Grb2-deficient mice 
die early in embryogenesis, making the analysis of lymphocytes and platelets impossible.105 
Therefore, heterozygous Grb2 knockout mice (Grb2+/-) were used as a model for the 
investigation of Grb2 function in T cell development. In response to TCR stimulation, Grb2+/- 
thymocytes show weakened activation of the MAP kinases p38 and JNK, but unaltered 
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activation of ERK, resulting in a decreased ability to undergo negative selection.106 
Meanwhile, these findings have been confirmed in mice with a conditional deletion of Grb2 in 
the T cell lineage. These Grb2-deficient thymocytes additionally show attenuated Ca2+ influx 
in response to TCR stimulation, which is attributed to a marked impairment of Lck activation 
at the top end of the signaling cascade.107 Recently, two independent studies described the 
role Grb2 in B cells using B cell-specific Grb2-deficient mouse lines.108,109 In contrast to T 
cells, enhanced BCR-induced Ca2+ influx was observed in both studies, while conflicting 
results on the impact of Grb2 on MAP kinase activation were reported. Grb2-deficiency also 
affects several other signaling pathways resulting in impaired germinal center formation and 
decreased survival.108,109 
Grb2 is also expressed in platelets and MKs where it interacts with a plethora of proteins 
(http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de/plateletweb.php110). In vitro studies 
proposed that the Grb2/SOS/Ras/Raf-1/mitogen-activated protein kinase/ERK kinase (MEK) 
pathway is critical for MK differentiation.111,112 Furthermore, biochemical experiments 
demonstrated the interaction of Grb2 with critical components of the GPVI signaling pathway, 
namely LAT, Syk and FcR γ-chain, in CVX stimulated platelets, implicating a role for Grb2 in 
the LAT signalosome downstream of GPVI.26 This is further supported by tyrosine 
phosphorylation of Grb2 in response to GPVI stimulation.113 Interestingly, 
immunoprecipitations in human platelets revealed that Grb2 associates much stronger with 
LAT after GPVI stimulation than the Grb2 related adapter Gads, which has a minor role in 
supporting GPVI signaling.31 Additionally, Grb2 may also be involved in integrin outside-in 
signaling, since it shows increased interaction with the adapter protein downstream of 
tyrosine kinase (Dok)-1 and Dok-3 in human platelets upon activation of integrin αIIbβ3.114 
However, due to the lack of an appropriate animal model, the exact role of Grb2 in platelet 
physiology and in distinct signaling pathways has remained elusive. 
 
1.7 Store-operated Ca2+ entry (SOCE) 
1.7.1 The history of SOCE 
Ca2+ is a ubiquitous second messenger in eukaryotic cells which controls a variety of cellular 
functions and therefore its spatial and temporal dynamics are tightly regulated.115 The 
concept of SOCE, initially termed capacitative Ca2+ entry, was established in 1986 by 
Putney.116 He proposed a Ca2+ influx mechanism where the depletion of the intracellular 
stores triggers the opening of Ca2+ channels (termed SOC channels) in the plasma 
membrane.18,116 Direct evidence in support of this model was provided by patch-clamp 
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studies that identified a SOC current which was named Ca2+-release-activated Ca2+(CRAC) 
current (ICRAC) in mast cells117 and Jurkat leukemic T cells.118,119  
Subsequent studies revealed that SOCE does more than just provide Ca2+ for refilling stores, 
but is itself the main Ca2+ entry mechanism in virtually all non-excitable cells,17,120 including 
platelets121-123 and immune cells.67 This is exemplified by humans suffering from severe 
immunodeficiency due to defective SOCE in T cells.124-128 However, the molecular 
mechanisms mediating this process, including the CRAC channels identity, remained elusive 
for two decades and different models have been proposed.18,120 
 
1.7.2 The mediators of SOCE – STIM and Orai 
In 2005, the first breakthrough was achieved by the identification of stromal interaction 
molecules as essential regulators of SOCE by two different RNA interference (RNAi) 
screens.129,130 STIM1 is a type I transmembrane molecule that resides predominantly in the 
endoplasmic reticulum (ER) membrane.129,131 In its intraluminal N-terminus, STIM1 
possesses a sterile α motif (SAM) and a canonical EF-hand motif which binds Ca2+, thereby 
sensing the store content. In the cytoplasmic C-terminal part, three coiled-coil (CC) domains 
and a lysine-rich and a serine-proline rich region have been identified (Figure 1-6 A).132,133  
In parallel with STIM1, its homolog STIM2 was also described as a regulator of SOCE.129 
STIM1 and STIM2 share 53% amino acid identity and exhibit a similar domain structure, but 
diverge significantly in their C-terminus.133 As STIM2 has a lower Ca2+ affinity than STIM1, 
and therefore can be active at small fluctuations of ER Ca2+ levels, it has been supposed that 
STIM2 maintains basal [Ca2+]i in resting cells.134 The majority of the studies, however, 
focused on STIM1, since this is the dominant STIM isoform in many cell types, including 
most immune cells67 and platelets.14 
Only one year later, the second milestone in revealing the mechanism of SOCE was the 
discovery of a new class of Ca2+ channels, the Orai proteins. Orai1 (also called CRAC 
modulator 1 - CRACM1) was identified by the use of genome wide RNAi screens in 
Drosophila S2 cells for inhibitors of SOCE and NFAT translocalization as well as by linkage 
analysis in human patients whose T cells lack functional SOCE.135-137  
Also two homologs of Orai1 were identified in mammals and named Orai2 (CRACM2) and 
Orai3 (CRACM3).135 All Orai isoforms can contribute to STIM1-mediated SOCE and may 
form heteromultimeric complexes.138 Orai1 is by far the best studied family member and 
critical for CRAC channel function in different immune cells67 and platelets (see below).14 
Orai1 is a type IV-A plasma membrane protein with four transmembrane domains, a CC 
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domain at the intracellular C-terminus and does not bear homology to any known channel.139 
By subsequent mutational analysis of critical amino acids, it was proven that this protein is 
not just a regulator of the CRAC, but indeed represents the pore-forming subunit.140-142  
The identification of STIM and Orai sparked a large number of studies describing SOCE and 
substantial advances in understanding the molecular regulation of SOCE were made 
(reviewed e.g. in 132, see also Figure 1-6 B). In the current model SOCE is initiated by binding 
of agonists to different kinds of receptors, like ITAM-coupled receptors or GPCRs which 
mediate the activation of PLCs (see above). PLC generates IP3 which in turn binds to IP3-
sensitive Ca2+ channels in the membrane of intracellular Ca2+ stores (the dense tubular 
system in platelets, the ER in most other cell types). The subsequent release of Ca2+ from 
the stores into the cytosol143 results in a decrease in Ca2+ store content and dissociation of 
the Ca2+ from the EF-hand motif of STIM. Subsequently, STIM multimerizes144,145 and 
translocates into puncta at ER-plasma membrane junctions.131,146 Here, STIM binds to CRAC 
channels formed by four Orai proteins147 in the plasma membrane, resulting in opening of the 
channel and subsequent Ca2+ influx (SOCE).  
 
Figure 1-6 STIM1 and store operated Ca2+ entry. (A) Molecular structure of STIM1. The N-terminal 
part of the protein is located in the endoplasmic reticulum (ER) lumen and comprises an EF-hand motif 
(EF) responsible for Ca2+ sensing. CAD indicates CRAC channel activation domain which directly 
binds to Orai and is required for CRAC channel activation. CC, coiled coil; K, lysine-rich; S/P 
serine/proline-rich; TM, transmembrane; (B) Simplified model of SOCE. For details see text. (Figure in 
B is taken from Baba and Kruosaki, Immunol Rev, 2009)148  
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Of pivotal importance in this process are aspartate and glutamate residues within the Ca2+ 
EF-hand motif of STIM1 which coordinate Ca2+ binding. Mutation of either D76, D84 or E87 
mimics the Ca2+ dissociated state of STIM1 and thus empty Ca2+ stores.129,149,150 This results 
in stimulus-independent STIM1 activation and constitutive Ca2+ influx. The in vivo 
consequences of such a mutation are discussed in the next section. 
 
1.7.3 Physiological consequences of mutations in STIM1 and Orai1 
The discovery of STIM and Orai proteins as essential mediators of SOCE has allowed the 
generation of genetic mouse models and the identification of mutations in human patients. 
Deficiency of STIM1 and Orai1 has been shown to affect many different cell types,151 
including platelets14 and immune cells.67 
Intracellular Ca2+ measurements in platelets from STIM1-deficient mice and from mice 
lacking functional Orai1 revealed severely defective Ca2+ responses to all major agonists and 
towards the SOCE-inducer thapsigargin (TG) which induces passive store depletion by 
blocking ER resident sarco-endoplasmic Ca2+ ATPases (SERCA).152-155 These results 
established SOCE as the major route of Ca2+ entry in platelets and STIM1 and Orai1 as 
critical mediators of this process. On the functional level, Stim1-/- and Orai1-/- platelets display 
a selective defect of GPVI-ITAM signaling that is less pronounced in Orai1-/- platelets,154,155 
reduced procoagulant activity,152,153,156 and a protection in collagen-driven thrombosis 
models, as well as in the transient middle cerebral artery occlusion model (tMCAO) of 
ischemic stroke.154,155 
The importance of CRAC channel function for CD4+ T cells function becomes apparent in 
patients with mutations in the ORAI1 gene which interfere with protein function or expression. 
These patients harbor normal numbers of T cells which, however, lack SOCE and show a 
reduced proliferative response to TCR stimulation. As a consequence, the patients suffer 
from severe immunodeficiency associated with recurrent life-threatening bacterial, fungal and 
viral infections. Without hematopoietic stem cell transplantation, patients die within the first 
year of life125,127,128,157 (reviewed in 158). CD4+ T cells from Orai1-deficient or Orai1 mutant 
mice also show impaired SOCE, cytokine production and effector functions, but the defects 
are milder compared to the human situation, especially in naïve CD4+ T cells, which was 
explained by expression of Orai2 and Orai3 in mouse CD4+ T cells.159-161 
CD4+ T cells derived from Stim1-/- mice show abolished SOCE and impaired cytokine 
production, clearly establishing STIM1 as the major isoform in CD4+ T cells, while STIM2 has 
a supporting function.162,163 Unexpectedly, Stim1-/- BMc mice develop a lymphoproliferative 
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phenotype with enlarged lymph nodes and splenomegaly and this phenotype is even more 
pronounced in mice with a T cell-specific deletion of both STIM isoforms (Stim1fl/fl Stim2fl/fl 
CD4-cre+/-).163 In the latter case, this observation is attributed to severely defective Treg 
development and function.163 In contrast, Treg cell frequencies and suppressive activity are 
normal in mice lacking STIM1 only, suggesting a T cell intrinsic defect and a SOCE-
dependent negative feedback loop to constrain excessive proliferation was proposed.162 
Despite the described defects, STIM1-deficient BMc mice are still able to mount T cell 
dependent antibody responses and the ability of T cells from these mice to induce graft-
versus-host disease is only slightly impaired compared to wildtype controls.162 In contrast, 
STIM1 BMc mice or mice with a T cell-specific loss of STIM1 are protected from 
inflammatory bowel disease157 and experimental autoimmune encephalitis,164,165 a model of 
multiple sclerosis, suggesting that SOCE may be of pivotal importance in these settings. A 
slight protection in the latter model was also observed upon STIM2 deficiency demonstrating 
a role in T cell physiology which may be of special importance in Th17 polarization.164,165 
Human patients lacking STIM1 show an almost identical clinical disease spectrum as Orai1-
deficient patients, including severe immunodeficiency166-168 (reviewed in 158). In addition, and 
partially comparable to mice, these patients exhibit lymphoproliferation and autoimmune 
cytopenias.166-168  
Of particular interest is the Stim1Sax mouse which was analyzed in 2007 in our laboratory. 
This mouse line carries an activating mutation (D84G) in the Ca2+-binding EF-hand motif of 
STIM1, abolishing Ca2+ binding and thus mimicking empty stores.149 Hence, this mouse 
model provides one of the rare examples how enhanced CRAC channel activation affects 
cell functions. Homozygous (Stim1Sax/Sax) mice are embryonically lethal with severe diffuse 
hemorrhages in different regions of the body, indicating hemostatic and/or vascular defects. 
Heterozygous (Stim1Sax/+) mice are born at normal Mendelian ratios, but exhibit 
splenomegaly and a pronounced macrothrombocytopenia. The latter is a consequence of 
increased [Ca2+]i in platelets which results in a preactivation state and subsequently leads to 
increased platelet clearance from the circulation. In addition, a selective unresponsiveness 
towards ITAM-coupled receptor agonists was observed. Stim1Sax/+ T cells exhibit 
spontaneous Ca2+ influx with elevated basal [Ca2+]i and enhanced Ca2+ mobilization in 
response to TG, but normal SOCE in response to TCR stimulation. Importantly, T cell 
development, proliferation and cytotoxic T cell function are normal in Stim1Sax/+ mice and – 
surprising to experts in the field132 – no signs of autoimmunity despite constitutive CRAC 
channel activity were observed. 
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1.8 CD84: an ITSM-bearing receptor of the hematopoietic system 
The signaling lymphocytic activation molecule (SLAM) receptors are recognized as important 
immunodulatory receptors and are expressed on the surface of a wide variety of 
hematopoietic cells.169 The SLAM family belongs to the group of immunoglobulin receptors 
and comprises 9 members, with SLAM (CD150) as their prototypical eponym. The family 
members are type I transmembrane proteins and share a common N-terminal ectodomain 
structure, featuring a membrane-distal Ig-like variable (V) domain, lacking disulfide bridges, 
and a membrane proximal Ig-like constant 2-type (C2) domain, stabilized by disulfide 
bonds.169 
A key feature of the SLAM receptor family is the presence of one or more immunoreceptor 
tyrosine-based switch motif (ITSM) in the cytoplasmic domains.169 The ITSM (consensus 
sequence: TxYxxI/V) differs from the ITAM, which consists of two YxxL/I sequences, but 
shows similarities to the ITIM (see above).170 ITSMs appear to be phosphorylated by Src 
kinases upon activation of the receptor by ligand binding or antibody (Ab)-mediated 
crosslinking.171,172 Similar to ITIMs, the phosphorylated ITSM can recruit SH2 containing 
molecules, such as the phosphatases SHP-1, SHP-2 and SHIP. Notably, unlike ITIMs, 
ITSMs also bind the adapters SLAM-associated protein (SAP also termed SH2D1A), Ewing’s 
sarcoma activated transcript 2 (EAT-2), Eat-2-related transducer (ERT) and the p85 
regulatory subunit of PI3K. Whether an ITSM transduces activating or inhibitory signals 
depends on the cell type and the cellular context of stimulation.169,170 
The SLAM receptor family has attracted much attention because inactivating mutations in 
Sh2d1a, encoding SAP, underlie most cases of X-linked lymphoproliferative syndrome 
(XLP).173 This immune disease is characterized by a profoundly abnormal response to 
infection with Epstein-Barr virus, the development of a lymphoproliferative disorder and 
dysgammaglobulinemia.169 
At least two SLAM family members are expressed in platelets: SLAM and CD84.174,175 SLAM 
becomes tyrosine phosphorylated in an aggregation dependent manner and SLAM-deficient 
platelets exhibit defective platelet aggregation in vitro and delayed arterial thrombus 
formation in vivo.175 
CD84 is a type I transmembrane glycoprotein comprising an N-terminal ectodomain, bearing 
one IgV and IgC2 domain (199 aa in mice), a transmembrane domain (25 aa) and a C-
terminal intracellular region (87 aa) containing two ITSMs.169,176 Interestingly, CD84 also 
contains an additional tyrosine residue which is located between the ITSMs and becomes 
phosphorylated upon platelet aggregation.175 Besides platelets, CD84 is also expressed in 
different immune cell populations, including B and T lymphocytes, granulocytes and dendritic 
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cells.169,174,177 Like most SLAM family members, CD84 can undergo homophilic 
interactions.178 Importantly, ligation of CD84 with monoclonal Ab (mAb) or recombinant CD84 
enhances IFNγ production and proliferation in T cells stimulated with low doses of anti-CD3 
mAb.172,178 
The signaling pathway downstream of CD84 has not been examined in detail. Ab-mediated 
crosslinking of CD84 results in phosphorylation of the ITSMs and the recruitment of the 
adapter SAP.172,175 In T cells, it has been demonstrated that the Src family kinase Lck 
mediates CD84 phosphorylation.172 It is presumed that, similar to CD150, SAP facilitates the 
recruitment of Fyn to the CD84/SAP complex, and additionally may also positively influence 
signaling by interfering with the binding of the phosphatase SHP-2.169,179 Interestingly, CD84 
can be tyrosine phosphorylated in SAP-deficient T cells from XLP patients,172 raising the 
possibility that CD84 phosphorylation does not require Fyn recruitment, while SAP itself may 
be still required for signaling transduction.180 Ab-mediated crosslinking of CD84 also induces 
receptor phosphorylation in B cells,181 and biochemical studies in transfected cell lines 
suggest that this may result in the recruitment of the SAP homolog EAT-2.181,182 
A functional role for CD84 has been described in a study using of CD84-deficient mice. It 
was demonstrated that CD84 is required for prolonged B cell and T cell interaction and its 
loss results in impaired germinal center formation.180 The platelet phenotype of CD84 
deficient mice has not been described yet, however, two findings implicate that CD84 and 
CD84 receptor signaling may be of relevance in platelets: (i) the cytoplasmic tail of CD84 
becomes phosphorylated in response to platelet aggregation, and (ii) wildtype platelets, but 
not SAP deficient platelets, are able to spread on immobilized CD84. Therefore, CD84 has 
been proposed to mediate contact dependent signaling and contribute to thrombus 
stabilization, similar to CD150.175 However, the role of CD84 in platelet aggregation and 
thrombus formation as well as the regulation of its surface regulation, remain elusive. 
 
1.9 Receptor proteolysis 
One way to downregulate platelet reactivity is to remove activatory receptors from the 
platelet surface by internalization183 or proteolytic cleavage.38 The extracellular cleavage of 
platelet receptors by (metallo)proteinases is termed ectodomain shedding and has been 
described for a number of major receptors, including GPIbα,184 GPVI,185,186 GPV,187,188 
semaphorin 4D,189 P-Selectin,190 and CD40L.191 
Two proteinases of the a disintegrin and metalloproteinase (ADAM) family have been 
identified to be involved in the extracellular cleavage of platelet receptors: ADAM10 and 
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ADAM17. The latter is the principal sheddase of GPIbα,184 whereas cleavage of GPV or 
GPVI can occur through either ADAM10 or ADAM17, depending on the shedding-inducing 
stimulus.37,192 
Shedding of GPIb184,185,193 and GPV37,188 from the platelet surface can be induced by 
activating human or mouse platelets with receptor agonists, while metalloproteinase-
dependent downregulation of GPVI in response to stimulation with GPVI agonists has been 
observed in human,186 but not in mouse platelets.185 However, GPVI can be released from 
the platelet surface in circulating murine platelets by in vivo administration of monoclonal 
anti-GPVI antibodies.20,183 Recently, a proteomic approach demonstrated that many platelet 
receptors, including CD84 (see previous chapter), might be cleaved from the surface of 
human platelets in a metalloproteinase-dependent manner, but details of this process 
remained elusive.194 
To study platelet receptor regulation in vitro, platelets can be treated with different agents 
that induce shedding of multiple platelet membrane receptors by distinct mechanisms (see 
Figure 1-7 and 38): The calmodulin inhibitor W7 induces the disruption of calmodulin from 
receptors, thereby facilitating ectodomain shedding, e.g. of GPIbα37,192 and GPV188 by 
ADAM17 and GPVI by ADAM10.186,192 In addition, W7 may also act in part by activating 
ADAMs themselves.38 N-ethylmaleimide (NEM) is a thiol-modifying reagent which directly 
activates ADAM10 and ADAM17 by acting on a cysteine-switch within the proteases. Like 
W7, NEM induces the loss of platelet receptor without accompanying platelet activation.38 
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) induces mitochondrial injury by 
 
Figure 1-7 Different ways leading to receptor shedding. Platelet activation by receptor agonists 
results in intracellular signaling events, which are involved in inside-out activation of 
metalloproteinases. In vitro, shedding can be induced by reagents acting in distinct manners and 
independently of platelet receptor stimulation. For details see text. 
 
23 
Introduction 
 
uncoupling oxidative phosphorylation and triggers receptor shedding mainly in an ADAM17-
dependent manner.184,192 The phorbol ester phorbol 12-myristate 13-acetate (PMA) is an 
activator of PKC thereby inducing ectodomain shedding, e.g. of GPV and GPIb, mainly by 
ADAM17.184,188 
Another mechanism to modulate platelet receptor signaling is proteolytic cleavage of the 
receptor by intracellular proteases like calpain. Calpain is a cysteinyl protease, in part 
regulated by Ca2+, and cleaves a number of proteins, many of them involved in the regulation 
of the cytoskeleton.195 Studies in platelets have demonstrated that calpain cleaves the 
intracellular part of β3 integrin,196 FcγRIIa,197 and PECAM-1198 which results in degradation or 
modification of the signal transducing cytoplasmic receptor tail.197,199 Of note, activation of 
signaling pathways leading to extracellular shedding is concomitant with activation of calpain 
(e.g. in response to calmodulin inhibitors),38,197 suggesting that intra- and extracellular 
cleavage events might be simultaneously operative in the downregulation of receptor 
signaling in platelets. 
 
1.10 Aims of this thesis 
The aim of this thesis was to investigate different aspects of receptor signaling and receptor 
regulation in cells of the hematopoietic system: 
The Stim1Sax/+ mouse provides a unique model to investigate the impact of constitutive Ca2+ 
influx on the physiology and function of different cell types. While deleterious to platelet 
function, T cells with Stim1Sax mutation have been found to behave surprisingly normal. Since 
the underlying mechanisms remained elusive, the first aim of the thesis was to examine the 
TCR signaling pathway and function of Stim1Sax/+ T cells by biochemical approaches. 
The formation of signaling complex called LAT signalosome is of central importance for 
proper signal transduction of (hem)ITAM receptors, such as the TCR as well as GPVI and 
CLEC-2 in platelets. Previous studies have shown that Grb2 is part of the LAT signalosome, 
but the exact function of this protein in platelets is unknown. Therefore, mice with 
MK/platelet-specific deletion of Grb2 were analyzed. 
Besides modulation of intracellular signaling pathways, regulation of receptor levels, either by 
internalization or intra- or extracellular proteolytic cleavage, is another important mechanism 
to modulate cell function. A proteomic approach provided first evidence for 
metalloproteinase-dependent cleavage of CD84 from the surface of human platelets. The 
object of this study was a detailed description of the mechanisms underlying the 
downregulation of CD84 receptor levels. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Reagent Company 
3,3,5,5-tetramethylbenzidine (TMB) BD Biosciences (Heidelberg, Germany) 
Adenosine diphosphate (ADP) Sigma-Aldrich (Schnelldorf, Germany) 
Agarose Roth (Karlsruhe, Germany) 
ALLN Calbiochem (Bad Soden, Germany) 
Amersham Hyperfilm ECL GE Healthcare (Little Chalfont, UK) 
Ammonium peroxodisulfate (APS)  Roth (Karlsruhe, Germany) 
Apyrase (grade III) Sigma-Aldrich (Schnelldorf, Germany) 
Aspirin® i.v. 500 mg Bayer (Wuppertal, Germany) 
Avertin® (2,2,2-tribromoethanol) Sigma-Aldrich (Schnelldorf, Germany) 
Bovine serum albumin (BSA) AppliChem (Darmstadt, Germany) 
Calcium chloride Roth (Karlsruhe, Germany) 
Carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) 
Sigma (Schnelldorf, Germany) 
Complete mini protease inhibitors (+EDTA) Roche Diagnostics (Mannheim, Germany) 
Convulxin (CVX) Enzo Lifesciences (Lörrach, Germany) 
Cyclosporin A Calbiochem (Bad Soden, Germany) 
dNTP mix Fermentas (St. Leon-Rot, Germany) 
EDTA   AppliChem (Darmstadt, Germany) 
Ethidium bromide Roth (Karlsruhe, Germany) 
Fat-free dry milk AppliChem (Darmstadt, Germany) 
Fentanyl Janssen-Cilag (Neuss, Germany) 
Fibrillar type I collagen (Horm) Nycomed (Munich, Germany) 
Flumazenil Delta Select (Dreieich, Germany) 
Isofluran CP® cp-pharma (Burgdorf, Germany) 
Fura-2 acetoxymethyl ester (AM) Invitrogen (Karlsruhe, Germany) 
GeneRuler 1kb DNA Ladder  Fermentas (St. Leon-Rot, Germany) 
GM6001 Calbiochem (Bad Soden, Germany) 
Heparin sodium Ratiopharm (Ulm, Germany) 
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Reagent Company 
Human fibrinogen Sigma-Aldrich (Schnelldorf, Germany) 
IGEPAL® CA-630 Sigma-Aldrich (Schnelldorf, Germany) 
Immobilon-P transfer membrane Millipore (Schwalbach, Germany) 
Indomethacin  Alfa Aesar (Karlsruhe, Germany) 
MDL 28170 Calbiochem (Bad Soden, Germany) 
Medetomidine (Dormitor) Pfizer (Karlsruhe, Germany) 
Midazolam (Dormicum) Roche (Grenzach-Wyhlen, Germany) 
Midori Green Advanced DNA stain Nippon Genetics Europe (Düren, 
Germany) 
Naloxon Delta Select (Dreieich, Germany) 
N-ethylmaleimide (NEM) Calbiochem (Bad Soden, Germany) 
PageRuler prestained protein ladder Fermentas (St. Leon-Rot, Germany) 
Phenol/chloroform/isoamyl alcohol Roth (Karlsruhe, Germany) 
Phorbol 12-myristate 13-acetate (PMA) Sigma (Schnelldorf, Germany) 
Pluronic F-127  Invitrogen (Karlsruhe, Germany) 
Prostacyclin (PGI2) Sigma (Schnelldorf, Germany) 
Protease inhibitor cocktail (100x) Sigma-Aldrich (Schnelldorf, Germany) 
Proteinase K Fermentas (St. Leon-Rot, Germany) 
Protein G Sepharose 4 Fast Flow GE Healthcare (Freiburg, Germany) 
Rotiphorese gel 30 acrylamide Roth (Karlsruhe, Germany) 
Sodium orthovanadate Sigma (Schnelldorf, Germany) 
Triton X-100 AppliChem (Darmstadt, Germany) 
Taq polymerase Fermentas (St. Leon-Rot, Germany) 
Taq polymerase buffer (10x) Fermentas (St. Leon-Rot, Germany) 
Tetramethylethylenediamine (TEMED) Roth (Karlsruhe, Germany) 
Thapsigargin (TG) Invitrogen (Karlsruhe, Germany) 
Thrombin (20 U/ml) Roche Diagnostics (Mannheim) 
Thrombin (100 U/ml) Sigma (Schnelldorf, Germany) 
Tween 20 Roth (Karlsruhe, Germany) 
U46619 Enzo Lifesciences (Lörrach, Germany) 
Western lightning chemiluminescence (ECL) PerkinElmer LAS (Boston, USA) 
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Collagen-related peptide (CRP) was kindly provided by Prof. Dr. S.P. Watson (University of 
Birmingham, UK). Rhodocytin was a generous gift from Prof. Dr. J. Eble (University Hospital 
Frankfurt, Germany). All other non-listed chemicals were obtained from AppliChem 
(Darmstadt, Germany), Sigma (Schnelldorf, Germany) or Roth (Karlsruhe, Germany). 
 
2.1.2 Cell culture materials 
70 µm nylon cell strainer BD Falcon (Heidelberg, Germany) 
β-mercaptoethanol Roth (Karlsruhe, Germany) 
Fetal calf serum (FCS) Gibco (Karlsruhe, Germany) 
L-glutamine Gibco (Karlsruhe, Germany) 
Non-essential amino acids Gibco (Karlsruhe, Germany) 
Phosphate buffered saline (PBS) Gibco (Karlsruhe, Germany) 
Penicillin/streptomycin Gibco (Karlsruhe, Germany) 
RPMI medium Gibco (Karlsruhe, Germany) 
Sodium pyruvate Gibco (Karlsruhe, Germany) 
Well plates (6-well, 12-well, 24-well or 96-well) Greiner (Frickenhausen, Germany) 
 
2.1.3 Kits 
ELISA kits: 
Mouse IFNγ ELISA Set BD Biosciences (Heidelberg, Germany) 
Mouse IL-1α ELISA MAX™ Standard Biolegend (Fell,Germany) 
Mouse IL-10 ELISA Ready-SET-Go!®  eBioscience (Frankfurt, Germany) 
Mouse IL-13 ELISA Ready-SET-Go!® eBioscience (Frankfurt, Germany) 
Mouse IL-2 ELISA Set BD Biosciences (Heidelberg, Germany) 
Mouse IL-3 ELISA MAX™ Standard Biolegend (Fell,Germany) 
Mouse IL-4 ELISA Set BD Biosciences (Heidelberg, Germany) 
Mouse IL-5 ELISA MAX™ Standard Biolegend (Fell,Germany) 
Mouse IL-6 ELISA MAX™ Deluxe Biolegend (Fell,Germany) 
Mouse TNF-α ELISA MAX™ Deluxe Biolegend (Fell,Germany) 
IP-ONE ELISA assay  Cisbio (Codolet, France) 
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Fixation and permeabilization of cells: 
Foxp3/transcription factor staining buffer set eBioscience (Frankfurt, Germany) 
CD4+ T cell isolation: 
Dynal® Mouse CD4 negative isolation kit Invitrogen (Karlsruhe, Germany) 
NuPAGE® Pre-cast gel system for electrophoresis: 
NuPAGE® Bis-Tris 4 - 12% Gel, 1.0 mm Invitrogen (Karlsruhe, Germany) 
NuPAGE® LDS Sample Buffer (4x) Invitrogen (Karlsruhe, Germany) 
SeeBlue® Plus2 Pre-Stained Standard Invitrogen (Karlsruhe, Germany) 
 
2.1.4 Antibodies 
2.1.4.1 Antibodies and reagents used for flow cytometry 
Antibodies and reagents used for analyses of immune cells:  
Antibodies were purchased from eBioscience (Frankfurt, Germany), Biolegend (Fell, 
Germany), BD Biosciences (Heidelberg, Germany) or Miltenyi Biotec (Bergisch Gladbach, 
Germany), as indicated.  
Antibodies are directed against the mouse protein, if not indicated otherwise. 
Antibody (anti-) Clone Species, isotype Company Dilution 
B220/Alexa647 RA3-6B2 rat, IgG2a, κ BD Biosciences 1:400 
CD3/PE-Cy5 145-2C11 hamster, IgG1, κ BD Biosciences 1:100 
CD4/PE GK1.5 rat, IgG2b, κ BD Biosciences 1:500 
CD4/Alexa647 RM4-5 rat, IgG2a, κ BD Biosciences 1:250 
CD4/APC-Cy7 L3T4 rat, IgG2b, κ BD Biosciences 1:400 
CD8/PE 53-6.7 rat, IgG2a, κ BD Biosciences 1:200 
CD8/PE-Cy5 53-6.7 rat, IgG2a, κ BD Biosciences 1:200 
CD8/PE-Cy7 53-6.7 rat, IgG2a, κ BD Biosciences 1:300 
CD11b/PE M1/70 rat, IgG2b, κ BD Biosciences 1:200 
CD25/PerCP-Cy5.5 PC61.5 rat, IgG1, λ eBioscience 1:100 
CTLA-4/biotin UC10-4B9 hamster, IgG eBioscience 1:50 
Foxp3/PE FJK-16s rat, IgG2a, κ eBioscience 1:50 
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Gr-1/FITC RB6-8C5 rat, IgG2b, κ BD Biosciences 1:1500 
Helios/FITC 22F6 Hamster, IgG Biolegend 1:20 
Ki67/FITC B56 mouse, IgG1, κ BD Biosciences 1:20 
human-CD84/FITC MZ18-21F6 mouse, IgG1 Miltenyi Biotec 1:11 
Isotype control/FITC MOPC-21 mouse, IgG1, κ BD Biosciences 1:20 
Isotype control/ 
PerCP-Cy5.5 
eBRG1  
 
rat, IgG1 eBioscience 1:100 
Streptavidine/FITC was purchased from DAKO (Hamburg, Germany).  
 
Antibodies and reagents used for platelet analyses: 
If not indicated otherwise, antibodies were purified in our laboratory. 
Antibody Clone Species, 
isotype 
Antigen Description/source 
p0p4 15E2 Rat, IgG2b GPIbα 193 
p0p6 56F8 Rat, IgG2b GPIX 200 
DOM 2 89H11 Rat, IgG2a GPV 200 
- 96H10 Rat, IgG2a CD9 unpublished 
JAQ1 98A3 Rat, IgG2a GPVI 201 
JON6 14A3 Rat, IgG2b αIIbβ3 unpublished 
INU1 - Rat, IgG1 CLEC-2 11 
JER1 10B6 Rat, IgG2a CD84 202 
- 2.4G2 Rat, IgG2b FcγRIIb/RIII 
(CD16/32) 
hybridoma HB-197 
purchased from ATCC203 
JON/A 4H5 Rat, IgG2b αIIbβ3 204 
WUG 1.9 5C8 Rat, IgG1 P-selectin unpublished 
- 12C6 Rat, IgG2b Integrin α2 unpublished 
Anti-integrin β1 
chain (CD29)/FITC 
9EG7  Rat, IgG2a Integrin β1 BD Biosciences  
The antibodies were labeled with fluorescein isothiocyanate (FITC) or with phycoerythrin 
(PE) by standard methods, as described previously.204 
Annexin V was purified in our lab and coupled to DyLight 488 by standard methods. 
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2.1.4.2 Antibodies and reagents used for in vitro assays, Western blotting and ELISA 
Western blotting and immunoprecipitation: 
Antibody Company/Description 
Rabbit anti-actin (no. A2066) Sigma-Aldrich (Deisenhofen, 
Germany) 
Rat anti-β3 integrin-HRP (clone 57B10) 200 
anti-Btk Kindly provided by Dr. M. Tomlinson 
anti-CLEC-2 Kindly provided by Dr. D. Mourão Sá 
Rabbit anti-CD84 (product M130) Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Rat anti-CD84-HRP (clone 10B6) 202 
Rabbit anti-GAPDH (14C10) Cell Signaling (Danvers, MA, USA) 
Mouse anti-Grb2 (clone 3F2) Millipore (Schwalbach, Germany) 
Rabbit anti-Grb2 (product C23) Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Rabbit anti-LAT (no. 9166) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-LAT (no. 06-807) (for IP) Millipore (Schwalbach, Germany) 
Rabbit anti-phospho-LAT (Y191) (no. 3584) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-phospho-LAT (Y132) (no. ab4476) Abcam (Cambridge, UK) 
Rabbit anti-phospho-Lck (Y505) (no. 2751) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-LSD1 (clone C69G12) Cell Signaling (Danvers, MA, USA) 
anti-NFAT Kindly provided by Prof. Dr. E. 
Serfling 
Rabbit anti-p38 MAPK (no. 9212) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-phospho-p38 MAPK (T180/Y182) XP® 
(clone D3F9) 
Cell Signaling (Danvers, MA, USA) 
Rabbit anti-p44/42 MAPK (ERK1/2) (no. 9102) Cell Signaling (Danvers, MA, USA) 
Mouse anti-phospho-p44/42 MAPK (ERK1/2) 
(T202/Y204) (clone E10) 
Cell Signaling (Danvers, MA, USA) 
Rabbit anti-PLCγ1 (no. 2822) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-phospho-PLCγ1 (Y783) (no. 2821) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-phospho-PLCγ1 (Y771) (no. 2350-1) Epitomics (Burlingame, CA, USA) 
Rabbit anti-PLCγ2 (product Q20) Santa Cruz Biotechnology 
(Heidelberg, Germany) 
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Rabbit anti-phospho-PLCγ2 (Y759) (no.3874) Cell Signaling (Danvers, MA, USA) 
Mouse anti-phosphotyrosine (clone 4G10) Millipore (Schwalbach, Germany) 
Rabbit anti-SAPK/JNK (clone 56G8) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-phospho-SAPK/JNK (T183/Y185) 
(no. 9251) 
Cell Signaling (Danvers, MA, USA) 
Sheep anti-SLP-76 (no. 06-548) Millipore (Schwalbach, Germany) 
Rabbit anti-phospho-Syk (Y525/526) (clone C87C1) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-Syk (clone D1I5Q) Cell Signaling (Danvers, MA, USA) 
Mouse anti-α-tubulin (clone B-5-1-2) Sigma-Aldrich (Deisenhofen, 
Germany) 
Rabbit anti-Vav1 (product C-14) Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Rabbit anti-Vav3 (no. 07-465) Millipore (Schwalbach, Germany) 
Rabbit anti-ZAP-70 XP® (clone D1C10E) Cell Signaling (Danvers, MA, USA) 
Rabbit anti-pZAP-70 (Y319)/pSyk (Y352) 
(clone 65E4) 
Cell Signaling (Danvers, MA, USA) 
Rabbit anti-mouse IgG HRP (no. P0260)  DAKO (Hamburg, Germany) 
Donkey anti-sheep IgG HRP (no. HAF016) R+D Systems (Abingdon, UK) 
Goat anti-rabbit IgG (H&L) HRP (no. 7074) Cell Signaling (Danvers, MA, USA) 
Donkey anti-rat IgG HRP (no. 712-034-153) Jackson ImmunoResearch (West 
Grove, PA, USA) 
Biotinylated Protein Ladder Detection Pack Cell Signaling (Danvers, MA, USA) 
 
ELISA: 
Mouse anti-human CD84 (clone MAX.3) 174,205 
Mouse anti-human CD84 biotin (clone 2.G7) eBioscience (Frankfurt, Germany) 
Rat anti-CD84 (clone 10B6) 202 
Hamster anti-CD84 biotin (clone CD84.7) Biolegend (Fell, Germany) 
Streptavidin-HRP (no. 016-030-084) Jackson ImmunoResearch (West 
Grove, PA, USA) 
Goat anti-mouse IgG (H+L) (no. 115-005-062) Jackson ImmunoResearch (West 
Grove, PA, USA) 
Nunc MaxiSorp™, F96-Wells Thermo Scientific (Braunschweig, 
Germany) 
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In vitro assays: 
Hamster anti-mouse CD3ε, functional grade purified eBioscience (Frankfurt, Germany) 
Goat anti-armenian hamster IgG (no. 127-005-160) 
 
Jackson ImmunoResearch (West 
Grove, PA, USA) 
Dynabeads® Mouse T-Activator CD3/CD28 Invitrogen (Karlsruhe, Germany) 
 
2.1.5 Mice 
Mice carrying the Grb2 gene with exon 2 flanked by loxP sites (Grb2fl)108 were kindly 
provided by Prof. Dr. Lars Nitschke (Division of Genetics, Department of Biology, University 
of Erlangen). To generate mice lacking Grb2 specifically in MKs and platelets, these mice 
were crossed with mice carrying the platelet factor 4 (Pf4)–cre transgene (Pf4-cre+/-)206 and 
the offspring was genotyped by PCR as described below. Absence of Grb2 protein in 
platelets of Grb2fl/fl/Pf4-cre+/- mice was confirmed by Western blot analysis (see results 
section). Littermates (Grb2fl/fl/Pf4-cre-/-) served as controls. The mice used for the 
experiments were on a C57Bl/6J background (F5). 
Stim1Sax mice (C3H background) were described previously149 and genotyped as described 
below. The generation of CD84-deficient animals has been described in the thesis “Studies 
on the function and regulation of CD84, GPVI and Orai2 in genetically modified mice” by Dr. 
Sebastian Hofmann (University of Würzburg, 2013). Mice deficient in ADAM10 were 
generated in our lab and provided by Dr. Markus Bender.192 Adam17 transgenic mice 
(ADAM17ex/ex)207 were received from Prof. Dr. Stefan Rose-John (Kiel, Germany). 
ADAM17ex/ex bone marrow chimeras were generated by irradiation (10 Gray) of 5 - 6 week 
old C57Bl/6J mice (Janvier Labs, Saint Berthevin, France) and transfer of 4x106 bone 
marrow donor cells. LAT-56 and Talin1-deficient208 mice have also been described. Animal 
studies were approved by the district government of Lower Franconia (Bezirksregierung 
Unterfranken). 
 
2.1.6 Buffers and media 
All buffers were prepared in deionized water obtained from a MilliQ Water Purification 
System (Millipore, Schwalbach, Germany). pH was adjusted with HCl or NaOH. 
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• ACK Lysing Buffer of erythrocyte lysis, pH 7.2 - 7.4 
NH4Cl 150 mM 
KHCO3 10 mM 
Na2EDTA 0.1 mM 
• Blocking solution for immunoblotting 
Washing buffer (TBS-T, see below)  
BSA or fat-free dry milk 5%  
• Cell culture medium 
RPMI  
FCS 10% 
Sodium pyruvate (100 mM) 1% 
L-Glutamine (200 mM) 1% 
Non-essential amino acids 1% 
β-mercaptoethanol 30 µM 
Penicillin/streptomycin  100 U/ml (each) 
• Coating buffer, pH 9.6 
Na2CO3 15 mM 
NaHCO3 85 mM 
• FACS buffer 
PBS (1x)  
FCS 1% 
NaN3 0.02% 
• Laemmli buffer for SDS-PAGE 
TRIS 40 mM 
Glycine 0.95 mM 
SDS 0.5% 
• Lysis buffer (for DNA isolation), pH 7.2 
TRIS base 100 mM 
EDTA 5 mM 
NaCl 200 mM 
SDS 0.2% 
Proteinase K (to be added directly before use) 100 µg/ml 
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• Lysis buffer 2x (for tyrosine phosphorylation assay), pH 7.5 
TRIS base 20 mM 
NaCl 300 mM 
EDTA 2 mM 
EGTA 2 mM 
IGEPAL CA-630 2% 
NaF 10 mM 
to be added directly before use:  
Na3VO4  2 mM  
Complete mini protease inhibitor or 
protease inhibitor cocktail (100x) 
1 tablet/10 ml 
2% 
• Lysis buffer 1x (for T cell experiments), pH 7.5 
TrisHCl 20 mM 
NaCl 150 mM 
NaF 10 mM 
Triton X-100 1% 
to be added directly before use:  
Pepstatin 3 µg/ml 
Leupeptin 5 µg/ml 
Aprotonin 10 µg/ml 
PMSF 1 mM 
Na3VO4 1 mM 
• MOPS-Buffer, 20x 
MOPS 1 M 
TRIS base 1 M 
SDS 69.3 mM 
EDTA 20.5 mM 
• Phosphate buffered saline (PBS), pH 7.14 
NaCl 137 mM 
KCl 2.7 mM 
KH2PO4 1.5 mM 
Na2HPO4 8 mM 
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• Sample buffer for agarose gels, 6x 
Tris buffer (150 mM) 33% 
Glycerine 60% 
Bromophenol blue (3',3",5',5"-tetrabromophenol-
sulfonphthalein) 
0.04% 
• SDS sample buffer, 4x 
β-mercaptoethanol (for reducing conditions) 20% 
TRIS buffer (1 M), pH 6.8 20% 
Glycerine 40% 
SDS 4% 
Bromophenol blue 0.04% 
• Separating gel buffer (Western Blot), pH 8.8 
TRIS/HCl 1.5 M 
• Stacking gel buffer (Western Blot), pH 6.8 
TRIS/HCl 0.5 M 
• Stripping buffer (Western Blot), pH 2.0 
PBS (1x)  
Glycine 25 mM 
SDS 1% 
• TAE buffer, 50x, pH 8.0 
TRIS 0.2 M 
Acetic acid 5.7% 
EDTA  50 mM 
• T cell isolation buffer 
PBS (1x)  
FCS 0.2% 
EDTA 2 mM 
• TE buffer, pH 8.0 
TRIS base 10 mM 
EDTA 1 mM 
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• Transfer buffer 
Tris Ultra 50 mM 
Glycine 40 mM 
Methanol 20% 
• Tris-buffered saline (TBS), pH 7.3 
NaCl 137 mM 
TRIS/HCl 20 mM 
• Tyrode’s buffer, pH 7.3 
NaCl 137 mM 
KCl 2.7 mM 
NaHCO3 12 mM 
NaH2PO4 0.43 mM 
CaCl2 0 or 2 mM 
MgCl2 1 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) 
5 mM 
to be added directly before use:  
BSA  0.35% 
Glucose  1% 
• Washing buffer for immunoblotting (TBS-T) 
TBS (1x)  
Tween 20  0.1%  
• Washing buffer for ELISA (PBS-T) 
PBS (1x)  
Tween 20  0.1% 
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2.2 Methods 
2.2.1 Mouse genotyping 
2.2.1.1 Isolation of genomic DNA from mouse tissue 
Approximately one third of a mouse ear was dissolved in 500 µl lysis buffer at 55°C under 
shaking conditions (900 rpm) in a Thermomixer comfort (Eppendorf, Hamburg, Germany) 
500 µl of phenol/chloroform/isoamyl alcohol were added and, after vigorous shaking, 
samples were centrifuged at 10,000 rpm for 10 min at room temperature (RT). The upper 
phase was carefully transferred to a new tube containing 500 µl isopropanol. After vigorous 
shaking, the samples were centrifuged at 14,000 rpm for 10 min at 4°C. Subsequently, the 
supernatant was removed and the DNA pellet was washed with 500 µl of 70% ethanol and 
centrifuged again at 14,000 rpm for 10 min at 4°C. Next, all the ethanol was removed and the 
pellet was dried for approximately 30 min at 37°C. Finally, the pellet was dissolved by adding 
75 µl TE buffer and shaking (300 rpm) for 30 min at 37°C, followed by short vortexing. 
Usually, 1 - 2 µl DNA solution were used for a PCR reaction. 
 
2.2.1.2 Detection of the PF4-Cre transgene by PCR 
Primers: 
PF4-Cre_fwd 5’ CCC ATA CAG CAC ACC TTT G 3’ 
PF4-Cre_rev 5’ TGC ACA GTC AGC AGG TT 3’ 
Pipetting scheme: 
2 µl genomic DNA 
5 µl Taq-buffer (10x) 
5 µl MgCl2 (25 mM) 
2 µl dNTPs (10 mM) 
2 µl PF4-Cre_fwd primer (1:10 in H2O, stock 1 µg/ml) 
2 µl PF4-Cre_rev primer (1:10 in H2O, stock 1 µg/ml) 
0.5 µl Taq-Polymerase (5 U/µl) 
31.5 µl H2O  
PCR-Program: 
95°C 5:00 min  
95°C 0:30 min  
58°C 0:30 min 35x 
72°C 0:45 min  
72°C 5:00 min   
4°C stop  
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Results (expected band sizes): 
wt:   no PCR product 
PF4-cre+:  450 bp 
 
2.2.1.3 Detection of the Grb2 floxed allele by PCR 
Primers: 
Grb2_LoxP fwd 5' CCA GCA CAC ATG TCC TGC CTT C 3' 
Grb2_LoxP rev 5' GGT GGC TCA CAA CCA CCT ATA AC 3' 
Pipetting scheme: 
1.2 µl genomic DNA 
5 µl Taq-buffer (10x) 
5 µl MgCl2 (25 mM) 
1 µl dNTPs (10 mM) 
1.5 µl Grb2_LoxP fwd primer (1:10 in H2O, stock 100 µM) 
1.5 µl Grb2_LoxP rev primer (1:10 in H2O, stock 100 µM) 
0.5 µl DMSO 
0.2 µl Taq-Polymerase (0.5 U/µl) 
34.1 µl H2O  
PCR-Program: 
94°C 4:00 min  
95°C 0:20 min  
58°C 0:20 min 35x 
72°C 0:30 min  
72°C 10:00 min   
4°C stop   
 
Results (expected band sizes): 
wt/wt:   241 bp 
floxed/floxed: 209 bp 
wt/floxed:  241 and 209 bp; 1 additional upper band 
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2.2.1.4 Agarose gel electrophoresis 
Agarose was dissolved in 1x TAE buffer by heating it in a microwave. Depending on the 
length of DNA fragments to be separated, different amounts of agarose were used (1 - 2%). 
When the temperature had decreased to approx. 60°C, 5 µl ethidiumbromide (2 mg/ml) or 
Midori green per 100 ml were added and the fluid was poured into a tray with a comb. After 
solidification of the gel, the tray was positioned in an electrophoresis chamber containing 
1x TAE buffer and the comb was removed. PCR reactions were mixed with 6x sample 
loading buffer and 20 µl were loaded into the slots of the gel. For size-separation DNA 
samples were run for approximately 45 min at about 100 -160 V, depending on the gel size. 
A 1 kb DNA ladder was used to determine the size of the DNA bands under UV light later on. 
 
2.2.1.5 Genotyping of Stim1Sax mice by Sysmex-analysis 
Alterations in mean platelet volume (MPV) and platelet count have previously been shown to 
reveal the genotype of Stim1Sax mice with 100% accuracy.149 Therefore, to genotype Stim1Sax 
mice, 50 µl blood were drawn from the retroorbital plexus of anesthetized mice using 
heparinized microcapillaries and collected into a 1.5 ml reaction tube containing 300 μl 
heparin in TBS (20 U/ml, pH 7.3). Platelet count and size were determined using a Sysmex 
KX-21N automated hematology analyzer (Sysmex Corp., Kobe, Japan). Mice with a platelet 
count of less than 30x103 platelets/µl diluted blood (approx. less than 30% of wildtype (wt) 
levels) and a MPV bigger than 7.0 fl (approx. 30% increase compared to wt) were regarded 
as carrier of the Stim1Sax mutation (Stim1Sax/+ mutant mice). 
 
2.2.2 Biochemistry 
2.2.2.1 Western blotting (immunoblotting) 
For Western blot analysis of the phosphorylation status of proteins, cell lysates were 
obtained as described in sections 2.2.4.6 and 2.2.6.4. Alternatively, for determination of Grb2 
expression levels, platelets or splenocytes were centrifuged at 2,800 rpm for 5 min and 
resuspended in lysis buffer containing 1.5% IGEPAL and protease inhibitors. After incubation 
for 20 min on ice and centrifugation at 14,000 rpm for 10 min at 4°C, the supernatant was 
obtained. 
Cell lysates were mixed with the respective amount of 4x SDS sample buffer and boiled for 
5 min at 95°C. For SDS-PAGE, 15 - 25 µl per sample were loaded onto a gel with a 4% 
stacking part and a 10 or 12% separating part, provided in a gel chamber filled with Laemmli 
 
39 
Materials and Methods 
 
buffer. Alternatively, a NuPAGE® Pre-cast gel system for electrophoresis with 4 - 12% Bis-
Tris gradient gel was used. 
After separation, the stacking part of the gel was removed and the gel was put into transfer 
buffer and subjected to immunoblotting. Transfer of proteins onto a polyvinylidene difluoride 
(PVDF) membrane was performed with a semi-dry blotting system for 70 min with 0.85 mA 
per cm2 membrane at RT. To avoid non-specific binding of antibodies, the membrane was 
blocked for at least 40 min in blocking buffer at RT. Subsequently, the membrane was 
incubated with the primary antibody, diluted in blocking buffer, at 4°C overnight with gentle 
shaking. Afterwards, the membrane was washed at least three times for 10 min at RT. Next, 
the membranes were incubated with the appropriate secondary HRP-labeled antibody for 1 h 
at RT. Finally, the membranes were washed several times and proteins were visualized by 
ECL using X-ray developing films or digitally by the use of the Fluorchem™ Q system 
(Protein Simple, Santa Clara, CA, USA). 
For stripping, membranes were incubated with stripping buffer for 20 - 25 min at RT under 
rotation. Afterwards, membranes were washed briefly several times in TBS-T to remove 
residual stripping buffer. Then, the membranes were blocked again and probed with 
antibodies as described.  
 
2.2.2.2 Immunoprecipitation 
For immunoprecipitation of individual proteins, platelet lysates were precleared with Protein 
G Sepharose for 1 h at 4°C under rotating conditions. The respective antibody and 
prewashed Protein G Sepharose were added to the resultant supernatant and rotated at 4°C 
for 2 h or overnight. The sepharose pellet was washed in a 1:1 mixture of 2x lysis buffer and 
Ca2+-free Tyrode’s buffer, containing 0.2% IGEPAL and protease inhibitors. Finally, 2x 
NuPAGE® LDS Sample Buffer was added to the sepharose pellet and the sample was boiled 
for 5 min at 95°C. Precipitated proteins were separated by SDS-PAGE and subjected to 
Western blotting. 
 
2.2.3 Generation of plasma and serum samples 
For generation of mouse plasma samples, blood was drawn with heparinized microcapillaries 
from the retroorbital plexus and collected in 1.5 ml reaction tubes containing heparin and 
GM6001. Samples were centrifuged at 2,800 rpm for 5 min at RT, then the supernatant was 
collected and centrifuged at 14,000 rpm for 10 min at RT. Finally, the supernatant was taken 
off and used for experiments. 
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Serum was prepared by drawing blood with non-heparinized microcapillaries and collected in 
1.5 ml reaction tubes without heparin. In some experiments, Tyrode’s buffer was provided in 
the reaction tube to achieve equal dilution like plasma samples, which required heparin. 
Clotting occurred at RT for 1 h. The samples were centrifuged for 10 min at 5,000 rpm, the 
supernatant was collected and centrifuged one more time as in the step before. Finally, the 
supernatant was used for experiments or frozen at -20°C for later use. 
 
2.2.4 In vitro analyses of platelet function 
2.2.4.1  Platelet preparation and washing 
Mice were bled under isoflurane anesthesia from the retroorbital plexus. 700 µl blood were 
collected into an 1.5 ml reaction tube containing 300 μl heparin in TBS (20 U/ml, pH 7.3). 
200 µl heparin were added and blood was centrifuged at 800 rpm (Eppendorf Centrifuge 
5415C) for 5 min at RT. Supernatant and buffy coat were transferred into a new tube 
containing 200 µl heparin and centrifuged at 800 rpm for 5 min at RT to obtain platelet rich 
plasma (prp). To prepare washed platelets, prp was centrifuged at 2800 rpm for 5 min at RT 
in the presence of prostacyclin (PGI2) (0.1 μg/ml) and apyrase (0.02 U/ml) and the pellet was 
resuspended in 1 ml Ca2+-free Tyrode’s buffer containing PGI2 and apyrase (0.02 U/ml). After 
5 min incubation at 37°C, the sample was centrifuged at 2,800 rpm for 5 min. After 
resuspending the platelets once more in 1 ml Ca2+-free Tyrode’s buffer, the platelet numbers 
were determined by taking a 1:1 dilution of the platelet solution and the platelet count was 
measured in a Sysmex KX-21N automated hematology analyzer. Finally, the pellet was 
resuspended in the appropriate volume of Tyrode’s buffer containing apyrase (0.02 U/ml) to 
reach the required platelet concentration for experimenets. 
For preparation of human platelets, blood (9 volumes) from healthy volunteers was collected 
in sodium citrate (1 volume). EDTA was added to a final concentration of 5 mM and prp was 
obtained by centrifugation at 300 g for 20 min. Prp was mixed 1:1 with PBS containing 5 mM 
EDTA and was centrifuged at 380 g in the presence of PGI2 (0.1 µg/ml) and apyrase 
(0.02 U/ml) for 20 min at RT. After two washing steps (Tyrode’s buffer with PGI2 and 
apyrase), pelleted platelets were resuspended in Tyrode’s buffer containing 2 mM Ca2+ and 
0.02 U/ml apyrase. 
 
2.2.4.2 Platelet counting 
For determination of platelet count and size, 50 µl blood were obtained from the retroorbital 
plexus of anesthetized mice using heparinized microcapillaries and collected into an 1.5 ml 
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reaction tube containing 300 μl heparin in TBS (20 U/ml, pH 7.3). PBS was added to receive 
a final 1:20 dilution and the sample was analyzed with a Sysmex KX-21N automated 
hematology analyzer. 
 
2.2.4.3 Flow cytometric analysis of platelets 
50 µl of blood were collected in 300 µl heparin in TBS (20 U/ml, pH 7.3) and 1 ml Tyrode’s 
buffer without Ca2+ was added. 50 µl of diluted blood were stained for 15 min at RT with 
saturating amounts of fluorophore-conjugated antibodies and analyzed directly after addition 
of 500 µl PBS.  
To analyze platelet activation responses, blood samples were washed twice (2,800 rpm, 
5 min, RT) in Tyrode’s buffer without Ca2+ and finally resuspended in Tyrode’s buffer 
containing 2 mM Ca2+. Platelets were activated with appropriately diluted agonists for 7 min 
at 37°C followed by 7 min at RT in the presence of saturating amounts of PE-coupled JON/A 
(4H5) and FITC-coupled anti-P-selectin (5C8) antibodies. The reaction was stopped by 
addition of 500 μl PBS and samples were analyzed with a FACSCalibur flow cytometer using 
Cell QuestTM software (BD Biosciences, Heidelberg, Germany). Platelets were identified by 
their forward/side scatter (FSC/SSC) characteristics. Obtained data was analyzed using 
FlowJo v7 (TreeStar, Ashland, OR, USA). 
 
2.2.4.4 Determination of phosphatidylserine exposure 
Washed platelets were adjusted to a concentration of 5x104/µl in Tyrode’s buffer containing 
2 mM Ca2+. 50 µl of this suspension was used for activation with agonists for 15 min at 37°C 
in the presence of DyLight-488 coupled annexin V. The reaction was stopped by addition of 
Tyrode’s buffer with 2 mM Ca2+ and the samples were immediately analyzed with a 
FACSCalibur flow cytometer. 
 
2.2.4.5 Aggregometry 
50 µl washed platelet suspension or heparinized prp (for measurements with ADP) at a 
concentration of 0.5x106 platelets/µl were transferred into a cuvette containing 110 µl 
Tyrode’s buffer with 2 mM Ca2+. For all measurements with washed platelets, except those 
with thrombin as agonist, Tyrode’s buffer containing 100 µg/ml human fibrinogen was used. 
Agonists were added as 100-fold concentrates and light transmission was recorded over 10 - 
15 min with an Apact 4-channel optical aggregation system (APACT, Hamburg, Germany). 
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For calibration of each measurement, Tyrode’s buffer (for washed platelets) or plasma (for 
prp) was set as 100% aggregation and washed platelet suspension or prp was set as 0% 
aggregation, before the agonist was added. 
 
2.2.4.6 Protein phosphorylation studies 
For platelet signaling studies using phospho-specific antibodies, washed platelets were 
prepared as described in 2.2.4.1, but without BSA supplementation in the Tyrode’s buffer in 
the last washing step. Platelets were adjusted to a concentration of 0.7x106/µl in BSA- and 
Ca2+-free Tyrode’s buffer and supplemented with EDTA (5 mM final concentration (f.c.)), 
apyrase (2 mM f.c.) and indomethacin (10 µM f.c.) to avoid effects of second wave mediators 
and to block aggregation. Platelets were stimulated with 0.5 µg/ml CVX under stirring 
conditions in an aggregometer at 37°C and the stimulation was stopped by mixing the 
platelet suspension with an equal volume of ice-cold 2x lysis buffer. Afterwards, platelet 
lysates were centrifuged at 14,000 rpm for 10 min at 4°C and the supernatant was mixed 
with 4x SDS sample buffer and subjected to Western blot analysis as described above. 
For global tyrosine phosphorylation studies, using the 4G10 antibody, platelet lysates were 
mixed with 4x NuPAGE® LDS Sample Buffer and incubated at 70°C for 5 min. Samples were 
separated by SDS-PAGE using the NuPAGE Pre-cast gel system for electrophoresis with 
4 - 12% Bis-Tris gradient gels in a MOPS-buffered system, followed by transfer onto a PVDF 
membrane. Membranes were blocked for 1 h in 5% milk in TBS-T and then incubated 
overnight with the anti-phosphotyrosine antibody 4G10, diluted in 5% BSA. Further steps 
were performed as described in 2.2.2.1. 
 
2.2.4.7 Spreading assay 
Glass coverslips (24x60 mm) were coated with 100 μg human fibrinogen under humid 
conditions at 4°C overnight and blocked for at least 1 h at RT with 1% BSA in sterile PBS. 
The coverslips were rinsed with Tyrode’s buffer and 30 - 60 µl washed platelets 
(300,000 cells/μl in Tyrode’s containing 2 mM Ca2+) were stimulated with thrombin 
(0.01 U/ml) and immediately added to the fibrinogen surface. Platelets were allowed to 
spread at RT for the indicated time points, and then the process was stopped by addition of 
300 µl 4% PFA/PBS. Excessive liquid was removed and platelets were visualized by 
differential interference contrast (DIC) microscopy with a Zeiss Axiovert 200 inverted 
microscope (100x/1.4 oil objective). Representative images were taken using a CoolSNAP-
EZ camera (Visitron, Munich, Germany) and evaluated according to different platelet 
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spreading stages with ImageJ (National Institutes of Health, Bethesda, MD, USA). Spreading 
stages were defined as follows: 1: round, no filopodia, no lamellipodia. 2: only filopodia. 
3: filopodia and lamellipodia. 4: full spreading 
 
2.2.4.8 Adhesion under flow 
Coverslips (24x60 mm) were coated with 200 µg/ml fibrillar type-I collagen (Horm) overnight 
at 37°C and blocked for 1 h with 1% BSA at RT. Blood (700 μl) was collected into 300 μl 
heparin in TBS (20 U/ml, pH 7.3) and two parts of blood were diluted with one part Tyrode’s 
buffer with 2 mM Ca2+. Platelets were labeled with a DyLight-488 conjugated anti-GPIX Ig 
derivative (0.2 μg/ml) for 5 min at 37°C. The diluted blood was filled into a 1 ml syringe and 
connected to a transparent flow chamber with a slit depth of 50 μm, equipped with the coated 
coverslips. Perfusion was performed using a pulse-free pump under high shear stress 
equivalent to a wall shear rate of 1,000 s-1 for 4 min. Thereafter, coverslips were washed by a 
2 min perfusion with Tyrode’s buffer at the same shear rate and phase-contrast and 
fluorescent images were recorded from at least five different microscope fields (40x 
objective) using a Zeiss Axiovert 200 microscope equipped with a CoolSNAP-EZ camera. 
Image analysis was performed off-line using MetaMorph® software (Molecular Devices, 
Biberach an der Riss, Germany). Thrombus formation was expressed as the mean 
percentage of the total area covered by thrombi (= surface coverage) and as the mean 
integrated fluorescence intensity per mm2 (= thrombus size). 
 
2.2.4.9 Measurements of intracellular Ca2+ levels 
Washed platelets were adjusted to a concentration of approximately 0.4x106/µl in Ca2+-free 
Tyrode’s buffer. 100 µl of this suspension were loaded with 5 µM fura-2-AM in the presence 
of 0.2 µg/ml Pluronic F-127 for 25 min at 37°C. After labeling, the platelets were washed 
once and resuspended either in 500 µl Tyrode’s buffer containing 1 mM Ca2+ (for 
measurement of Ca2+ influx) of 2 mM EGTA (for measurements of store release). This cell 
suspension was transferred into a cuvette, which had been blocked for 30 min with 1% BSA 
in water at RT, and fluorescence was measured with a PerkinElmer LS 55 fluorimeter (Perkin 
Elmer, Waltham, MA, USA) under stirring conditions. Excitation was alternated between 340 
and 380 nm and emission was measured at 509 nm. Basal Ca2+ levels were recorded for 
50 s before the indicated reagent or agonist was added. Each measurement was calibrated 
using 1% Triton X-100 and EGTA. 
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2.2.4.10 Clot retraction 
Mice were bled from the retroorbital plexus under isoflurane anesthesia and up to 1 ml blood 
was collected into a 1.5 ml reaction tube containing 70 μl citrate. Platelets were isolated, 
washed once in Ca2+-free tyrode’s buffer and adjusted to a concentration of 3x105/µl in the 
pooled platelet poor plasma which was obtained during platelet isolation. 250 µl of the 
platelet suspension were mixed with 1 µl erythrocyte suspension in an aggregometry cuvette 
and supplemented with 20 mM CaCl2 (f.c.) for recalcification. Clot formation was induced by 
adding high concentrations of thrombin (5 U/ml f.c.). Clot retraction was recorded with a 
digital camera over a time span of 4.5 hours after activation. 
 
2.2.4.11 Shedding of glycoproteins from the platelet surface 
Washed platelets resuspended at a concentration of approximately 3x105/µL in Tyrode’s 
buffer containing 2 mM Ca2+ and 0.02 U/ml apyrase were treated for 1 h with CCCP 
(100 µM), W7 (150 µM), DMSO (vehicle control), for 20 min with NEM (2 mM) or for 15 min 
with PMA (50 ng/ml) at 37°C. Where indicated, platelets were pretreated with the calpain 
inhibitors calpeptin (5 µg/ml), ALLN (50 µM) or MDL 28170 (50 µM) and/or the broad range 
metalloproteinase inhibitor GM6001 (100 µM) for 15 min at 37°C, or with DMSO as a vehicle 
control. Alternatively, platelets were treated for 1 h with the platelet agonists CVX, CRP, 
rhodocytin or thrombin. Where indicated, aggregation of mouse platelets was inhibited with 
saturating concentrations of the integrin αIIbβ3 blocking antibody JON/A F(ab)2.204 
For flow cytometric analysis, a small sample volume was diluted 1:15 in PBS, stained with 
FITC-labeled antibodies and analyzed as described in 2.2.4.3.  
For detection of soluble CD84 (sCD84), samples were centrifuged at 2,800 rpm for 5 min at 
RT and the supernatants were analyzed using the CD84 ELISA system, as described below. 
For Western blot analysis, platelets were lysed by addition of a 4:1 mixture of 4x SDS sample 
buffer (non reducing) and 10% IGEPAL directly into the platelet suspension. Samples were 
boiled for 5 min at 95°C and subjected to Western blot analysis, as described in 2.2.2.1. 
 
2.2.4.12 Detection of cleaved soluble CD84 by ELISA 
Detection of soluble mouse CD84  
Nunc MaxiSorp™ plates were coated overnight with 50 µl of 10 µg/ml JER1 antibody, diluted 
in coating buffer. On the next day, the plates were washed 3 times with PBS-T and blocked 
for at least 1 h with 10% fat free milk in PBS. After one washing step, 50 µl of the 
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supernatant from platelets treated with different shedding inducing agents or agonists (see 
above), plasma or serum samples were transferred to the wells and incubated for 2 h at RT 
under slight agitation. After five washing steps, plates were incubated with biotinylated 
mCD84.7 antibody (10 µg/ml), diluted in 10% fat-free milk in PBS-T, for 1 h at RT (50 µl/well). 
Plates were washed five times and incubated for 45 min with HRP-labeled streptavidin, 
diluted 1:3000 in 1% fat-free milk in PBS-T (50 µl/well). After five washing steps, plates were 
developed using 3,3,5,5-tetramethylbenzidine (TMB). The reaction was stopped by addition 
of 2 M H2SO4 (50 µl/well) and absorbance at 450 nm and 620 nm (background) was 
measured with a Multiskan Ascent Plate Reader (Thermo Scientific). 
Detection of soluble human CD84 
The ELISA was performed in a similar way as the mouse sCD84 ELISA. MAX.3 antibody 
(10 µg/ml) was used for coating the plates, biotinylated 2G7 (5 µg/ml) served as the detection 
antibody. 
 
2.2.5 In vivo analyses of platelet function 
2.2.5.1 Intravital microscopy of FeCl3-injured mesenteric arterioles 
Mice (15 - 18 g body weight) were anesthetized and the mesentery was exteriorized through 
a midline abdominal incision. Arterioles with a diameter of 35 - 60 µm were visualized using a 
Zeiss Axiovert 200 inverted microscope (10x/0.25 air objective) equipped with a 100 W HBO 
fluorescent lamp and a CoolSNAP-EZ camera. Injury was induced by topical application of a 
3 mm2 filter paper saturated with 20% FeCl3. Adhesion and aggregation of fluorescently 
labeled platelets (achieved by previous intravenous injection of a DyLight-488 conjugated 
anti-GPIX Ig derivative) in arterioles was monitored for 40 min or until complete occlusion 
occurred (blood flow stopped for >1 min). When indicated, acetylsalicylic acid (Aspirin® i.v.; 
1 mg/kg body weight) was injected intravenously 10 min prior to the experiment. 
Digital images were recorded and analyzed using MetaMorph software. All FeCl3-injury 
experiments shown in this study were performed and evaluated by Martina Morowski in our 
research group. 
 
2.2.5.2 Mechanical injury of the abdominal aorta 
The abdominal cavity of anesthetized mice (20 - 26 g body weight) was opened by a 
longitudinal midline incision and the abdominal aorta was carefully exposed. A Doppler 
ultrasonic flow probe (Transonic Systems, New York, USA) was placed around the aorta and 
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mechanical injury was induced by firm compression with a forceps and blood flow was 
monitored for 30 min or until full occlusion. When indicated, acetylsalicylic acid (1 mg/kg 
body weight) was injected intravenously 10 min prior to the experiment. All aorta injury 
experiments shown in this study were performed by Martina Morowski in our research group. 
 
2.2.5.3 Bleeding time assay 
Mice were anesthetized using triple anesthesia (dormitor, dormicum and fentanyl) and a 
1 mm segment of the tail tip was cut off using a scalpel. Blood drops were gently absorbed 
every 20 s using a filter paper without touching the wound site. When no blood was observed 
on the paper, bleeding was determined to have ceased. Experiments were stopped after 
20 min by cauterization. When indicated, acetylsalicylic acid (1 mg/kg body weight) was 
injected intravenously 10 min prior to the experiment. 
 
2.2.5.4 Transient middle cerebral artery occlusion (tMCAO) model 
Experiments were conducted on 8 - 12 week old mice by Dr. Peter Kraft and colleagues in 
the group of Prof. Dr. Guido Stoll (Department of Neurology, University Hospital, Würzburg) 
according to the recommendations for research in mechanism-driven basic stroke studies.209 
tMCAO was induced under inhalation anesthesia with the intraluminal technique.210 Briefly, a 
midline neck incision was made and a standardized silicon rubber–coated 6.0 nylon 
monofilament (6021PK10, Doccol, Redlands, CA, USA) was inserted into the right common 
carotid artery and advanced via the internal carotid artery to occlude the origin of the middle 
cerebral artery. After 60 min, the filament was withdrawn to allow reperfusion.  
24 h after tMCAO the global neurological status was assessed by the Bederson score.211 
Motor function and coordination were graded with the grip test.212 
For determination of the ischemic brain infarct volume, mice were euthanized 24 h after 
induction of tMCAO and brain sections were stained with 2% 2,3,5-triphenyltetrazolium 
chloride (TTC; Sigma-Aldrich). Planimetric measurements were performed using ImageJ 
software and used to calculate lesion volumes, which were corrected for brain edema as 
described.213  
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2.2.6 Isolation and analyses of immune cells 
2.2.6.1 Isolation and processing of lymphoid tissues and blood cells 
Mice were sacrificed and spleen, thymus and lymph nodes (inguinal, brachial, axillary, 
superficial cervical, mesenteric and lumbal) were dissected and placed in PBS/ 1% FCS on 
ice. After collection of all tissues, organs were rubbed through 70 µm cell strainers with a 
plunger of a syringe to receive a single cell suspension. The suspensions were centrifuged in 
15 or 50 ml Falcon tubes at 480 g for 5 min at 4°C (Heraeus Multifugen3S-R). Next, lymph 
node and thymus cell pellets were resuspended in an appropriate volume (≈ 5 ml) of cell 
medium or PBS/ 1% FCS for counting. Cell pellets from spleen cells were depleted from red 
blood cells by resuspension 5 ml ACK buffer (hypo-osmotic shock). Supernatant was then 
rinsed through a 70 µm cell strainer into a 15 or 50 ml Falcon tube and, after refilling with 
PBS/ 1% FCS, centrifuged as before. Finally, cell pellets were resuspended in an appropriate 
volume for counting (5 - 10 ml).  
Cell counts were determined with a Sysmex KX-21N automated hematology analyzer or with 
a counting chamber, using trypan blue staining to exclude dead cells.  
To isolate immune cells from the blood compartment, blood was drawn from the retroorbital 
plexus with heparinized microcapillaries and collected in 1.5 ml reaction tubes containing 
heparin. Samples were centrifuged at 2,800 rpm for 5 min at RT and the blood cell pellet was 
resuspended in ACK buffer (resuspension volume: 1.5 ml for samples up to 100 µl and 10 ml 
for samples of 700 µl blood). Samples were centrifuged at 2,800 rpm for 5 min and the 
supernatant and red blood cell debris was aspirated. Cell pellets were resuspended in 
PBS/ 1% FCS. 
 
2.2.6.2 Flow cytometric analysis of immune cells 
Usually, the volumes for 1x106 cells of single cell suspensions were transferred into a v-
bottomed 96-well plate, filled with FACS buffer and washed by centrifugation for 3 min at 
480 g. The supernatant was discarded and the Fc-receptors were blocked by resuspension 
of cells in 25 µl FACS buffer containing 2.4G2 antibody (10 µg/ml f.c.) and incubation for at 
least 15 min on ice. Next, appropriately diluted antibodies were added in a volume of 25 µl 
FACS buffer, resulting in a total staining volume of 50 µl. After a minimum incubation time of 
15 min on ice in the dark, cells were washed in FACS buffer, resuspended and transferred 
into an appropriate tube for FACS analysis and measured in a total volume of about 300 µl 
FACS buffer.  
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For intracellular staining of Ki-67, Foxp3 and cytotoxic T lymphocyte antigen 4 (CTLA-4) 
expression, the cells were first blocked and then stained with antibodies directed against 
surface antigens, as described above. For fixation and permeabilization, cells were washed 
once with FACS buffer and resuspended in 100 µl of freshly prepared Foxp3 fixation/ 
permeabilization buffer, and then incubated for at least 30 min at RT in the dark. Then the 
fixation reagent was removed by washing the cells with permeabilization buffer. The cells 
were blocked for 30 min on ice in 25 µl of a 1:50 dilution of rat serum in permeabilization 
buffer. Next, antibodies, appropriately diluted in 25 µl permeabilization buffer, were added 
and allowed to bind for at least 30 min on ice. After two washing steps (the first one in 
permeabilization buffer, the second one in FACS buffer), the cells were ready for flow 
cytometric analysis as described above. 
Measurements of immune cells were carried out on a FACSCaliburTM flow cytometer using 
Cell QuestTM software or on a FACSCanto™ II operating with FACSDiva™ software (BD 
Biosciences, Heidelberg, Germany). Compensation was performed prior to each experiment. 
Obtained data was analyzed using FlowJo v7. Dot plots and histograms are shown as log10 
fluorescence intensities on a four-decade scale. 
 
2.2.6.3 Isolation of CD4+ T cells 
CD4+ T cells were purified from lymph node cell suspensions and red blood cell depleted 
spleen cell suspensions of wt or Stim1Sax/+ mice by magnetic depletion of cells positive for 
CD8, CD45R (B220), CD11b (Mac1), Ter-119 or CD16/CD32 using the Dynal® Mouse CD4 
negative isolation kit and the MACSiMAG™ Separator (Miltenyi Biotec, Bergisch Gladbach, 
Germany). When cells were isolated from pure lymph node suspensions, the amount of 
beads was reduced to 1/3 of the manufacturer’s recommendation. Cell count of the purified 
cells was determined as described above. The cell purity of CD4+ T cells, as assessed by 
flow cytometry (CD4+CD3+ cells), was 93% or higher. 
 
2.2.6.4 In vitro stimulation of T cells for signaling studies (anti-CD3 crosslinking) 
Either lymph node cells or purified CD4+ T cells (see above) were used for these 
experiments. When lymph node cells were used, comparable frequencies of B and T cells 
between wt and Stim1Sax/+ samples were confirmed by flow cytometry.  
Freshly isolated CD4+ T cells were allowed to rest for at least 1 h at a cell concentration of 
about 5x106/ml in cell culture medium at 37°C in the incubator before being subjected to the 
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next steps. When indicated, cyclosporin A (10 µg/ml f.c.) or DMSO, as vehicle control, was 
added to the media. 
The cells were centrifuged at 480 g for 5 min and adjusted to a concentration of 1x106/ml in 
ice cold PBS containing either 0 or 2 mM Ca2+. When indicated, cyclosporin A (10 µg/ml f.c.) 
or DMSO, as vehicle control, was added to the buffer. Hamster anti-mouse CD3ε antibody 
was added at a final concentration of 10 µg/ml and cells were incubated for 15 - 20 min on 
ice. To remove unbound antibody, additional buffer was added and the cells were centrifuged 
at 480 g at 4°C for 5 min. Next, cells were resuspended at a concentration of 1x106/ml in 
their respective buffer (at RT), spread into four 1.5 ml reaction tubes and briefly incubated at 
37°C in a Thermomixer. Stimulation was initiated by addition of 10 µl prediluted goat anti-
armenian hamster IgG (110 µg/ml) per 100 µl cell suspension resulting in a final antibody 
concentration of 10 µg/ml. Incubation was stopped by addition of ice cold PBS and 
centrifugation at 14,000 rpm for 5 min at 4°C. Finally, the supernatant was removed and the 
cell pellets were either frozen or directly lysed in lysis buffer.  
 
2.2.6.5 Cell fractionation for determination of NFAT localization 
CD4+ T cells were stimulated as described above. Cell pellets were washed twice in PBS and 
then resuspended in hypotonic lysis-buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, 
pH 7.5; 60 µl for 1x106 cells). After 15 min incubation on ice, cells were transferred onto a 
QiaShredder Column (Qiagen, Hilden, Germany) and centrifuged at 14,000 rpm for 2 min at 
4°C. To separate the nuclear from the cytosolic fraction, the flowthrough was centrifuged for 
15 min at 800 rpm at 4°C. The supernatant (= cytosolic fraction) was collected and the 
remaining nuclei were washed twice in hypotonic wash buffer (10 mM Tris-HCl, 10 mM NaCl, 
3 mM MgCl2, 0.5% IGEPAL; pH 7.5). Finally, the purified nuclei were lysed with hypertonic 
lysis buffer (20 mM Tris-HCl, 280 mM NaCl, 10 mM NaF, 2% Triton X 100; pH 7.5; 60 µl for 
1x106 cells) and centrifuged at 12,500 rpm for 10 min at 4°C. The supernatant was collected 
for Western blotting. The cell fractionation of CD4+ T cells depicted in this thesis was 
performed by Dr. Christoph Hintzen. 
 
2.2.6.6 Measurement of IP3 production  
8x106 lymph node cells were centrifuged in an 1.5 ml reaction tube and adjusted to a 
concentration of 1x106 cells/ml (800 µl) in a modified phosphate-free Tyrode’s buffer, 
containing 0.2% BSA, 50 mM LiCl2 and either 0 or 2 mM CaCl2. Hamster anti-mouse CD3ε 
antibody was added at a final concentration of 10 µg/ml and cells were incubated for 
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15 - 20 min on ice. To remove unbound antibody, additional buffer was added and the cells 
were centrifuged at 2,800 rpm at 4°C for 5 min. Next, cells were resuspended at a 
concentration of 1x106/ml (800 µl) in their respective buffer (at RT) and briefly incubated at 
37°C in a Thermomixer. The cells were activated by addition of 80 µl prediluted goat anti-
armenian hamster IgG (110 µg/ml), resulting in a final antibody concentration of 10 µg/ml for 
15 min at 37°C (300 rpm). After stimulation, the cells were centrifuged at 2,800 rpm for 5 min 
at RT and the pellet was lysed in 133 µl lysis buffer provided within the IP-ONE ELISA kit.  
50 µl of lysed lymph node cells were used for the IP1 ELISA assay which was used with the 
following modifications: Standard, IP1-conjugate and the monoclonal antibody were diluted 
1:1 in assay dilutent and instead of the kit’s plate, a Nunc MaxiSorp™ plate, coated with 
10µg/ml goat-anti mouse antibody, was used for the experiments. 
The T cell and B cell frequencies were determined for each sample by flow cytometry to 
ensure comparability between wt and Stim1Sax/+ samples. 
 
2.2.6.7 Determination of cytokine levels 
For in vitro stimulation of T cells, 24-well plates were coated with 300 µl of hamster anti-
mouse CD3ε antibody (10 µg/ml in PBS) and incubated at 4°C overnight. The next day, wells 
were washed twice with PBS, before 2x106 splenocytes, in a volume of 1 ml cell culture 
medium, were transferred into each well. Untreated plates served as negative control. After 
48 h of incubation, the cell supernatants were transferred into 1.5 ml reaction tubes and 
centrifuged at 14,000 rpm for 5 min. Supernatants were frozen at -20°C for later analysis. 
Alternatively, 1x106 splenocytes in 1 ml cell culture medium were stimulated with 25 µl 
Dynabeads® Mouse T-Activator CD3/CD28 beads, according to the manufacturer’s 
instruction. 
Cytokine levels in cell culture supernatants were determined with the ELISA kits listed in the 
“Materials” section in combination with Nunc MaxiSorp™ plates, according to the 
manufacturer’s instruction.  
 
2.2.7 Statistical analysis 
If not stated otherwise, the results shown are mean ± SD. When applicable, a modified t-test 
(Welch’s test) was used to analyze differences between two groups. The Fischer’s exact test 
was applied to assess variance in occurrence of occlusion. For analysis of more than two 
groups, one-way Anova and the Bonferroni multiple comparison post-hoc test were applied. 
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For analysis of the Bederson score and the grip test analysis, the Mann-Whitney-U-test was 
applied. p-values <0.05 were considered as statistically significant (*), p<0.01 (**) and 
p<0.001 (***). 
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3 Results 
3.1 Investigation of T cell receptor signaling in Stim1Sax/+ mice  
STIM1 is established as an essential mediator of SOCE in lymphocytes67 and platelets.14 
Substitution of critical aspartate and glutamate residues within the EF-hand motif of STIM1 
has been previously shown to abolish Ca2+ binding and to render the protein constitutively 
active in vitro129,150 and in vivo,149 resulting in continuous Ca2+ influx and elevated intracellular 
Ca2+ levels ([Ca2+]i) (see introduction). T cells from mice with such a STIM1-activating 
mutation (D84G, Stim1Sax/+ mice) exhibited no obvious overt phenotype, but were not studied 
in detail so far. Therefore, one aim of this thesis was to investigate the impact of elevated 
[Ca2+]i on TCR signaling and T cell function using Stim1Sax/+ mice. These signaling studies 
were performed in collaboration with the group of Dr. Heike Hermanns (Rudolf Virchow 
Center for Experimental Biomedicine, Würzburg). 
 
3.1.1 Normal T cell development in Stim1Sax/+ mice 
To confirm the previous observation of unaltered T cell development and distribution in 
Stim1Sax/+ mice,149 lymphocyte frequencies in lymphoid organs were determined by flow 
cytometry. In line with the previous results, thymocyte subset composition based on CD4 and 
CD8 expression was indistinguishable between wildtype (wt) and Stim1Sax/+ mice, indicating 
normal T cell development (Figure 3-1 A). Likewise, the prevalence of CD4+ and CD8+ cells 
(CD4+ and CD8+) and B cells (B220+) in lymph nodes and spleen did not differ significantly. 
In spleen a slight tendency towards lower lymphocytes frequencies was observed (Figure 
3-1 A), which most likely originates from the disproportionately high expansion of non-
lymphoid cells (149 and data not shown). Similar to lymph node and spleen, the blood cell 
composition of Stim1Sax/+ mice was comparable to wt mice, except for a slight, but significant 
increase in Gr-1lowCD11b+ myelomonocytic cells (Figure 3-1 B). Stim1Sax/+ mice developed a 
pronounced splenomegaly, and, in contrast to the observation of Grosse et al.,149 an 
elevation of total spleen cell numbers was observed (Figure 3-1 C). 
 
3.1.2 NFAT resides in the nucleus of Stim1Sax/+ CD4+ T cells in the absence of 
stimulation 
One of the major effects of Ca2+ influx into T cells is the activation of the Ca2+/calmodulin-
dependent phosphatase calcineurin, which dephosphorylates nuclear factor of activated T  
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Figure 3-1 Unaltered T cell development and lymphocyte subsets in Stim1Sax/+ mice. (A) 
Thymocyte subsets (upper panel) and lymphocyte subsets in lymph nodes and spleen (middle and 
lower panel) of wt and Stim1Sax/+ were analyzed by flow cytometry. Representative dot plots are shown 
on the left, bar graphs depict the mean population frequencies ± SD. (B) Flow cytometric analysis of 
blood immune cell composition. (C) Total spleen cell numbers in wt and Stim1Sax/+ mice. (n≥3 per 
group); * p<0.05 and ** p<0.01 
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cells (NFAT), thereby facilitating its transfer from the cytoplasm into the nucleus (Figure 
3-2 A).68 Therefore, it was investigated whether the elevation in [Ca2+]i which had previously 
been observed in Stim1Sax/+ T cells149 is sufficient to induce the translocation of NFAT into the 
nucleus. To this aim, CD4+ T cells isolated from wt and Stim1Sax/+ animals were stimulated by 
antibody-mediated crosslinking of the CD3 receptor (further on also termed anti-CD3 
crosslinking), mimicking TCR-dependent activation. The lysates of these cells were 
separated into a nuclear and cytoplasmic fraction and NFAT levels in each fraction were 
determined by Western blotting (Figure 3-2 B). In the presence of extracellular Ca2+, NFAT 
was found to be localized almost exclusively in the cytoplasmic fraction in non-stimulated wt 
CD4+ T cells, but rapidly shifted into the nucleus within 2 minutes after stimulation. This 
translocation was transient since NFAT was equally distributed between the two fractions 
after 5 minutes of stimulation and finally, 15 minutes after the stimulus, the initial cytoplasmic 
localization was re-established. In sharp contrast, NFAT was found to be localized in the 
nucleus of Stim1Sax/+ CD4+ T cells at every time point examined, even in the absence of 
stimulation. 
 
 
Figure 3-2 NFAT always resides in the nucleus in Stim1Sax/+ CD4+ T cells in the presence of 
extracellular Ca2+. (A) Schematic representation of the NFAT shuttling mechanism between 
cytoplasm and nucleus; CaM, calmodulin; GSK3, glycogen synthase kinase 3 (B) Analysis of NFAT 
localization. CD4+ T cells were preincubated with anti-CD3 antibody, followed by crosslinking with a 
secondary antibody for the indicated time points in the presence or absence of extracellular Ca2+.The 
cell lysates were fractionated into the cytoplasmic (c) and the nuclear (n) fraction and samples were 
subjected to Western blotting and stained with an anti-NFAT antibody. GAPDH and LSD1 were used 
to control the purity of the cytoplasmic and nuclear fraction, respectively. 
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In the absence of extracellular Ca2+, both the stimulation-induced NFAT translocation in wt 
CD4+ T cells as well as constitutive localization of NFAT in the nucleus of Stim1Sax/+ CD4+ 
T cells were abolished, highlighting the importance of extracellular Ca2+ influx in this process. 
These data clearly indicated that the continuous Ca2+ influx triggered by the Stim1Sax 
mutation results in intracellular Ca2+ levels sufficient to activate the phosphatase calcineurin 
and to promote NFAT translocation. 
 
3.1.3 Altered phosphorylation of PLCγ1 in Stim1Sax/+ CD4+ T cells due to 
calcineurin activity 
In the next experiment, the impact of elevated [Ca2+]i on the TCR proximal signaling steps 
was investigated. For this, the phosphorylation status of essential proteins in the TCR-
signaling pathway was analyzed by Western blotting. Stimulation of wt and Stim1Sax/+ CD4+ T 
cells by anti-CD3 crosslinking resulted in a comparable and transient phosphorylation of Lck, 
a member of the Src kinase family which initiates TCR signaling by phosphorylation of the 
ITAMs within the TCR-associated CD3 chains (Figure 3-3). Similarly, ZAP-70, a kinase 
binding to phosphorylated ITAMs and a substrate of Lck, became phosphorylated 2 minutes 
after stimulation to a similar extent in CD4+ T cells of wt and Stim1Sax/+ mice. Moreover, 
phosphorylation patterns were not affected by the withdrawal of extracellular Ca2+ (Figure 
3-3), indicating that extracellular Ca2+ influx does not affect these signaling events at the 
proximal end of the TCR signaling cascade.  
 
Figure 3-3 Impaired PLCγ1 phosphorylation in the presence, but not in the absence of 
extracellular Ca2+ in Stim1Sax/+ CD4+ T cells. Wt and Stim1Sax/+ CD4+ T cells were stimulated by 
antibody-crosslinking of the CD3 receptor for the indicated time points in the presence (2 mM) or 
absence (w/o) of extracellular Ca2+. Cell lysates were subjected to Western blotting and the membrane 
was probed with the indicated antibodies. 
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To investigate downstream signaling events, the phosphorylation status of PLCγ1 was 
analyzed using a phospho-specific antibody directed against tyrosine 783 (Y783). 
Phosphorylation of PLCγ1 at this site has been reported to be required for the enzyme’s 
activity.214,215 Strikingly, while in wt CD4+ T cells phosphorylation of PLCγ1 became clearly 
visible 2 and 5 minutes after activation, phosphorylation of PLCγ1 at Y783 was completely 
abolished in Stim1Sax/+ CD4+ T cells. However, this was only observed in the presence of 
extracellular Ca2+, since phosphorylation of PLCγ1 at Y783 was completely restored upon 
withdrawal of Ca2+ from the medium (Figure 3-3). Hence, it can be concluded that the 
continuous Ca2+ influx, triggered by the Stim1Sax mutation, interferes with proper 
phosphorylation of PLCγ1 in CD4+ T cells. 
The permanent localization of NFAT inside the nucleus of Stim1Sax/+ CD4+ T cells implicated 
constitutive calcineurin activity. To investigate a possible impact of calcineurin on the 
phosphorylation status of PLCγ1, CD4+ T cells were pretreated with the calcineurin inhibitor 
cyclosporin A (CsA) in Ca2+ containing buffer. In wt CD4+ T cells, CsA treatment had virtually 
no effect on PLCγ1 phosphorylation (Figure 3-4, upper panel). In marked contrast, CsA 
rescued the phosphorylation of PLCγ1 at Y783 in Stim1Sax/+ CD4+ T cells, resulting in a 
comparable phosphorylation pattern as observed under Ca2+-free conditions (Figure 3-4, 
lower panel). Therefore, calcineurin activity is involved in the translation of elevated [Ca2+]i 
into impaired PLCγ1 phosphorylation in Stim1Sax/+ CD4+ T cells. 
 
Figure 3-4 Impaired phosphorylation of PLCγ1 in Stim1Sax/+ CD4+ T cells can be rescued by CsA. 
CD4+ T cells were stimulated by antibody-crosslinking of the CD3 receptor for the indicated time points 
in the presence (2 mM) or absence (w/o) of extracellular Ca2+. When indicated, cells were pretreated 
with CsA. Cell lysates were subjected to Western blotting and stained with anti-p-PLCγ1 (Y783) 
antibody and reprobed with anti-PLCγ1 antibody.  
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3.1.4 Despite alterations in the phosphorylation pattern, the enzymatic activity 
of PLCγ1 in Stim1Sax/+ CD4+ T cells is unaltered 
Phospho-specific antibodies directed against critical residues are a powerful and easy to use 
tool to directly visualize the phosphorylation status of distinct amino acids. However, the 
drawback of this technique is that phosphorylation of a single residue may not reflect the 
protein’s catalytic activity, especially when a protein possesses various phosphorylation 
sites. To address this issue, PLCγ1 was immunoprecipitated, transferred onto a membrane, 
and its overall tyrosine phosphorylation status was analyzed using the pan anti-phospho-
tyrosine antibody 4G10. T cells from Stim1Sax/+ mice clearly exhibited PLCγ1 phosphorylation 
upon stimulation in the presence of extracellular Ca2+ despite the loss of phosphorylation at 
Y783, however, to a slightly lesser extent than wt T cells (Figure 3-5). This indicated that 
other tyrosine residues than Y783 become phosphorylated at PLCγ1 in Stim1Sax/+ T cells. To 
show this directly, a phospho-specific antibody against the activation-induced 
phosphorylation site Y771216,217 was tested. Surprisingly, this antibody revealed elevated 
phosphorylation of PLCγ1 at this tyrosine residue in Stim1Sax/+ T cells when extracellular Ca2+ 
was present. Analogous to phosphorylation at Y783, but with opposing effect, withdrawal of 
extracellular Ca2+ abolished the enhanced phosphorylation at Y771 in Stim1Sax/+ T cells,  
 
 
Figure 3-5 Altered phosphorylation pattern of PLCγ1 in Stim1Sax/+ T cells. Wt and Stim1Sax/+ lymph 
node cells were stimulated by anti-CD3 crosslink for 2 min or left untreated, in the presence (2 mM) or 
absence (w/o) of extracellular Ca2+. PLCγ1 was immunoprecipitated and the samples were blotted and 
stained with 4G10 (total pY) or anti-p-PLCγ1 antibodies (either specific for Y771 or Y783). Membranes 
were reprobed with anti-PLCγ1 antibody as a loading control. 
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resulting in a signal similar to wt cells. In summary, this data shows that the continuous Ca2+ 
influx, triggered by the Stim1Sax mutation, leads to changes in the phosphorylation pattern of 
PLCγ1 on at least two different tyrosine residues, where both, abolished (Y783) as well as 
elevated (Y771) phosphorylation can be observed. 
To investigate the consquences of these alterations of PLCγ1 phosphorylation on the 
enzyme’s activity, indirect measurements of inositol-1,4,5-trisphosphate (IP3) production 
were performed using an IP1 ELISA (Figure 3-6). The intracellular half life of IP3 is very short 
before it is transformed to IP2 and IP1. Addition of LiCl (50 mM) to the cell medium blocks IP1 
degradation leading to its accumulation. Therefore, wt and Stim1Sax/+ T cells were stimulated 
by anti-CD3 crosslinking for 15 minutes and the IP1 production was quantified.  
 
Figure 3-6 Unaltered PLCγ1 activity in Stim1Sax/+ mice. Quantification of produced IP1 upon 
stimulation. Lymph node cell suspensions from wt and Stim1Sax/+ mice were left untreated or 
stimulated by anti-CD3 crosslink for a time frame of 15 min. Cells were lysed and IP1, a specific 
metabolite of IP3, was quantified using an ELISA assay. Results are given as the mean IP1 
concentration (nM) ± SD (n=3 per group). 
Neither in the presence (corresponding to an altered phosphorylation pattern of Stim1Sax/+ 
PLCγ1), nor in the absence of extracellular Ca2+, differences in IP1 production between wt 
and Stim1Sax/+ T cells were measured, implicating normal catalytic activity of PLCγ1 in mutant 
cells. Of note, withdrawal of extracellular Ca2+ resulted in generally decreased IP1 production 
in wt and Stim1Sax/+ samples, when compared to the respective counterparts that had been 
stimulated in the presence of Ca2+ (Figure 3-6). To conclude, the alterations in PLCγ1 
phosphorylation induced by continuous Ca2+ influx did not translate into functional changes of 
PLCγ1 activity. 
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3.1.5 Impaired Th2-type cytokine production of Stim1Sax/+ T cells 
So far, the immediate impact of the Stim1Sax mutation and accompanying Ca2+ influx on 
signaling proteins downstream of the TCR in the first minutes after stimulation had been 
described. To gain insight into the functional, long-term consequences of elevated [Ca2+]i and 
the constitutive nuclear NFAT localization, the ability of Stim1Sax/+ T cells to control cytokine 
production was investigated. T cells in spleen cell suspensions were stimulated with plate-
bound anti-CD3 antibody and the levels of various cytokines in the cell supernatant were 
determined 48 h later. Proliferation of both wt and Stim1Sax/+ T cells became apparent by a 
change in color of the cell medium and increased size of T cells (data not shown). A robust 
and comparable production of the Th1-type cytokines IFNγ, IL-2 and TNFα, as well as of IL-3 
and IL-6 was measured, while IL1α was not detectable in the supernatants of cells from both 
mouse lines (Figure 3-7). In sharp contrast, Stim1Sax/+ T cells produced significantly less Th2-
type cytokines, namely IL-4, IL-5 and IL-13 (IL-4: 380 ± 168 vs. 102 ± 36 ng/ml; p<0.05; IL-5: 
250 ± 86 vs. 60 ± 56 ng/ml p<0.01; IL-13: 4398 ± 638 vs. 1278 ± 417 ng/ml; p<0.001) and 
also exhibited a tendency towards less IL-10 (4720 ± 1733 vs. 2623 ± 1112 ng/ml; p=0.058).  
Similar results were observed when splenocytes were stimulated with beads coated with 
anti-CD3 and anti-CD28 antibodies (data not shown). Furthermore, comparable changes in 
the cytokine profile of Stim1Sax/+ T cells were observed on the mRNA level by RT-PCR after 
anti-CD3/CD28 bead-stimulation of purified CD4+ T cells for 3 or 6 hours (Christoph Hintzen, 
personal communication). Of note, control samples of wt and Stim1Sax/+ splenocytes that had 
been cultured in the absence of stimulation, did not show any signs of proliferation and 
released no cytokines into the supernatant. Likewise, no or negligibly low cytokine levels 
were observed in plasma of either mice (data not shown). 
 
Figure 3-7 Impaired production of IL-4, IL-5 and IL-13 in Stim1Sax/+ mice. Freshly isolated 
splenocytes from wt or Stim1Sax/+ mice were cultured at 2x106 cells/ml with 10 µg/ml of plate-bound 
anti-CD3 for 48 h. Cytokine levels were determined in the supernatant by ELISA. Bars represent 
means ± SD (n≥4 per group); * p<0.05; ** p<0.01; *** p<0.001. n.d., not detectable 
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In summary, T cells from Stim1Sax/+ mice showed impaired production of Th2-type cytokines, 
but despite permanent nuclear NFAT localization, did not exhibit spontaneous proliferation or 
cytokine production in the absence of a stimulus. 
 
3.1.6 High prevalence of regulatory T cells in the spleen of Stim1Sax/+ mice 
Since it has previously been shown that the absence of STIM1 and STIM2 in T cells results 
in abolished Ca2+ influx and defective development and function of Tregs,163 the impact of 
continuous Ca2+ influx on Tregs was analyzed. Interestingly, Stim1Sax/+ mice exhibited a 
pronounced elevation of Treg (CD4+ Foxp3+) frequencies in spleen (wt: 11.03 ± 1.50% vs. 
Stim1Sax/+: 18.02 + 2.76% of CD4+ cells; p<0.01), but not in blood or lymph nodes, where 
normal or only slightly increased frequencies were found, respectively (Figure 3-8 A and B). 
The increase in Treg population was already observed in spleens of 6-week old Stim1Sax/+ 
mice (data not shown). Corrected for the increased splenic cell numbers (Figure 3-1 C), the 
elevation in Treg frequencies resulted in an approximately 2-fold increase  
 
 
Figure 3-8 Elevated Treg numbers in Stim1Sax/+ spleens. (A) Treg frequencies were determined in 
blood, lymph nodes and spleen by flow cytometry (% of Foxp3+ events within the CD4+ cell 
population). (B) Representative dot plots depicting Treg populations in spleen of wt and Stim1Sax/+ 
mice. (C) Absolute numbers of Tregs in spleen of wt and Stim1Sax/+ mice. (D) CD25 and CTLA-4 
expression of splenic Tregs, as determined by flow cytometry. Bars represent means ± SD (n≥3 per 
group); * p<0.05; ** p<0.01 
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of the Treg numbers in Stim1Sax/+ spleens compared to wt controls (wt: 1.36 ± 0.34 x106 vs. 
Stim1Sax/+: 2.88 ± 0.31 x106 cells; p<0.01, Figure 3-8 C). Flow cytometric analysis of receptor 
surface expression detected a tendency to decreased levels of the α-chain of the high-affinity 
IL-2 receptor, CD25, and a significantly reduced expression of CTLA-4 (mean fluorescence 
intensity (MFI) wt: 44.81 ± 2.24 vs. Stim1Sax/+ 36.85 ± 0.89; p<0.05) of splenic Stim1Sax/+ 
Tregs (Figure 3-8 D). Of note, no alterations in CTLA-4 or CD25 expression were observed 
on lymph node Tregs (data not shown). 
Regulatory T cells can either be generated in the thymus or extrathymically by proliferation or 
peripheral conversion. To test whether the elevated Treg cell numbers originated from 
enhanced Treg generation in the thymus, the frequency of Tregs in the CD4+ CD8- thymocyte 
population was determined. As depicted in Figure 3-9 A, the frequencies of Tregs were 
comparable between wt and Stim1Sax/+ mice, indicating unaltered Treg development. This is 
in accordance with the expression of Helios, a proposed marker for thymus-derived Tregs,218 
which was similar in wt and Stim1Sax/+ splenic Tregs (Figure 3-9 B).  
 
 
Figure 3-9 Unaltered Treg generation and proliferation in Stim1Sax/+ mice. (A) Treg frequencies in 
thymus (% of Foxp3+ events within the CD4+CD8- cell population) and (B) frequency of Helios+ Tregs 
in spleen were determined by flow cytometry. Right to the bar graphs, representative dot plots are 
depicted. (C) Populations of Ki67+ Treg (CD4+ Foxp3+) and conventional (CD4+ Foxp3-) T cells were 
determined by flow cytometry. Bars represent means ± SD (n≥3 per group). 
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Next, the proliferation of Tregs was assessed by the use of an antibody against Ki-67, a 
protein exclusively expressed in dividing, but not in resting cells.219 The frequency of 
proliferating (Ki-67+) Tregs was similar in spleens of 6-week-old mice and not significantly 
decreased in 3-month-old mice, when compared to the respective wt littermates (Figure 
3-9 C). Of note, proliferation of conventional T cells (non-Treg; CD4+ Foxp3-) was also 
comparable between wt and Stim1Sax/+ animals, excluding non-proportional proliferation of 
different cell type subsets as the origin of elevated Treg frequencies. 
Hence, neither enhanced generation of Tregs in the thymus nor exaggerated proliferation in 
the periphery appear to be the sole cause for the elevated Treg numbers in the spleen of 
Stim1Sax/+ animals. 
 
 
3.2 Analysis of Grb2-deficiency in platelets 
Grb2 is an ubiquitously expressed adapter protein involved in growth factor receptor and 
ITAM-coupled receptor signaling.94,98 In B cells108,109 and thymocytes,107 Grb2-deficiency 
resulted in opposing effects on signaling of the BCR and pre-TCR, respectively. Although it 
has been shown that Grb2 becomes phosphorylated upon GPVI/ITAM signaling and upon 
spreading, its role in platelet development and physiology remains unclear. Therefore, this 
part of the thesis investigates the role of Grb2 in platelet activation and development, with a 
special focus on (hem)ITAM receptor signaling. These experiments were performed together 
with Dr. Sebastian Dütting in our research group. 
 
3.2.1 Grb2 is dispensable for platelet generation  
To analyze the role of Grb2 in platelet physiology and development in vivo, mice with a MK- 
and platelet-specific deletion were generated, since constitutive Grb2-deficiency results in 
early embryonic lethality due to defective endoderm differentiation.105 Therefore, mice 
carrying two loxP sites flanking exon 2 of the Grb2 gene (Grb2fl)108 were intercrossed with 
transgenic mice expressing Cre-recombinase under the control of the platelet/MK-specific 
platelet factor 4 (PF4) promoter (Pf4-cre+/-).206 In the resulting Grb2fl/fl/Pf4-Cre+/- mice (further 
on referred to as Grb2-/- mice) absence of Grb2 in platelets was confirmed by Western blot 
analysis, whereas the protein was still present in splenocytes (Figure 3-10 A). 
Grb2fl/fl/Pf4-Cre-/- littermates (further on referred to as Grb2+/+ or wt) served as wt controls in 
the experiments.  
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Figure 3-10 Specific deletion of Grb2 in platelets does not impair platelet production. 
(A) Analysis of Grb2 expression in wt (Grb2+/+), Grb2+/- and Grb2-/- platelets and splenocytes by 
Western blot analysis. Expression of β3 integrin (GPIIIa) and actin were used as loading controls. (B) 
Peripheral platelet counts and (C) platelet volume of wt and Grb2-/- mice measured with a blood cell 
counter are depicted. Results are mean ± SD of 7 mice per group. (D) Expression of glycoproteins on 
the platelet surface was determined by flow cytometry. Data are expressed as MFI ± SD (n=4) and are 
representative of 3 individual experiments. (Dütting,* Vögtle* et al., Circ Res 2013)220 
Grb2-/- mice were born in Mendelian ratios, appeared healthy and did not show any signs of 
spontaneous bleeding (Table 3-1 and data not shown). Platelet count and platelet size, as 
determined with an automated blood cell counter, as well as the surface expression of major 
platelet glycoproteins, did not differ from wt controls (Figure 3-10 B - D). This data indicated 
that Grb2 is dispensable for platelet formation. 
 
Table 3-1 Offspring from matings of Grb2fl/fl/Pf4-cre-/- with Grb2fl/fl/Pf4-cre+/- mice. 
Genotype number of mice frequency expected frequency 
Grb2fl/fl/Pf4-cre-/- 283 51.8% 50% 
Grb2fl/fl/Pf4-cre+/- 263 48.2% 50% 
total 546 100% 100% 
 
 
3.2.2 Diminished responses to GPVI and CLEC-2 stimulation, but unaltered 
integrin outside-in signaling in Grb2-/- platelets 
To determine whether the lack of Grb2 had functional consequences on platelet activation, 
platelets were stimulated with different agonists inducing ITAM-coupled or G protein-coupled 
receptor (GPCR) signaling and analyzed by flow cytometry. Two markers for platelet 
activation were used: Activation of the αIIbβ3 integrin was assessed with the JON/A-PE 
antibody, which specifically binds the activated conformation of the integrin,204 and 
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degranulation was measured by surface expression of P-selectin, which is stored in α-
granules in resting platelets and becomes exposed to the platelet surface upon activation-
induced granule fusion with the plasma membrane.  
Grb2-deficient platelets showed normal responses to the GPCR agonists thrombin, ADP and 
the stable TxA2 analogue U46619 (Figure 3-11). In contrast, integrin activation and P-selectin 
exposure upon stimulation of the ITAM-coupled collagen receptor GPVI, either with collagen-
related peptide (CRP) or the snake venom toxin CVX were severely reduced in Grb2-
deficient platelets. This defect was apparent at high as well as at low agonist concentrations. 
Moreover, impaired platelet activation was also observed in response to rhodocytin, a snake 
venom toxin that activates platelets via the hemITAM receptor CLEC-2. This defect was, 
however, less pronounced than the one observed for GPVI, since the reduction in integrin 
activation became apparent only at low, but not at high agonist concentrations (Figure 3-11). 
 
 
Figure 3-11 Impaired αIIbβ3 integrin activation and degranulation in response to (hem)ITAM-
coupled receptor agonists. Flow cytometric analysis of integrin αIIbβ3 activation (upper panel) and 
degranulation-dependent P-selectin exposure (lower panel) in response to the indicated agonists in wt 
and Grb2-/- platelets. Results are MFI ± SD of 4 mice per group and representative of 4 individual 
experiments. RC, rhodocytin; U46, U46619; * p<0.05, ** p<0.01 and *** p<0.001. (Dütting,* Vögtle* et 
al., Circ Res 2013)220 
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Platelets of mice heterozygous for the deletion of the Grb2 gene (Grb2fl/+/Pf4-Cre+/-; Grb2+/-), 
had reduced levels of Grb2 (Figure 3-10). In flow cytometry, these platelets exhibited an 
intermediate phenotype when stimulated with GPVI agonists, indicating that Grb2 regulates 
GPVI signaling in a quantitative manner (Figure 3-12 A). 
Furthermore, the integrin activation response was compared to mice deficient in LAT, 
another adapter protein that has been shown to be involved in platelet (hem)ITAM receptor 
signaling and to interact with Grb2 in different cell types.31,79 Like in Grb2-/- platelets, no 
defects in response GPCR agonists was observed in platelets of LAT-deficient mice. 
However, the (hem)ITAM receptor signaling defect was more pronounced in Lat-/- platelets as 
compared to Grb2-/- platelets, especially for CLEC-2 (Figure 3-12 B).  
In summary, Grb2-deficiency resulted in defects of (hem)ITAM receptor signaling, with the 
strongest effects observed for GPVI, while leaving GPCR signaling fully intact. 
 
Figure 3-12 Grb2-deficiency produces a milder phenotype than LAT deficiency. Flow cytometric 
analysis of integrin αIIbβ3 activation in response to the indicated agonists in (A) wt, Grb2+/- and Grb2-/- 
platelets and (B) wt, Lat-/- and Grb2-/- platelets. Results are MFI ± SD of 4 mice per group and 
representative of 2 individual experiments. RC, rhodocytin; U46, U46619; * p<0.05, ** p<0.01 and 
*** p<0.001 as compared to the respective group. 
To investigate how these defects in integrin activation and degranulation affected the ability 
of Grb2-/- platelets to aggregate, ex vivo aggregation studies were performed. In line with the 
data from the flow cytometry studies, platelets from Grb2-/- animals aggregated normally 
upon stimulation with the GPCR agonists thrombin, U46619 and ADP at every agonist 
concentration tested (Figure 3-13). In contrast, the response to the GPVI agonists CRP and 
collagen was partially impaired at intermediate and abrogated at low agonist concentrations 
in Grb2-deficient platelets. Similarly, no aggregation of Grb2-/- platelets was observed at low 
doses of the CLEC-2 agonist rhodocytin. The observed defects, however, were overcome at 
high agonist concentrations, where light transmission traces of Grb2-/- platelets reached 
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similar maximal aggregation rates as wt platelets, but showed a slightly delayed aggregation 
onset. 
 
 
Figure 3-13 Impaired aggregation response of Grb2-/- platelets in response to (hem)ITAM 
receptor agonists. Washed platelets from wt (black line) and Grb2-/- (gray line) mice were activated 
with the indicated concentrations of ADP, U46619, thrombin, collagen, CRP or rhodocytin and light 
transmission was recorded on a Fibrintimer 4-channel aggregometer. ADP measurements were 
performed in platelet rich plasma (prp), all other measurements were performed in buffer in the 
presence of 100 μg/ml human fibrinogen (except for thrombin). Representative aggregation traces of 
at least 3 individual experiments are depicted. (Dütting,* Vögtle* et al., Circ Res 2013)220 
Ligand binding to integrin αIIbβ3 triggers outside-in signaling, leading to cytoskeletal 
reorganization and platelet spreading.13 It has been proposed that Grb2 plays a role in this 
process as well as in the formation of actin-rich protrusions.114,221 To test this directly, Grb2-/- 
and wt platelets were allowed to spread on a fibrinogen-coated surface in the presence of 
low concentrations of thrombin. Grb2-/- and wt platelets formed filopodia and lamellipodia to 
the same extent with similar kinetics resulting in comparable numbers of fully spread 
platelets after 30 minutes (Figure 3-14 A). Likewise, no differences in spreading between wt 
and Grb2-/- platelets were observed when the experiments were performed in the presence of 
apyrase and indomethacin, to inhibit second wave mediators, in the presence as well as 
absence of thrombin (data not shown). 
Another process that depends on integrin outside-in signaling is clot retraction.222 Therefore, 
clot formation in prp was induced by addition of a high dose of thrombin (5 U/ml) and 20 mM 
CaCl2. The subsequent clot retraction was monitored over time, but differences between wt 
and Grb2-deficient platelets were neither observed in the kinetics of the retraction process 
(Figure 3-14 B) nor in the volumes of the extruded fluid (wt: 94.4 ± 2.8% vs. Grb2-/-: 90.7 ± 
6.3% of initial volume). 
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Figure 3-14 Unaltered integrin outside-in signaling in Grb2-/- platelets. (A) Washed platelets of wt 
and Grb2-/- mice were allowed to spread on fibrinogen (100 μg/ml) for 30 min after stimulation with 
0.01 U/ml thrombin. Representative differential interference contrast images of 2 individual 
experiments (left) and statistical evaluation of the percentage of spread platelets at different spreading 
stages (right). 1: round, 2: only filopodia, 3: filopodia and lamellipodia, 4: fully spread. (B) Clot 
retraction of prp upon activation with 5 U/ml thrombin in the presence of 20 mM CaCl2 at the indicated 
time points (n=3 for wt and n=7 for Grb2-/-). (Dütting, Vögtle et al., Circ Res 2013)220 
In summary, the results from the clot retraction and spreading experiments indicated that 
Grb2 is not required for αIIbβ3 signaling processes. 
 
3.2.3 Defective Ca2+ mobilization in Grb2-/- platelets in response to the GPVI 
agonist CRP 
Agonist-induced platelet activation initiates signaling cascades that lead to PLC activity and 
subsequent IP3 production. IP3 in turn releases Ca2+ from intracellular stores, thereby 
triggering Ca2+ influx from the extracellular space inside the cell. This process, termed 
SOCE, is required for proper platelet activation (see introduction). 
To investigate whether the observed GPVI signaling defect was based on impaired Ca2+ 
signaling, we studied agonist-induced changes in [Ca2+]i fluormetrically.  
Store release, measured as elevation in [Ca2+]i in the absence of extracellular Ca2+ in 
response to thrombin was unaltered in Grb2-/- platelets as compared to wt controls (Figure 
3-15 A and B). In line with this, Ca2+ influx in the presence of extracellular Ca2+ was also 
indistinguishable between wt and knock-out. In contrast, store release in Grb2-/- platelets 
upon stimulation with CRP was severely impaired (wt: 113 ± 9 nM vs. Grb2-/-: 68 ± 15 nM; 
p<0.01). Similarly, the influx of Ca2+ in response to CRP was reduced in duration and 
amplitude (wt: 345 ± 48 nM vs. Grb2-/-: 156 ± 55 nM; p<0.05; Figure 3-15 A, B). Notably, 
induction of SOCE by passive store depletion with the SERCA pump inhibitor thapsigargin 
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(TG) did not lead to any differences in the kinetics of Ca2+ mobilization between wt and 
Grb2-/- platelets (Figure 3-15 C and D). This demonstrated that the defects seen for CRP are 
due to GPVI signaling defects and not to alterations in the store content or changes in the 
SOCE machinery. 
 
Figure 3-15 Defective GPVI-induced Ca2+ mobilization. (A) Time course of intracellular Ca2+ 
mobilization in wt (black line) and Grb2-/- platelets (gray line) in response to thrombin and CRP 
(addition indicated by an arrow). The experiment was performed in the absence (0.5 mM EGTA, upper 
panel) and in the presence (1 mM CaCl2, lower panel) of extracellular Ca2+. (B) Maximal increase of 
intracellular Ca2+ concentration (∆[Ca2+]i) of wt and Grb2-/- platelets after activation with the indicated 
agonists (thrombin 0.05 U/ml, CRP 1 μg/ml). (C) Time course of intracellular Ca2+ mobilization after 
treatment with thapsigargin (TG, upper panel). The measurement was started in Ca2+-free medium 
and Ca2+ was added after 350 s of recording. The boxed area comprises the time frame prior to 
addition of extracellular Ca2+ and is shown magnified in the lower panel. (D) Maximal increase of 
[Ca2+]i after treatment with TG in the presence and absence of extracellular Ca2+. 
The traces shown in (A) and (C) are representative of at least 3 individual experiments. Results in (B) 
and (D) are given as mean ∆[Ca2+]i (nM) ± SD, n=3-4 per group. * p<0.05 and ** p<0.01 (Dütting,* 
Vögtle* et al., Circ Res, 2013)220 
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3.2.4 Grb2-/- platelets exhibit impaired procoagulant activity and defective 
aggregate formation on collagen under flow  
Upon activation platelets expose negatively charged phosphatidylserine (PS) on their outer 
surface thereby providing a platform for key activators of the coagulation system. Since it is 
well established that this process requires prolonged high intracellular Ca2+ levels,9 the 
impact of impaired Ca2+ mobilization in Grb2-/- platelets on procoagulant activity was 
investigated. To do so, wt and Grb2-/- platelets were stimulated with different agonists and PS 
exposure was measured by binding of DyLight-488 labeled annexin V in flow cytometry 
(Figure 3-16). Upon platelet stimulation with a combination of thrombin and CRP, as well as 
with a high dose of rhodocytin (1 µg/ml), the majority of wt platelets exposed PS on their 
surface. In sharp contrast, in Grb2-deficient platelets only partial responses were observed 
under these conditions (CRP + thrombin: wt: 90 ± 3% vs. Grb2-/-: 37 ± 6% annexin V+ 
platelets; p<0.001 rhodocytin: wt: 90 ± 3% vs. Grb2-/-: 28 ± 9%; p<0.001). Furthermore Grb2-/- 
platelets displayed virtually abolished PS exposure in response to weaker stimuli which still 
produced a profound PS exposure in wt platelets.  
 
Figure 3-16 Defective procoagulant activity of Grb2-/- platelets. Flow cytometric analysis of PS 
exposure in response to the indicated agonists in wt and Grb2-/- platelets. Washed platelets were 
stimulated with the indicated agonists and stained with annexin V-DyLight-488 in the presence of 
Tyrode’s buffer containing 2 mM Ca2+. Results are percentage of annexin V positive platelets ± SD of 
6 wt and 5 Grb2-/- mice and representative of 2 individual experiments. Thr, thrombin; RC, rhodocytin. 
** p<0.01 and *** p<0.001. (Dütting,* Vögtle* et al., Circ Res, 2013)220 
In summary, these results demonstrated a prominent role for Grb2 in facilitating (hem)ITAM-
induced coagulant activity in platelets. 
So far, platelet function of Grb2 under static or stirring conditions was analyzed. At sites of 
vascular injury, however, platelet adhesion and aggregation are critically influenced by shear 
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forces. Furthermore, released second-wave mediators become rapidly diluted in flowing 
blood. Therefore, to address the function of Grb2 under more physiological conditions, 
platelet adhesion and thrombus formation on a collagen-coated surface under flow in an ex 
vivo whole blood perfusion system were analyzed. When blood from wt animals was 
perfused over immobilized collagen at a shear rate of 1000 s-1, the platelets rapidly adhered 
and formed aggregates that grew into large three-dimensional thrombi within the 4 minutes 
observation period (Figure 3-17). In sharp contrast, adhesion of Grb2-/- platelets was 
markedly reduced, and the subsequent formation of stable three-dimensional aggregates 
was virtually abrogated. As a consequence, the surface area covered by platelets and the 
thrombus volume at the end of the perfusion period were reduced by approximately 94% in 
Grb2-/- platelets (p<0.001) compared to wt (Figure 3-17). 
These results demonstrated that Grb2 is essential for ex vivo platelet adhesion and 
aggregate formation on collagen under flow conditions. 
 
Figure 3-17 Impaired adhesion and defective aggregate formation of Grb2-/- platelets on 
collagen under flow. (A) Whole blood from wt or Grb2-/- mice was perfused over a collagen-coated 
surface (0.2 mg/ml) at a shear rate of 1000 s-1. Representative phase contrast images (upper panel) 
and fluorescence images (lower panel) of aggregate formation on collagen after 4 min of perfusion 
time. Bar, 50 µm. (B) Means of surface coverage (left) and relative thrombus volume, expressed as 
integrated fluorescence intensity (IFI) (right) ± SD of 4 wt and 5 Grb2-/- mice. *** p<0.001 (Dütting,* 
Vögtle* et al., Circ Res, 2013)220 
3.2.5 Impaired hemostasis and partially defective arterial thrombus formation 
in Grb2-/- mice 
To investigate the role of Grb2 in hemostasis, a tail bleeding time assay was performed. After 
cutting off a 1 mm segment of the tail tip, bleeding in wt animals usually ceased within 400 s 
and averaged at 197 ± 107 s (Figure 3-18). Grb2-/- mice, however, exhibited prolonged 
(381 ± 237 s; p<0.001) and highly variable bleeding times, suggesting thrombus instability. A 
similar phenotype has also been described for other mouse lines with defects in (hem)ITAM 
signaling, e.g. mice deficient in the adapter protein LAT.88 
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Figure 3-18 Impaired hemostasis in Grb2-/- mice. A 1 mm 
segment of the tail tip of anesthesized mice was cut off using 
a scalpel. Blood drops were absorbed every 20 s using a 
filter paper without touching the wound site until bleeding 
ceased. Each symbol represents the bleeding time of one 
animal. *** p<0.001. (Dütting,* Vögtle* et al., Circ Res, 
2013)220 
 
 
In the next step, the requirement of Grb2 in platelets for thrombus formation in vivo was 
addressed by subjecting Grb2-/- mice to two different models of arterial thrombosis. These 
experiments were performed in collaboration with Martina Morowski in our laboratory. In the 
first model, the abdominal aorta was mechanically injured by firm compression with a forceps 
and blood flow was monitored with an ultrasonic Doppler flow probe. In this model thrombus 
formation occurs in a highly GPVI/PLCγ2-dependent manner, since GPVI-deficient mice do 
not occlude.223 In the wt control group, 13 out of 14 animals formed vessel occluding thrombi 
within 10 minutes (mean occlusion time: 303 ± 101 s; Figure 3-19 A). Unexpectedly, Grb2-/- 
mice formed occlusive thrombi with similar kinetics and frequencies (occlusion in 11/12 
animals; mean occlusion time: 351 ± 98 s). Comparable results were also obtained in the 
second model of arterial thrombosis, where mesenterial arterioles are chemically injured by 
topical application of FeCl3 and thrombus formation is more dependent on soluble 
mediators.224 Both wt and mutant animals formed thrombi within a similar time frame (mean 
occlusion time: wt: 16.14 ± 5.71 min vs. Grb2-/-: 12.56 ± 1.94 min; Figure 3-19 B). These 
results argue against a prominent role of Grb2 in intravascular thrombus formation. 
Ischemic stroke is the second leading cause of death and severe disability worldwide.3 
Platelets are critically involved in its pathogenesis by mechanisms involving GPIb and GPVI 
dependent platelet adhesion and activation,225 but the exact underlying mechanisms remain 
unknown. To investigate how Grb2 deficiency impacts ischemic stroke, mice were 
challenged in the transient middle cerebral artery occlusion (tMCAO) model of experimental 
focal cerebral ischemia. These experiments were performed in close collaboration with Dr. 
Peter Kraft (research group of Prof. Dr. Guido Stoll; Department of Neurology, University of 
Würzburg) 
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Figure 3-19 Unaltered thrombus formation and stroke outcome in Grb2-/- mice. (A, B) Time to 
stable vessel occlusion of wt and Grb2-/- mice upon vascular injury. (A) The abdominal aorta was 
injured by firm compression with a forceps and blood flow was monitored with an ultrasonic flow probe 
for 30 min or until full vessel occlusion. Each symbol represents one animal. (B) Small mesenteric 
arterioles were injured by topical application of FeCl3 and thrombus formation of platelets 
(fluorescently labeled) was monitored using intravital microscopy. Each symbol represents one 
arteriole. (C-E) Consequences of cerebral ischemia induced by tMCAO. (C) The infarct volumes were 
determined by TTC staining of coronal brain sections 24 h after tMCAO. Bars represent mean infarct 
volumes ± SD of 7 wt vs. 8 Grb2-/- animals. (D) Bederson score and (E) grip test assessed 24 h after 
tMCAO. Each symbol represents one animal. 
Transient cerebral ischemia in this model was induced by advancing a filament through the 
carotid artery into the middle cerebral artery. This reduces the cerebral blood flow by more 
than 90%. After 1 h the thread was withdrawn to allow reperfusion and mice were analyzed 
24 h later. 
The volume of the infacted area, apparent as white tissue in 2,3,5-triphenyltetrazolium 
chloride (TTC) stained coronal brain sections, were comparable in wt and Grb2-/- mice (mean 
infarct volume: wt: 97 ± 38 mm3 vs. Grb2-/-: 83 ± 20 mm3; p=0.41; Figure 3-19 C). In 
accordance with these results, wt and mutant mice were indistinguishable in their Bederson 
scores, assessing global neurological function and in the grip test, which assesses motor 
function and coordination of the mice (Figure 3-19 D, E). In conclusion, Grb2 is dispensable 
for ischemic brain infarction following tMCAO.  
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The absence of a protective effect of Grb2 deficiency in in vivo models of arterial thrombisis 
and ischemic brain infarction was surprising in face of the robust GPVI signaling defects of 
Grb2-/- platelets observed in vitro and ex vivo. As a possible explanation, defective GPVI 
signaling may be compensated in vivo by agonists that stimulate GPCR-dependent signaling 
pathways, for example by TxA2, as shown previously.226 
To test the importance of costimulatory signals on platelet activation, wt and Grb2-/- platelets 
were stimulated with an intermediate dose of CRP in combination with the GPCR agonist 
ADP or the stable TxA2 analogue U46619 and analyzed for integrin activation and P-selectin 
exposure in flow cytometry. As depicted in Figure 3-20 A, ADP and U46619 alone only 
induced mild integrin activation and no P-selectin exposure in wt and mutant platelets. 
Consistent with the role of GPCR agonsits as amplifiers of platelet activation,10 wt platelets 
treated with a GPCR agonist together with CRP exhibited strong integrin activation and P-
selectin exposure. Detailed analysis revealed that the MFIs upon costimulation significantly 
exceeded the hypothetical values that would have been expected under the assumption of 
additive agonist effects (Figure 3-20 B, upper panel). Thus, this observation clearly points 
towards synergistic effects of GPCR and GPVI agonists. Strikingly, these synergistic effects 
were even more pronounced in Grb2-/- platelets (Figure 3-20). Despite the weak potency of 
CRP, U46619 or ADP to induce integrin activation or P-Selectin exposure in mutant platelets 
alone, combinations of CRP with U46619 or ADP resulted in robust responses. This became 
especially apparent upon costimulation with CRP and ADP, where the MFIs of Grb2-/- 
platelets reached values similar to those observed for wt platelets stimulated with CRP alone. 
However, the response of Grb2-deficient platelets to any CRP/GPCR agonist combination 
remained significantly weaker compared to the respective wt samples. Direct comparison of 
the measured MFIs to the hypothetical MFIs, that would have resulted from additive effects 
of the agonists, clearly revealed the strong synergistic effects of GPVI and GPCR agonists in 
Grb2-deficient platelets, that exceeded the additive effects by a factor up to 3. (Figure 3-20 
B, lower panel) 
In summary, these experiments demonstrated that (i) GPCR and GPVI signaling pathways 
synergize in platelet activation and (ii) that the residual signaling capacity of GPVI in Grb2-
deficient platelets may be of functional relevance in the presence of other agonists.  
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Figure 3-20 Costimulation of Grb2-/- platelets with CRP and GPCR agonists results in strong 
synergistic effects. (A) Flow cytometric analysis of integrin αIIbβ3 activation (upper panel) and 
degranulation-dependent P-selectin exposure (lower panel) in response to the indicated combinations 
of agonists in wt and Grb2-/- platelets. Results are MFI ± SD of 3-4 mice per group and representative 
of 2 individual experiments. U46, U46619. * p<0.05, ** p<0.01 and *** p<0.001 as compared to wt 
controls. (B) Alternative presentation of the data in A, upper panel, highlighting the synergistic effects. 
MFIs from GPCR stimulated platelets are opposed to the MFIs of platelets stimulated with the 
respective GPCR agonist in combination with 1 µg/ml CRP. Wt platelets are shown in the upper panel, 
Grb2-/- platelets in the lower. Dashed lines represent hypothetical values that would have resulted from 
sole additive effects of the GPCR agonist and CRP (MFI [GPCR agonist only] + (MFI [CRP only] – MFI 
[resting])). * p<0.05, ** p<0.01 and *** p<0.001 comparing values of costimulated platelets with the 
respective calculated value, assuming additive effects (dashed line). 
The next goal was to collect evidence for a compensatory role of GPCR signaling in vivo. 
Therefore, it was intended to inhibit GPCR signaling in vivo and to investigate the outcome 
on thrombosis and hemostasis in wt and Grb2-/- mice. Clopidogrel and acetylsalicylic acid 
(ASA, or Aspirin®) are widely used antithrombotics, which interfere with GPCR signaling by 
blocking P2Y receptors or TxA2 production, respectively. Clopidogrel, however, was not 
suitable for the planned studies, since previous experiments by others have demonstrated a 
severe impairment of thrombus formation in wt mice,227 which would make it difficult to detect 
differences between wt and Grb2-/- mice. In contrast, treatment with ASA has only mild 
effects on hemostasis and thrombosis in wt mice226,227 and furthermore TxA2-induced 
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signaling has previously been shown to partially compensate for the loss of GPVI.226 
Therefore, mice received 1 mg/kg body weight ASA intravenously 10 minutes prior to 
experiments. This concentration resembles the dose recommended for primary prevention of 
cardiovascular disease.228  
In a first set of experiments, platelets from wt and Grb2-/- mice treated with ASA were 
subjected to aggregometry and their ability to aggregate upon stimulation with collagen was 
compared to platelets of untreated mice. It is well established that under these conditions 
platelet aggregation is amplified by the release of second wave mediators, e.g. ADP and 
TxA2.32 As depicted in Figure 3-21, ASA treatment had little effect on the aggregation 
response of wt platelets. The light transmission traces of platelets from ASA treated animals 
reached comparable maximal aggregation values at all tested collagen concentrations, but a 
slight delay in aggregation onset was observed at lower agonist concentrations. This 
indicated a minor requirement for TxA2-mediated amplification of the aggregation process in 
the presence of intact GPVI signaling. In contrast, ASA treatment of Grb2-/- mice led to 
impaired aggregation compared to untreated Grb2-/- mice at intermediate collagen 
concentrations. This became apparent especially at a collagen concentration of 3 µg/ml, at 
which the full aggregation response of Grb2-deficient animals was almost completely 
abolished upon pretreatment with ASA. As already mentioned, ASA pretreatment did not 
impair the response of wt platelets to the same collagen concentration (Figure 3-21).  
In conclusion, these experiments revealed that TxA2 can partially compensate for impaired 
GPVI signaling. Consequently, inhibition of TxA2 production by a low dose of ASA raised the 
required concentration of the GPVI agonist collagen necessary to induce full platelet 
aggregation in Grb2-/- mice. 
 
 
Figure 3-21 ASA treatment raises the threshold concentration required for thrombus formation 
in Grb2-/- mice. Washed platelets from wt (black lines) and Grb2-/- (gray lines) mice, treated or not with 
ASA (1 mg/kg i.v.) 10 min prior to bleeding, were activated with the indicated concentrations of 
collagen and light transmission was recorded on a Fibrintimer 4-channel aggregometer. The 
aggregation traces shown are representative of 2 measurements. 
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Having demonstrated the functional relevance of the inhibition of TxA2 production in vitro, 
ASA treated animals were subjected to the tail bleeding time assay and the previously 
mentioned in vivo thrombosis models. 
In the model of mechanical injury of the abdominal aorta, ASA treatment had no significant 
effect on thrombus formation in wt mice; vessel occlusion was observed in 14 of 15 animals 
(mean occlusion time: 296 ± 84 s, Figure 3-22 A). Strikingly, a strong effect was seen in the 
 
 
Figure 3-22 Impaired thrombus formation in Grb2-/- mice upon treatment with ASA. (A, B) Time 
to stable vessel occlusion of wt and Grb2-/- mice without or with ASA treatment (1 mg/kg i.v.) 10 min 
before the start of the experiment. (A) The abdominal aorta was injured by firm compression with a 
forceps and blood flow was monitored for up to 30 min. (B) Small mesenteric arterioles were injured by 
topical application of FeCl3 and thrombus formation was investigated by intravital microscopy. (C) Tail 
bleeding times of wt and Grb2-/- mice without or with ASA treatment (1 mg/kg i.v.) 10 min before the 
start of the experiment. Each symbol represents one animal (A, C) or one arteriole (B). * p<0.05, 
** p<0.01 and *** p<0.001. The data for untreated animals is the same as shown in Figure 3-19 and 
Figure 3-18. (Dütting,* Vögtle* et al., Circ Res, 2013)220 
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mutant mice where 7/17 vessels did not occlude (p<0.05), and occlusion times for the 
remaining vessels were increased compared to the wt group (419 ± 99 s; p<0.01). 
Similar effects were observed in the model of FeCl3-induced injury of mesenteric arterioles. 
Albeit treatment of Grb2-/- mice did not prevent vessel occlusion in this model, the mean time 
to occlusion was significantly prolonged compared to ASA-treated wt mice (wt: 17.89 ± 4.13 
min vs. Grb2-/-: 25.73 ± 5.20 min, p<0.01; Figure 3-22 B). These findings confirm that the 
GPVI signaling defect in these animals is at least in part compensated for by TxA2-dependent 
activation pathways in vivo. 
In contrast, ASA treatment prolonged tail bleeding times of wt and Grb2-/- mice to a similar 
extent (Figure 3-22 C). 
 
3.2.6 Grb2 stabilizes the LAT signalosome  
To characterize the molecular basis of Grb2 in transmitting (hem)ITAM-mediated signaling, 
signaling studies were performed. Grb2 was immunoprecipitated from lysates of untreated 
platelets or platelets stimulated with the GPVI agonist CVX and samples were analyzed 
using a pan anti-phospho-tyrosine (anti-pY) antibody (4G10). This antibody is extremely 
sensitive and thus can detect small amounts of co-immunoprecipitated proteins. 
As depicted in Figure 3-23 A, few tyrosine phosphorylated proteins (approx. 38, 50, 95 and 
150 kDa) were immunoprecipated from stimulated wt lysates, but not from Grb2-/- lysates, 
confirming the specificity of the system. Very prominent was the band at 38 kDa that most 
likely represents LAT since (i) this protein is well established to appear at this size in anti-pY 
blots,26 (ii) LAT has been reported to interact with Grb2 (see introduction) and (iii) 
immunoprecipitation (IP) of LAT itself yielded a band at the same size (Figure 3-23 A). 
Confirmation that the 38 kDa band corresponded to LAT came from the group of our 
collaboration partner, Prof. Dr. Steve Watson (University of Birmingham, UK). In their 
experiments, LAT was directly identified with a specific antibody in Grb2-IPs from lysates of 
wt mouse platelets stimulated with the GPVI agonist CRP or the CLEC-2 agonist rhodocytin 
(Figure 3-23 B). These results are in line with previous results obtained with human 
platelets31 and demonstrated that Grb2 forms part of the LAT signalosome in mouse platelets 
upon induction of (hem)ITAM receptor signaling. 
Comparison of the tyrosine phosphorylation patterns of whole cell lysates from wt and Grb2-/- 
platelets revealed no global impairment of tyrosine phosphorylation events in Grb2-deficient 
platelets (Figure 3-23 A, lanes WCL). Most of the bands coming up after stimulation with 
CVX had the same intensity in wt and Grb2-/- platelets with the prominent exception of two 
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bands comigrating with LAT (38 kDa) and PLCγ2 (approx. 150 kDa) that were weaker in the 
samples of mutant platelets. A possible explanation would be that signal transduction upon 
GPVI signaling is disrupted during transmission from the cell surface to the effector proteins. 
 
Figure 3-23 Grb2 interacts with LAT upon stimulation with (hem)ITAM receptor agonists. 
(A) Washed platelets (7x108/ml) from wt and Grb2-/- mice were stimulated with 0.5 μg/ml CVX in the 
presence of indomethacin (10 µM) and apyrase (2 U/ml) under stirring conditions for 30 s at 37°C. 
Grb2 and LAT were immunoprecitated, the proteins were separated by SDS-Page and transferred 
onto a PVDF membrane. The membrane was probed with an anti-pY mAb (4G10) and reprobed with 
anti-Grb2 and anti-actin antibodies. (B) Washed platelets (5x108/ml) were stimulated with 10 µg/ml 
CRP or 300 nM rhodocytin (RC) for 90 s and subsequently lysed with NP-40 detergent. Grb2 was 
immunoprecipitated and proteins were transferred onto a PVDF membrane. The membrane was 
probed with an anti-pY mAb (4G10), and reprobed with anti-LAT and anti-Grb2 antibodies. Figure (B) 
was kindly provided by Dr. Craig Hughes from the group of Prof. Dr. Steve Watson. WB, Western 
blotting; WCL, whole cell lysate. (Dütting,* Vögtle* et al., Circ Res, 2013)220 
To address this further, wt and Grb2-/- platelets were stimulated with the strong GPVI agonist 
CVX and changes in protein tyrosine phosphorylation of key components of the ITAM 
signaling cascade were further analyzed by Western blotting. Stimulation of GPVI induces 
Src-dependent phosphorylation of the FcR γ-chain ITAM, enabling the docking and activation 
of Syk. This tyrosine kinase initiates a downstream signaling cascade, that involves formation 
of a protein complex comprising LAT, SLP-76, Vav1/Vav3, Tec family kinases and PI3K and 
culminates in the activation of PLCγ2 (see introduction and 12). Notably, Syk phosphorylation 
at Y519/520, which has been reported to reflect the kinase’s activity,229 was  
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Figure 3-24 Defective ITAM-induced signaling in Grb2-/- platelets. (A) Washed platelets (7x108/ml) 
from wt and Grb2-/- mice were stimulated with 0.5 μg/ml CVX in the presence of indomethacin (10 µM) 
and apyrase (2 U/ml) under stirring conditions at 37°C. Aliquots were taken at the indicated time points 
and subsequently lysed with NP-40 detergent. Proteins were separated by reducing SDS-PAGE, 
blotted on a PVDF membrane, and stained using the indicated phospho-specific antibodies. Staining 
of the respective non-phosphorylated proteins or actin served as loading controls. The result shown is 
representative for three individual experiments. (B) Washed platelets (5x108/ml) were stimulated with 
0.5 μg/ml CVX in the presence of indomethacin (10 µM) and apyrase (2 U/ml) for the indicated time 
points and subsequently lysed with NP-40 detergent. Syk, LAT, SLP-76, Vav1, Vav3, and PLCγ2, 
were immunoprecipitated and proteins were separated by SDS-PAGE and transferred to a PVDF 
membrane. The membrane was probed with an anti-pY mAb (4G10), and reprobed with anti-Syk, LAT, 
SLP-76, Vav1, Vav3, and PLCγ2 antibodies. WB, Western blotting; WCL, whole cell lysate (Dütting,* 
Vögtle* et al., Circ Res, 2013)220 
maintained in Grb2-deficient animals, indicating normal Syk activation (Figure 3-24 A). In 
contrast, phosphorylation of LAT at Y136 (corresponding to Y132 in human), the high affinity 
binding site for PLCγ2, and at Y195 (Y191 in human), which is bound by Grb2 and 
contributes to PLCγ2 activation,79 was strongly reduced in Grb2-deficient platelets compared 
to wt platelets, resulting in reduced phosphorylation of PLCγ2 (Y759; Figure 3-24 A). These 
results were confirmed and further expanded by IP studies of our collaboration partners in 
Birmingham (Figure 3-24 B): Proteins upstream of the LAT signalosome, namely FcR γ-chain 
and Syk exhibited unaltered overall tyrosine phosphorylation in Grb2-/- platelets, while 
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phosphorylation of proteins within or downstream of the LAT signalosome, like SLP-76, LAT, 
Vav3 and PLCγ2, was strongly impaired. These results position Grb2 as a central adapter 
molecule within the LAT signalosome in platelets, stabilizing the protein complex by direct 
association, thereby enabling downstream signaling and platelet activation. 
Analogous to the GPVI signaling studies, platelets were also stimulated with rhodocytin, an 
agonist of the hemITAM receptor CLEC-2, to analyze the role of Grb2 in the signaling 
pathway downstream of this receptor. Like for GPVI, phosphorylation of proteins located 
upstream of the LAT signalosome, most importantly CLEC-2 itself and Syk, was not affected 
in Grb2-deficient platelets, while phosphorylation of proteins within or downstream the LAT 
signalosome was reduced (Figure 3-25). Of note, although the decrease in LAT 
phosphorylation in Grb2-/- platelets appeared to be similar defective after GPVI or CLEC-2 
stimulation, the effect of Grb2 deficiency on PLCγ2 phosphorylation was milder after CLEC-2 
stimulation (Figure 3-24 vs. Figure 3-25).  
 
Figure 3-25 Impaired hemITAM signaling in Grb2-/- platelets. (A, B) Washed platelets (7x108/ml (A) 
or 5x108/ml (B)) from wt and Grb2-/- mice were stimulated with 2.0 μg/ml rhodocytin (RC) in the 
presence of indomethacin (10 µM) and apyrase (2 U/ml) under stirring conditions at 37°C. Aliquots 
were taken at the indicated time points and the sample were processed as in Figure 3-24. WB, 
Western blotting; WCL, whole cell lysate (Dütting,* Vögtle* et al., Circ Res, 2013)220 
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Grb2 is an established mediator of Ras-mitogen activated protein (MAP) kinase signaling in 
receptor tyrosine kinase, as well as in BCR and TCR signaling. In platelets, the MAP kinases 
p38, JNK and ERK1/2 are activated upon stimulation with various agonists, but the 
knowledge about their function and signaling pathways is limited.230 Therefore, MAP kinase 
signaling in Grb2-deficient platelets was investigated in collaboration with Carmen Schäfer 
from the group of Dr. Heike Hermanns (Rudolf Virchow Center for Experimental Biomedicine, 
Würzburg). Interestingly, Grb2-deficient platelets stimulated with CVX exhibited an impaired 
phosphorylation of ERK1/2 as compared to wt platelets, whereas phosphorylation of p38 was 
unaltered (Figure 3-26 A). Increased phosphorylation of JNK in response to platelet 
stimulation was observed neither in wt nor in Grb2-/- platelets. Of note, ERK1/2 
phosphorylation was normal in Grb2-deficient platelets upon platelet stimulation with 
thrombin (data not shown). 
 
 
Figure 3-26 Defective ERK1/2 phosphorylation 
in Grb2- and LAT-deficient platelets. Washed 
platelets (7x108/ml) from Grb2-/- mice (A) or Lat-/- 
mice (B) with their respective wt control were 
stimulated with 0.5 μg/ml CVX in the presence of 
indomethacin (10 µM) and apyrase (2 U/ml) under 
stirring conditions at 37°C. Aliquots were taken at 
the indicated time points and subsequently lysed 
with NP-40 detergent. Samples were blotted on a 
PVDF membrane and stained using the indicated 
phospho-specific antibodies. Staining of the 
respective non-phosphorylated proteins, GAPDH 
or tubulin served as loading controls. The results 
shown are representative for three individual 
experiments. (Dütting,* Vögtle* et al., Circ Res, 
2013)220 
 
 
 
 
 
To address a possible involvement of the LAT-Grb2 interaction in MAP kinase activation, 
ERK1/2 signaling was analyzed in LAT-deficient platelets. A similar reduction in ERK1/2 
phosphorylation compared to Grb2-/- was seen in Lat-/- platelets (Figure 3-26 B), indicating 
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that Grb2-dependent recruitment of SOS1 to the LAT signalosome participates in ERK1/2 
activation. Alternatively, impaired ERK1/2 phosphorylation may also be a result of impaired 
PKC-activity, as a consequence of reduced PLCγ2-mediated DAG production.231  
 
 
3.3 Studies on the proteolytic regulation of CD84 receptor levels in 
platelets 
Beside ITAM coupled receptors platelets also harbor receptors with ITIM or ITSM, with the 
SLAM family members CD150 and CD84 belonging to the latter group. CD84 is abundantly 
expressed on human and mouse platelets and has initially been supposed to strengthen 
platelet-platelet interactions upon platelet aggregation.175 
Besides modulation of intracellular signaling pathways, regulation of receptor levels, either by 
internalization or intra- or extracellular proteolytic cleavage, represents another important 
mechanism to downregulate platelet reactivity. Extracellular cleavage by metalloproteinases, 
a process termed shedding, has already been demonstrated for several prominent platelet 
receptors. A proteomic approach provided the first evidence for CD84 cleavage from the 
surface of human platelets in a metalloproteinase-dependent manner, but details of this 
process remained elusive.194 Therefore, the mechanisms underlying the regulation of CD84 
receptor levels were studied in detail together with Dr. Sebastian Hofmann in our research 
group.202 
 
3.3.1 CD84 is cleaved from the surface of human and mouse platelets 
The starting point to investigate the proteolytic regulation of CD84 was a publication from 
Fong et al., who identified soluble CD84 in the supernatant of activated human platelets 
using a mass spectrometric approach.194 To study this process in more detail, washed 
human platelets were stimulated with thrombin or the GPVI agonist CRP and surface 
expression levels of CD84 were measured by flow cytometry (Figure 3-27). Indeed, 
substantial downregulation of CD84 surface levels in response to CRP and moderate 
downregulation in response to thrombin were detected. Importantly, these effects were 
inhibited in the presence of the broad range metalloproteinase inhibitor, GM6001. These data 
confirmed that CD84 surface expression in human platelets decreases in response to agonist 
stimulation in a metalloproteinase-dependent manner. 
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Figure 3-27 CD84 is cleaved from human platelets in a metalloproteinase dependent manner. 
Washed human platelets were stimulated with CRP (40 µg/ml) or thrombin (0.5 U/ml) for 1 h at 37°C in 
the presence or absence of the broad range metalloproteinase inhibitor GM6001 (100 µM). (A) 
Platelets were stained with the FITC-labeled anti-CD84 antibody for 15 min and analyzed directly by 
flow cytometry. (B) Alternatively, platelets were centrifuged and supernatants were applied on a 
MAX.3-coated ELISA plate and CD84 was detected using 2G7-biotin as described in the Methods 
section. Results are mean ± SD (n=3 individuals, representative of 2 individual experiments), * p<0.05; 
** p<0.01 and *** p<0.001. (Hofmann,* Vögtle* et al., J Thromb Haemost, 2012)202 
Total surface expression levels of CD84, as measured by flow cytometry, may also be 
influenced by internalization or exposure of additional CD84 proteins originating from 
intracellular pools. To circumvent this limitation, an ELISA system, using two monoclonal 
antibodies directed against distinct epitopes on the extracellular domain of human CD84 was 
established for direct measurements of soluble CD84 (sCD84) in the platelet supernatant. As 
shown in Figure 3-27 B, the release of sCD84 from thrombin- and CRP-stimulated human 
platelets was confirmed by this technique. 
Next, the regulation of CD84 was analyzed in mouse platelets, since genetic mouse models 
allow a deeper analysis of the underlying molecular mechanisms. In a first set of 
experiments, washed mouse platelets were activated with thrombin, the GPVI agonists CRP 
and CVX or the CLEC-2 activating snake venom protein rhodocytin. The release of sCD84 
was determined with a newly established ELISA system, designed to detect the extracellular 
domain of mouse CD84. High levels of sCD84 were measured in the supernatant of wt 
platelets in response to stimulation with each of these agonists, compared to the untreated 
control (Figure 3-28 A). In contrast, virtually no sCD84 was detected when the experiments 
were performed in the presence of GM6001, strongly suggesting that CD84 cleavage was 
mediated by metalloproteinases. The specificity of the ELISA system was confirmed in 
experiments with supernatants from CD84-/- platelets, where only background signals were 
obtained (Figure 3-28 A). 
Blocking platelet aggregation with inhibitors of integrin αIIbβ3 has previously been shown to 
influence CD40L191, but not GPVI shedding.186 To investigate whether CD84 shedding is 
influenced by αIIbβ3 signaling and aggregation, integrin αIIbβ3 binding to fibrinogen was  
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Figure 3-28 Metalloproteinase-dependent shedding of CD84 from mouse and human platelets. 
(A) Washed wt mouse platelets were incubated with CVX (1 µg/ml), CRP (40 µg/ml), rhodocytin (RC, 
2 µg/ml) or thrombin (0.5 U/ml) for 1 hour at 37°C in the presence or absence of the broad range 
metalloproteinase inhibitor GM6001 (100 µM). Supernatants of platelets were applied on a JER1-
coated ELISA plate and mouse CD84 was detected using mCD84.7-biotin as described in the 
Methods section. Platelet supernatants from CD84-deficient (Cd84-/-) mice served as controls. n.d., not 
detectable. (B) Washed mouse platelets were incubated with CRP (40 µg/ml) or thrombin (0.1 U/ml) in 
the presence or absence of 25 µg/ml JON/A F(ab)2 and ELISA was performed as described. (C) 
Washed mouse (left panel) or human platelets (right panel) were incubated with CCCP (100 µM) or 
W7 (150 µM) for 1 hour at 37°C, NEM (2 mM) for 20 min or PMA (50 ng/ml) for 15 min at 37°C in the 
presence or absence of GM6001. ELISA was performed as described. DMSO treatment served as 
control. Results of all experiments are mean ± SD (n=4 mice or 3 individuals per group, representative 
of 2-3 individual experiments). * p<0.05, ** p<0.01 and *** p<0.001 (Hofmann,* Vögtle* et al., 
J Thromb Haemost, 2012)202 
blocked with F(ab)2 fragments of the JON/A antibody.204 Less sCD84 was detected after CRP 
and thrombin stimulation in the presence of JON/A F(ab)2, indicating that cleavage of CD84 
was, at least in part, dependent on platelet aggregation (Figure 3-28 B). Of note, addition of 
JON/A F(ab)2 after the agonist incubation period did not reduce the sCD84 signal in ELISA, 
excluding that the F(ab)2 interfered with the signal (data not shown). These results were 
confirmed with platelets from mice lacking the cytoskeletal protein talin1, which is required for 
inside-out activation of integrins (data not shown). 
To further assess the mechanisms underlying CD84 ectodomain shedding, washed mouse 
platelets were treated with different agents known to induce shedding of multiple platelet 
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membrane receptors by distinct mechanisms38 and cleavage of CD84 from the platelet 
surface was measured by sCD84 ELISA.  
The calmodulin inhibitor W7 induces the disruption of calmodulin from receptors, thereby 
facilitating ectodomain shedding by ADAM10 and ADAM17. NEM is a thiol-modifying reagent 
which directly activates the metalloproteinases by acting on a cysteine switch within the 
proteases (see introduction). Both reagents induced marked ectodomain shedding of CD84 
as revealed by detection of high levels of sCD84 in the platelet supernatant compared to the 
untreated control. This effect was virtually abolished in the presence of GM6001 (Figure 
3-28 C). CCCP induces mitochondrial injury and triggers receptor shedding mainly in an 
ADAM17-dependent manner.184,192 Compared to W7 and NEM, this agent induced only a 
mild GM6001-sensitive increase in sCD84 in the platelet supernatant. Similar results were 
obtained with human platelets for these three reagents (Figure 3-28 C). PMA is an activator 
of PKC, thereby inducing ectodomain shedding mainly by ADAM17.184,188 PMA treatment of 
mouse platelets resulted only in weak metalloproteinase-dependent shedding of sCD84 as 
compared to untreated controls, while in human platelets, the increase in sCD84 levels in 
response to PMA was slightly more pronounced (Figure 3-28 C). 
 
3.3.2 Dual regulation of CD84 by calpain and metalloproteinases 
To gain deeper insights, the processing of CD84 in response to shedding inducing agents 
was analyzed by Western blotting, using two different antibodies: JER1 (anti-CD84N-term), 
which also served as the capture antibody for the soluble fragment in ELISA experiments, 
and the polyclonal antibody, M-130, which has been raised against the intracellular 
C-terminal part of CD84 (anti-CD84C-term). 
The band of the full length murine CD84 protein appeared between 55 and 72 kDa under 
non-reducing conditions, much higher than the calculated molecular weight of approximately 
37 kDa, because CD84 is highly glycosylated.174 In unstimulated platelets, M-130 detected 
only the full length protein, while an additional band at a size of approximately 15 kDa 
appeared in NEM-treated platelets (Figure 3-29 A, lower left). As at the same time the band 
intensity of the full length protein decreased, it is conceivable that this 15 kDa band 
represents the C-terminal remnant of CD84, which is generated by shedding of the receptor 
ectodomain. This assumption was confirmed by the finding that GM6001 abrogated the 
appearance of this additional band in the lysate of NEM treated platelets. Also the band 
intensity of the full length protein recovered (Figure 3-29 A, lower left). 
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Figure 3-29 Calpain and metalloproteinases cleave CD84 independently. (A) Washed platelets 
from wt mice were preincubated at 37°C for 15 min in the presence or absence of GM6001 (100 µM), 
and/or calpeptin (5 µg/ml), an inhibitor of calpain. Shedding was induced with CCCP (100 µM, 1 h), 
W7 (150 µM, 1 h), and NEM (2 mM, 20 min). DMSO or buffer served as control. CD84 was detected 
by Western blotting with anti-CD84N-term antibody JER-1 and anti-CD84C-term antibody M-130. GPIIIa 
was used as a loading control (pooled platelets from 5 mice, representative of 3 individual 
experiments). (B) Washed platelets from wt mice were preincubated at 37°C for 15 min in the 
presence or absence calpeptin (5 µg/ml). Shedding was induced with W7 (150 µM, 1 h) or NEM 
(2 mM, 20 min). Soluble CD84 in the supernatant was detected by ELISA. Results are mean ± SD 
(n=4 mice per group, representative of 2 individual experiments). (Hofmann,* Vögtle* et al., J Thromb 
Haemost, 2012)202 
Given the considerable GM6001-sensitve release of sCD84 into the supernatant upon 
platelet treatment with CCCP or W7 (Figure 3-28 C), which in case of W7 even exceeded the 
effect of NEM, it was surprising not to detect the C-terminal remnant in the respective 
lysates. Nevertheless, the band of the full length protein was clearly reduced in intensity after 
CCCP treatment compared to the untreated control or even absent after W7 treatment 
(Figure 3-29 A, lower left). 
One possible explanation was that CD84, in addition to ectodomain shedding, may be 
cleaved in its intracellular C-terminus and that this cleavage interferes with binding of the 
anti-CD84C-term antibody, M-130. This assumption was further supported by the fact that a 
shift in molecular weight of CD84 was detectable with the anti-CD84N-term antibody in the 
lysates of platelets treated with W7 or CCCP, indicating a shortening of the protein. 
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Moreover, this shift as well as the lack of binding of the anti-CD84C-term antibody was not 
influenced by GM6001, excluding metalloproteinases as mediators of this process. 
As a possible candidate enzyme for mediating this intracellular cleavage the cysteinyl 
protese calpain was identified, since (i) it has previously been recognized that shedding by 
metalloproteinases often occurs concomitantly with activation of calpains38 and (ii) 
calmodulin-binding proteins are frequently substrates for calpains.232 This hypothesis was 
further strengthened by bioinformatical analysis of the CD84 C-terminus with an online 
prediction tool (http://calpain.org).233 The potential cleavage site with the highest score in the 
murine CD84 protein was found at an arginine residue at position 270, which is located 
between the two ITSMs (Figure 3-30). Of note, this arginine residue, as well as the 
biochemical properties of the adjacent amino acids, are highly conserved in mammals, 
implying a functional relevance of this sequence (Figure 3-30 B). 
 
Figure 3-30 Bioinformatical information about cleavage of CD84 by calpain. (A) Predicted calpain 
cleavage within the murine CD84 protein as predicted by the online prediction tool http://calpain.org 
(SVM RBF kernel prediction model).233 Top 10 cleavage site predictions are shown on the left, a 
graphical illustration of the results, ranging from amino acid 241 to 300, is shown on the right. (B) 
Sequence alignment of the C-terminal part of CD84 proteins form different species (www.uniprot.org, 
program: clustalO). Highlighted are the two ITSMs, the predicted calpain cleavage site and a tyrosine 
residue (Y280 and Y296 in mouse and human, respectively), that has been reported to become 
phosphorylated upon platelet aggregation.175 
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To collect experimental evidence for calpain-mediated cleavage of the CD84 C-terminus, the 
calpain-inhibitor calpeptin was used. Strikingly, preincubation of platelets with calpeptin 
abolished the shift in the molecular weight of CD84 seen in the lysates of W7 and CCCP 
treated platelets with the anti-CD84N-term antibody JER1 (Figure 3-29 A, upper right) and also 
allowed the detection of the C-terminal remnant with the anti-CD84C-term antibody M-130 
(Figure 3-29 A, lower right). Moreover, also the binding of anti-CD84C-term antibody to the full 
length CD84 protein was enhanced. Together, these observations demonstrated that calpain 
can cleave both the full length CD84 protein as well as the remnant generated by 
metalloproteinases. The band intensity for this remnant was strong after W7 and NEM 
treatment and weak for lysates of CCCP-treated platelets, nicely correlating with the results 
obtained with the sCD84 ELISA system (Figure 3-28 C). Of note, no C-terminal remnant was 
detected upon platelet treatment with PMA (data not shown). Therefore, PMA was excluded 
from further Western blot analyses. 
When platelets were preincubated with calpeptin and GM6001 in combination, the 
appearance of the 15 kDa remnant (detected by anti-CD84C-term) as well as the shift in 
molecular weight and the decrease in band intensity (anti-CD84N-term) were diminished, 
showing additive effects of the two inhibitors (Figure 3-29 A, right). Importantly, all bands 
detected by both antibodies in these studies were specific for CD84 as no signal was 
obtained when the experiments were performed with Cd84-/- platelets (data not shown). Since 
there had been concerns about the specificity of calpeptin,234 two other membrane-
permeable calpain inhibitors, MDL 28170 and ALLN were tested. Like calpeptin, these two 
inhibitors blocked the shift of the full length CD84 protein in anti-CD84N-term blots and rescued 
the detection of the C-terminal remnant with the anti-CD84C-term antibody upon W7 treatment, 
confirming the role for calpain in this process (data not shown).  
In order to estimate whether inhibition of calpain activity interferes with CD84 ectodomain 
shedding by metalloproteinases, ELISA measurements were conducted. The levels for 
sCD84 were unaltered in the presence of calpeptin (Figure 3-29 B). 
These results demonstrated that CD84 is proteolytically regulated by two independent 
mechanisms: extracellular ectodomain shedding by metalloproteinase(s) and intracellular 
cleavage by calpain. Apparently, shedding was functional under calpain-inhibiting conditions 
and vice versa. A summary of these results is shown schematically in Figure 4-1.  
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3.3.3 ADAM10 is critical for CD84 ectodomain cleavage in murine platelets 
Having identified calpain as the protease for intracellular cleavage of CD84, it was sought to 
identify the metalloproteinase that is required for extracellular cleavage. Two possible 
candidates are ADAM10 and ADAM17, which are both GM6001-sensitive and expressed in 
platelets.38 To test their individual contribution, platelets from Adam17ex/ex bone marrow 
chimeric (BMc) mice were studied. These mice exhibit a virtually complete loss of ADAM17 
protein in hematopoietic cells, including platelets.192,207 While parallel performed flow-
cytometric control measurements showed absence of GPIb shedding in Adam17ex/ex platelets 
in response to CCCP, W7, NEM and PMA (data not shown), levels of released sCD84, as 
 
 
Figure 3-31 ADAM10 is essential for CD84 ectodomain shedding. Washed platelets from (A) 
Adam17ex/ex bone marrow chimeric mice and (B) Adam10-/- mice with their respective wt controls were 
treated with CCCP (100 µM, 1 h), W7 (150 µM, 1 h), NEM (2 mM, 20 min), PMA (50 ng/ml, 15 min) or 
DMSO as a vehicle control. sCD84 in the supernatants was detected by ELISA as described in 
Methods. Results are mean ± SD (n=4 mice per group, representative of 2 individual experiments). 
* p<0.05 and ** p<0.01 (C, D) Western blot detection of CD84 in lysates of platelets from mice with the 
indicated genotype. A10, Adam10-/-; A17, Adam17ex/ex; wt are the corresponding controls. Platelets 
were incubated with calpeptin (5 µg/ml, 37°C, 15 min) or vehicle control and shedding was induced as 
described above. (2 mice pooled per group, representative of 2-3 individual experiments). (Hofmann,* 
Vögtle* et al., J Thromb Haemost, 2012)202 
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determined by ELISA, were indistinguishable between wt and Adam17ex/ex platelets, 
excluding a major role of ADAM17 in CD84 ectodomain shedding under these experimental 
conditions (Figure 3-31 A). 
To investigate the dependence of CD84 shedding on ADAM10, platelets from mice with a 
MK- and platelet-specific deficiency of ADAM10 (Adam10fl/fl/PF4-Cre+/- mice, further on 
referred to as Adam10-/-) were analyzed.192 In sharp contrast to wt and Adam17ex/ex platelets 
treated with either agent, sCD84 was virtually not detectable in the supernatant of Adam10-/- 
treated platelets (Figure 3-31 B). These results were confirmed by Western blot analysis, 
where the band intensity of the C-terminal remnant in the lysates of Adam17ex/ex platelets 
was indistinguishable from that of wt platelets, but no C-terminal remnant was detectable in 
Adam10-/- platelets (Figure 3-31 C and D).  
Taken together, these data established ADAM10 as the principal sheddase cleaving CD84 in 
mouse platelets, while ADAM17 is not significantly involved in this process. 
In the next step, it was investigated whether ADAM10 is also the principal sheddase for 
CD84 cleavage in response to stimulation with platelet receptor agonists. Platelets from wt 
and Adam10-/- mice were stimulated with the GPVI agonists CRP and CVX, the CLEC-2 
agonist rhodocytin and the GPCR-agonist thrombin. As illustrated in Figure 3-32 A, none of 
these agonists induced significant ectodomain shedding in the absence of ADAM10, as 
measured by ELISA.  
To gather information on shedding kinetics and to investigate the intracellular cleavage by 
calpain, wt and Adam10-/- platelets were stimulated for different times in the presence or 
absence of calpeptin and lysates were subjected to Western blotting. Shedding, visualized by 
detection of the 15 kDa remnant with the anti-CD84C-term antibody M-130, occurred within 5 
minutes in response to all agonists and the band intensity increased over time (Figure 3-32 
B), revealing that CD84 shedding is a rather slow process. Remarkably, rhodocytin induced 
also strong activation of calpain, as indicated by the lack of binding of anti-CD84C-term in the 
absence of calpeptin, as well as by the shortened CD84 protein detected by the anti-
CD84N-term antibody, in the absence of calpeptin. In contrast, the other agonists only 
moderately activated calpain. No C-terminal remnant was detected in lysates of platelets 
deficient in ADAM10, confirming the results from the ELISA. Calpain activity was unaffected 
by the absence of the metalloproteinase, as apparent in rhodocytin stimulated samples. 
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Figure 3-32 ADAM10 cleaves CD84 in response to platelet receptor stimulation. (A) Washed 
mouse platelets from wt and Adam10-/- mice were incubated with CVX (1 µg/ml), CRP (40 µg/ml), 
rhodocytin (RC, 2 µg/ml) or thrombin (0.5 U/ml) for 1 hour at 37°C. Soluble CD84 was detected by 
ELISA as described in Methods. Results are mean ± SD (n=4 mice per group, representative of 3 
individual experiments). ** p<0.01 and *** p<0.001. (B) Washed platelets from wt and Adam10-/- mice 
were preincubated for 15 min at 37°C with calpeptin (5 µg/ml) or vehicle control, prior to stimulation for 
5 min, 15 min or 1 h with the agonists described above. Platelet lysates were subjected to Western 
blotting. (4 mice pooled per group, representative of 3 individual experiments). (Hofmann,* Vögtle* et 
al., J Thromb Haemost, 2012)202 
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3.3.4 High concentrations of sCD84 in mouse plasma  
To investigate whether CD84 shedding occurs in vivo, the levels of sCD84 in mouse plasma 
were determined by ELISA. Indeed, significant levels of sCD84 could be detected in the 
plasma of wt mice, while only background signals were obtained from plasma of Cd84-/- mice 
(Figure 3-33 A). Of note, sCD84 plasma levels in Adam10-/- mice were markedly reduced 
compared to wt mice, demonstrating that shedding by platelet ADAM10 occurs constitutively 
in vivo and accounts for approximately half of the total sCD84 protein found in the plasma of 
normal healthy mice. To investigate whether ADAM17 plays a role in CD84 shedding in vivo, 
sCD84 plasma levels of bone marrow chimeras with platelets double-deficient in ADAM10 
and ADAM17 (Adam10-/-/Adam17ex/ex)192 were measured. As depicted in Figure 3-33 A, the 
levels of sCD84 were not further reduced in plasma of double deficient bone marrow 
chimeras compared to ADAM10 single deficient mice. In line with this, plasma levels of wt 
and Adam17ex/ex bone marrow chimeras were indistinguishable (data not shown). Therefore, 
a role for ADAM17 in regulating plasma levels of sCD84 in healthy mice can be excluded. 
In order to test whether CD84 shedding occurs during normal blood clotting, non-
anticoagulated whole blood was allowed to clot in vitro and sCD84 levels were measured in 
the obtained serum. In wt mice, levels of sCD84 increased approximately two-fold in serum 
compared to the respective plasma samples (Figure 3-33 B). In contrast, sCD84 
concentrations in the serum of Adam10-/- mice did not differ from those found in plasma, 
demonstrating that ADAM10 is the only protease that sheds CD84 during blood clotting. 
 
Figure 3-33 CD84 is constitutively shed from platelets and present in mouse plasma. (A) sCD84 
levels in the plasma of Adam10-/- and Adam10-/-/Adam17ex/ex mice, their respective wt controls and 
Cd84-/- mice were determined by ELISA. (B) sCD84 levels in the plasma and serum of wt, Adam10-/- 
and Cd84-/- mice were measured by ELISA. Serum and plasma samples were obtained from the same 
animals and analyzed within a single experiment. Bar graphs represent mean ± SD (n=4 mice per 
group representative of 2 individual experiments). * p<0.05, ** p<0.01 and *** p<0.001 (Hofmann,* 
Vögtle* et al., J Thromb Haemost, 2012)202 
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4 Discussion 
4.1 Constitutive Ca2+ influx alters phosphorylation, but not activation of 
PLCγ1 
STIM1 is established as an essential mediator of SOCE in lymphocytes67 and platelets.14 The 
Stim1Sax/+ mouse is heterozygous for a gain of function mutation of the STIM1 protein and 
thus provides a model to investigate the impact of constitutive Ca2+ influx on T cell physiology 
and signaling pathways.149 The data presented in this thesis reveal an altered 
phosphorylation pattern of the key enzyme PLCγ1 upon TCR stimulation in Stim1Sax/+ T cells, 
which was, at least in part, a consequence of calcineurin activity. The enzymatic activity of 
PLCγ1 was, however, not altered and withdrawal of extracellular Ca2+ re-established the 
phosphorylation pattern of wt T cells. Additionally, a decreased production of Th2-type 
cytokines of Stim1Sax/+ T cells was detected. 
Ca2+ influx triggered by TCR stimulation results in the activation of the Ca2+/calmodulin-
dependent phosphatase calcineurin, which facilitates the translocation of NFAT from the 
cytoplasm into the nucleus, a critical event for T cell activation and proliferation.68 In 
Stim1Sax/+ T cells, NFAT was found in the nucleus independently of TCR stimulation, 
inidicating that calcineurin is constitutively active even in unstimulated cells (Figure 3-2). This 
assumption was confirmed by a direct measurement of calcineurin activity (Christoph Hintzen 
and Attila Braun, personal communication). Despite this observation, the T cell compartment 
was similar to wt in Stim1Sax/+ mice (Figure 3-1) and no signs of hyperproliferation or 
autoimmune reactions were observed.149 As suggested by Grosse et al.,149 this may be 
explained by the different spatial and temporal features of the constantly elevated Ca2+ entry 
triggered by the Stim1Sax mutation compared to the TCR-induced Ca2+ influx which involves a 
robust and sustained rise localized at the immunological synapse.235,236 Another physiological 
consequence that one may have anticipated from constitutive nuclear NFAT localization is 
anergy, a state of unresponsiveness towards antigenic stimulation. In a current model, 
anergy is triggered by Ca2+/calcineurin signaling in response to isolated stimulation of the 
TCR in the absence of costimulation, resulting in the activation of NFAT, but not of its 
interaction partner AP-1. In the absence of AP-1, NFAT is supposed to impose a genetic 
program of anergy that counters the cell activation program of the NFAT/AP-1 complex.70,71 
However, Stim1Sax/+ T cells proliferated normally towards TCR stimulation in vitro149 and 
produced reasonable amounts of cytokines (Figure 3-7). This result is similar to T cells from 
transgenic mice, which harbor a constitutively active form of calcineurin.237 The absence of 
an anergic phenotype, may be explained by the difference of the low sustained rise of [Ca2+]i 
in Stim1Sax/+ T cells to the transient, but high increase of [Ca2+]i of an anergy inducing 
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stimulus.71 Additionally, the constitutively elevated [Ca2+]i in Stim1Sax/+ T cells may lead to an 
adaptation to elevated Ca2+ levels of the T cell already during T cell development, where 
calcineurin has been shown to play a role.238 Independently of the underlying cause, the data 
demonstrates that nuclear NFAT localization does not necessarily lead to an anergic 
phenotype, at least upon stimulation in vitro. Whether Stim1Sax/+ T cells preferentially 
differentiate into anergic cells in response to certain stimuli in vivo, as supposed for Golli-
deficent T cells during EAE,239 remains to be investigated. 
Analysis of the more upstream signaling events revealed normal phosphorylation of the 
kinases Lck and Zap-70 upon TCR-complex ligation. Surprisingly, however, PLCγ1 
phosphorylation at Y783 was completely abolished in Stim1Sax/+ T cells when stimulated in 
the presence of extracellular Ca2+. This (de)phosphorylation was regulated in a Ca2+-
dependent and highly dynamic manner, since withdrawal of extracellular Ca2+ rescued the 
phosphorylation at this residue (Figure 3-3). Phosphorylation of Y783 is carried out by Itk in 
T cells240,241 and is reported to be required for the activation of the enzyme’s lipase 
activity.214,215 Similar to withdrawal of extracellular Ca2+, treatment of Stim1Sax/+ T cells with 
the calcineurin inhibitor CsA also recovered Y783 phosphorylation, demonstrating that 
calcineurin is involved in the loss of phosphorylation (Figure 3-4). A direct dephosphorylation 
of Y783 by calcineurin can, however, be excluded, since it is a serine/threonine phosphatase 
and thus phosphotyrosines are no proper substrates. Preliminary experiments in the group of 
Dr. Heike Hermanns point towards a participation of the tyrosine-specific protein 
phosphatase SHP-1 downstream of calcineurin (Christoph Hintzen and Heike Hermanns, 
personal communication). In addition, enhanced phosphorylation at Y771, a less well 
characterized PLCγ1 phosphorylation site, was identified in Stim1Sax/+ T cells upon 
stimulation in the presence of extracellular Ca2+. Withdrawal of extracellular Ca2+ reduced 
phosphorylation to normal levels (Figure 3-5). The molecules involved in this altered 
phosphorylation remain to be identified.  
Despite this altered phosphorylation pattern, the lipase activity of PLCγ1 in Stim1Sax/+ T cells 
was not different from wt T cells under all tested conditions (Figure 3-6). While a previous 
study reported that Y783 phosphorylation itself is not sufficient for PLCγ1 activation upon 
epidermal growth factor stimulation in vitro,242 the results presented here indicate that Y783 
may be even bypassed. Whether, and if yes to which extent, phosphorylation at Y771 can 
compensate for the loss of Y783 phosphorylation remains to be investigated. In vitro studies 
in heterologous cell systems reported a negligible role for Y771 phosphorylation in regulating 
PLCγ1 activity.215,243 However, it has to be mentioned that Y771, similar to primary wt T cells 
(Figure 3-5), is hardly phosphorylated in cell lines242 and that observations from in vitro cell 
 
95 
Discussion 
 
culture systems may not always directly apply to primary cells. Apart from that, a role of Y775 
phosphorylation215 and the recruitment of PLCγ1 accessory molecules such as coronin-1, 
whose absence dramatically impairs activity, but not phosphorylation of PLCγ1,244 may also 
be considered. In conclusion, the altered phosphorylation pattern of PLCγ1 may reflect a 
piece of a cellular program that allows largely undisturbed signaling process in the presence 
of elevated [Ca2+]i. Whether other Ca2+/calmodulin binding proteins, e.g. CamKII and IV 
participate,72 remains to be investigated. 
Upon TCR stimulation, naïve T cells can differentiate into different CD4+ T helper (Th) cell 
subsets, which have distinct functions and secrete different effector cytokines (see 
introduction). Studies in STIM1- and Orai1-deficient mice revealed a critical role of SOCE for 
the function of all Th subsets (Th1, 2 and 17) with Th17 cells showing the greatest 
dependence on this Ca2+ entry pathway.67,245 Measurements of cytokine levels after 
stimulation of T cells in vitro revealed an impaired secretion of the Th2-type cytokines IL-4, 5 
and 13 and a tendency towards less IL-10 in Stim1Sax/+ T cells. The level of the Th1 cytokine 
IFNγ was moderately, but not significantly elevated, while all other cytokines tested were 
released to a similar extent by wt and Stim1Sax/+ T cells (Figure 3-7). When no polarizing 
cytokines are added to an in vitro culture, like in the illustrated experiment, Th1/Th2 
differentiation is mainly controlled by the strength of TCR signaling. In general, weak 
signaling favors Th2 differentiation, while stronger signals result in Th1 differentiation and 
suppression of Th2 differentiation.58,59 Therefore, these observations implicate that 
stimulation resulted in a stronger signal in Stim1Sax/+ T cells than compared to their wt 
counterparts, what fits to the expectations of elevated [Ca2+]i. It will be interesting to 
determine if this reduced capability of Th2-type cytokine production is of functional relevance 
in vivo, e.g. in mouse models of Th2 cell-mediated immune disorders like allergic asthma.246 
Stim1Sax/+ animals showed increased frequencies and numbers of Tregs in the spleen (Figure 
3-8). This was of particular interest since mice with a conditional deletion of both Stim genes 
exhibit a pronounced defect in Treg development and decreased Treg populations in thymus 
and secondary lymphoid organs.163,247 However, Treg frequencies in the thymus, lymph 
nodes and blood were unaltered in Stim1Sax/+ animals, indicating that an increased thymic 
output of Tregs is not responsible for the elevated numbers observed in spleen (Figure 3-8 
and Figure 3-9). Also the proliferation of splenic Tregs was similar between wt and mutant 
mice, excluding an enhanced proliferation as the underlying cause (Figure 3-9). Alternatively, 
elevated Treg cell numbers may originate from enhanced differentiation of naïve T cells into 
Tregs in the periphery (see introduction).57 Expression of Helios, a reported marker for Tregs 
of thymic, but not peripheral origin,218 was, however, comparable within wt and Stim1Sax/+ 
Treg populations (Figure 3-9). But since the utility of Helios to discriminate between thymic 
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and induced Tregs has been questioned in recent studies,248,249 increased differentiation of 
naïve T cells into Tregs in Stim1Sax/+ spleens cannot finally be excluded. Another explanation 
may be an increased survival of Stim1Sax/+ Tregs. Indeed, a recent study demonstrated that 
Treg homeostasis is regulated by pro- and anti-apoptotic pathways in a highly dynamic 
manner.250 It remains to be investigated whether Stim1Sax/+ Tregs show an anti-apoptotic 
phenotype, but also why they preferentially accumulate in the spleen. 
 
4.2 Grb2 stabilizes the LAT signalosome 
Adapter proteins exert essential functions in signaling processes downstream of (hem)ITAM-
coupled receptors in hematopoietic cells. In platelets, the formation of a signaling complex 
called the LAT signalosome, comprised of different adapter and effector proteins is central 
for proper signal transduction of the (hem)ITAM-coupled receptors GPVI and CLEC-2. The 
role of the adapter proteins Gads, SLP-76 and LAT in GPVI and CLEC-2 signaling has been 
addressed in previous studies by the use of knockout mice, but due to the lack of an 
appropriate animal model, the function of Grb2 in this process long remained unclear. In this 
study, a novel genetic mouse model with a MK/platelet-specific deletion of Grb2 was used to 
study the role of Grb2 in platelets in vitro and in vivo. Grb2-deficient platelets displayed 
severely impaired (hem)ITAM signaling, but unaltered GPCR function and integrin signaling. 
This highly specific defect resulted in impaired hemostasis and partially defective arterial 
thrombus formation. 
Grb2 is widely expressed throughout the body and associates with a large variety of 
receptors and signaling pathways in different cell types.74,94,96,98 Its physiological importance 
is highlighted by the early embryonic lethality of Grb2-/- mice due to defective differentiation of 
endodermal cells and formation of the epiblast.105 Grb2 is also strongly expressed in the 
hematopoietic system and a role of the Grb2/SOS1/Ras/Raf-1/MEK pathway in 
thrombopoietin receptor (c-Mpl) induced ERK1/2 activation during MK differentiation was 
suggested.251 However, platelet count and size (Figure 3-10) and bone marrow MK numbers 
(data not shown) were normal in mice with a MK-specific Grb2-deficiency demonstrating that 
Grb2 is dispensable for megakaryopoiesis and platelet production in vivo. This might at least 
partially be explained by compensatory alternative pathways downstream of c-Mpl leading to 
ERK1/2 activation, involving either the small GTPase Rap1111 or PKC-mediated Raf1 
activation, independently of Ras.252,253 
A previous study also presumed a role for Grb2 in integrin outside-in signaling since an 
increased association between Grb2 and Dok-1 and Dok-3 upon activation of integrin αIIbβ3 
was detected.114 However, in this thesis unaltered platelet spreading on fibrinogen and 
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normal clot retraction in the absence of Grb2 was observed (Figure 3-14), excluding a major 
function of the adapter in integrin outside-in signaling. This might be explained by the fact 
that Dok-3 is not expressed in mouse platelets.114 In addition, biochemical studies using 
phosphorylated β3 peptides initially suggested that Grb2 is recruited to a conserved tyrosine 
motif within the β3 cytoplasmic tail, which becomes phosphorylated upon platelet 
aggregation254 and is required for processes like clot retraction.255 However, a direct 
interaction of Grb2 to the β3 cytoplasmic tail upon aggregation has not been reported to date 
and further studies proposed other proteins (e.g. SHC, Dok2 and myosin) as main interaction 
partners of the β3 integrin.256,257 The results presented here support this notion. Like Grb2, 
the adapter proteins Gads and LAT are also dispensable for spreading of mouse 
platelets.31,86 In contrast SLP-76 is required for this process.91,258 It is currently unknown how 
SLP-76 can serve this function independently of the other adapter proteins.258 
Grb2 has been implicated in antigen receptor signaling in lymphocytes. Recent reports 
showed a prominent role of the adapter during B cell maturation by negatively regulating 
proximal BCR signaling108,109 and an important function in thymic selection by amplifying TCR 
signaling.106,107 Similar to the BCR and TCR complexes, the GPVI/FcR γ-chain complex and 
CLEC-2 in platelets use a (hem)ITAM signaling module to transduce extracellular signals, 
thereby mediating platelet activation, aggregation, and thrombus formation (see introduction). 
Previous studies in human platelets demonstrated that Grb2 binds to the membrane bound 
adapter molecule LAT26 and that it is phosphorylated after GPVI-stimulation,113 indicating a 
role of Grb2 in ITAM signaling in platelets. However, given the opposing effects of Grb2-
deficiency in B and T cells, the exact function of the adapter in platelets was unclear. 
In this study, Grb2-deficient platelets exhibited markedly impaired integrin αIIbβ3 activation, 
degranulation and aggregation in response to GPVI and CLEC-2 stimulation, while the 
response towards GPCR agonists was unaltered (Figure 3-11 and Figure 3-13). Animals 
heterozygous for Grb2 deletion, had reduced levels of Grb2 (Figure 3-10) and showed an 
intermediate phenotype of integrin activation (Figure 3-12). Thus, like in T cells Grb2 
positively regulates platelet (hem)ITAM signaling in a quantitative manner.106,107 The selective 
(hem)ITAM signaling defect of Grb2-/- platelets phenocopied the defects seen in LAT-
deficient mice, although to a somewhat lesser extent, but is considerably more pronounced 
than in platelets lacking the Grb2-related adapter Gads.31,77 The direct comparison of LAT 
and Grb2-deficient platelets for integrin αIIbβ3 activation by flow cytometry revealed only 
minor, but significant differences in response to CRP and a moderate difference in response 
to the more powerful GPVI agonist CVX (Figure 3-12). This result suggests that the disrupted 
Grb2-LAT interaction may be the main underlying cause for the GPVI signaling defect in 
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LAT-deficient mice. The difference between the two strains may be explained by the 
presence of the functional Grb2 homolog Gads, which also binds to LAT in response to CRP, 
but to a lesser extent than Grb2.31 Interestingly, the hemITAM signaling defect was by far 
more pronounced in Lat-/- as compared to Grb2-/- platelets, in which the response to high 
doses of rhodocytin was only mildly impaired. Additionally, the phosphorylation defect of 
PLCγ2 in Grb2-/- platelets was less severe in response to CLEC-2 stimulation as compared to 
GPVI stimulation while the decrease in LAT phosphorylation was comparable (Figure 3-24 
vs. Figure 3-25). These results implicate that the function of Grb2 downstream of CLEC-2 
may be compensated for by an independent mechanism that requires LAT, but not 
necessarily LAT phosphorylation. A differential requirement for adapter proteins in GPVI 
versus CLEC-2 signaling has also been previously reported for SLP-76, whose lack can be 
overcome by high concentrations of rhodocytin,39,44 but not of GPVI agonists.76,85,86 
While in flow cytometry remarkable GPVI signaling defects were observed at high agonist 
concentrations, defects in the maximum aggregation response became apparent only at low 
and intermediate agonist concentrations (Figure 3-13). This difference to flow cytometry data 
is most likely a consequence of different experimental conditions: in aggregometry high 
concentrations of washed platelets are used, enabling platelets to amplify the activation 
process by the release of second wave mediators which signal via GPCRs.32 In contrast, flow 
cytometric experiments are performed with diluted washed blood where the release of 
second wave mediators is less relevant. This was confirmed by measurements with platelets 
from mice treated with ASA, which blocks the generation of TxA2. Under these conditions, 
Grb2-/- platelets showed aggregation defects at higher concentrations of collagen compared 
to untreated controls (Figure 3-21). 
The GPVI signaling defect in Grb2-/- platelets translated into severely impaired platelet 
adhesion and aggregate formation on collagen under flow (Figure 3-17) and defective 
procoagulant activity in vitro (Figure 3-16). A similar phenotype has been reported in mice 
lacking LAT,31,87 again indicating a prominent role for Grb2 in thrombus formation by linking 
signaling molecules within the LAT signalosome. Of note, platelet aggregation under flow has 
been reported to be unaltered in the absence of Gads.31 
Comparable to immune receptor stimulation, agonist-induced platelet activation requires an 
increase in [Ca2+]i that is mainly triggered by PLC-mediated IP3 production, resulting in Ca2+ 
store release and subsequent Ca2+ entry.14 The tyrosine phosphorylation cascade leading to 
PLCγ activation shows striking similarities between GPVI, the BCR, and the TCR, involving 
phosphorylation of accessory receptor chains, activity of Src and Syk family kinases and the 
scaffold function of various adapter proteins, like SLP-65/SLP-76 and LAT (see introduction 
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and Figure 1-3).12,64,74 The presented findings clearly show that the Grb2 function in platelets 
resembles its function in TCR signaling in thymocytes, in that in both cell types deletion of 
Grb2 results in impaired Ca2+ signaling (Figure 3-15).107 This is in contrast to B cells, where 
Ca2+ influx is enhanced in the absence of the adapter.108,109 However, despite the same 
outcome, the mechanism by which Grb2 exerts its effect differs between thymocytes and 
platelets: In thymocytes, the signaling defect observed upon Grb2-deficiency was attributed 
to impaired activation of the Src-kinase Lck at the top end of the TCR signaling cascade, and 
may only partially, if at all, be caused by defects at the level of the LAT signalosome.102,107 By 
contrast, Grb2 in platelets appears to act downstream of platelet GPVI solely at the level of 
the LAT signalosome. The results demonstrate that Grb2 interacts with LAT after (hem)ITAM 
stimulation (Figure 3-23) and that in the absence of Grb2 the tyrosine phosphorylation of LAT 
at Y136 and Y195 (corresponding to LAT Y132 and Y191 in human, respectively) is reduced 
(Figure 3-24 andFigure 3-25). Grb2 strongly associates via its SH2 domains with three 
phosphotyrosines of LAT (Y171, Y191, Y226),78,99,100,259 whereas PLCγ preferentially binds at 
Y132.99,259,260 Previous studies in T cell lines have shown that mutations of the Gads/Grb2 
binding residues of LAT (Y171, Y191, Y226) result in reduced binding of PLCγ1 to LAT and 
attenuation of downstream signaling events including tyrosine phosphorylation of the 
phospholipase.99,102,260,261 Therefore, a concept of cooperative binding among LAT-
associated proteins that stabilize the signaling complex has been proposed.79,102,262 In line 
with this, Grb2-deficient platelets displayed reduced tyrosine phosphorylation of the key 
downstream signaling molecules PLCγ2, SLP-76, and Vav3 after GPVI and CLEC-2 
stimulation, whereas tyrosine phosphorylation of proteins that operate upstream of the LAT 
signalosome e.g. FcR γ-chain, CLEC-2, and Syk was maintained (Figure 3-24 and Figure 
3-25). Taken together, the present observations emphasize that Grb2 is an important adapter 
protein of the LAT signalosome, which stabilizes this signaling complex by its direct 
association after (hem)ITAM-induced stimulation thereby enabling downstream signaling and 
platelet activation. 
This conclusion is also supported by a platelet study using transgenic mice. Ragab et al. took 
advantage of a mouse line, where the three C-terminal tyrosine residues (Y171, Y191 and 
Y226), which are essential for Grb2 binding, were mutated to phenylalanine (LAT3YF 
mice).263 This study demonstrated that these three tyrosine residues are required for 
membrane association and activation of PLCγ2 in response to platelet stimulation with CVX. 
Additionally, platelet aggregation, PLCγ2 phosphorylation and aggregation under flow were 
strongly impaired or abolished in these mice,263 similar to Lat-/- mice.31,86 However, from this 
study it could not be directly concluded to what extent defective Grb2 binding produces the 
phenotype, since also the Grb2 family member Gads binds to the same tyrosine residues 
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within the LAT protein.99,100,259 Gads is a relative and a functional homolog of Grb2 and 
besides binding to LAT, both proteins can also bind and couple SLP-76 to LAT, albeit Gads 
seems to do this more efficiently.104 Previous studies in DT40 B cell and Jurkat T cell lines 
have demonstrated that the recruitment of SLP-76 to the plasma membrane is essential for 
ITAM-signaling.104,264 This seems to be also the case for platelets, since the expression of a 
membrane targeted SLP-76 mutant dramatically enhanced P-selectin exposure in response 
to CVX.258 Because Gads binds to SLP-76 with higher affinity than Grb2,103 and due to its 
established role in TCR signaling81,92 it was anticipated that Gads, but not Grb2, is the main 
effector in GPVI signaling.12 The role of Gads was, however, questioned in a study by 
Hughes et al. which showed a marked interaction of phosphorylated LAT with Grb2, but only 
weak interaction with Gads and in addition a very mild phenotype of Gads-/- platelets.31 The 
results presented in this thesis clearly establish a dominant role of Grb2 in GPVI signaling as 
compared to Gads. Referring to the model discussed above, the stabilization of the LAT 
signalosome by Grb2 and possibly the Grb2/SOS1-mediated LAT-oligomerization102 may 
serve as the structural basis required for retaining SLP-76 in the correct membrane 
compartment, thereby enabling downstream signaling and platelet activation.  
The residual phosphorylation of LAT and PLCγ2 in the absence of Grb2 implicates that other 
proteins may partially compensate for its loss and, as mentioned above, the functional Grb2 
homolog Gads is an obvious candidate. It will be very interesting to generate mice double 
deficient in Grb2 and Gads and to investigate whether their phenotype resembles LAT-
deficient animals or whether double deficiency results in a complete block of GPVI activation, 
as observed for Slp-76-/- platelets.76,85,86 In addition, these mice might also explain the less 
pronounced hem(ITAM) signaling defect in Grb2-/- mice compared to Lat-/- mice (Figure 3-12).  
Besides LAT, further interaction partners of Grb2 in platelets are known 
(http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de/plateletweb.php).110 Therefore, it is 
feasible that Grb2 also exerts functions beyond LAT-dependent signaling. Subtle effects on 
other signaling pathways, however, may have been masked by the pronounced (hem)ITAM 
signaling defect that arose from the deletion of the protein. Comparison of LAT-deficient mice 
with mice double-deficient in LAT and Grb2 will be a useful approach to address this 
question. With regard to human platelets it is conceivable that Grb2 may contribute to the 
signaling pathway of the ITAM-bearing platelet Fc receptor, FcγRIIa.265,266 Indeed, two 
studies in human platelets revealed that Grb2 associates to phosphorylated signaling 
molecules upon crosslinking of FcγRIIa.267,268 However, FcγRIIa is not expressed in murine 
platelets, demonstrating a principal limitation of mouse studies. Certainly further 
investigations, e.g. by using FcγRIIa transgenic mice,269 are required to address this issue. 
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Platelets express three different members of MAPK family: p38, JNK and ERK1/2.230 Here it 
was found that Grb2 is a positive regulator of ERK1/2 signaling and that p38 was not affected 
by the loss of Grb2. Activation of JNK in wt platelets was not observed upon stimulation with 
CVX. Furthermore, the data demonstrated that Grb2 mediates ERK1/2 activation in a LAT-
dependent manner, since LAT-deficiency resulted in a similar impairment of ERK1/2 
activation (Figure 3-26). This can be explained by recruitment of SOS1 to the LAT-Grb2 
complex which in turn activates the Ras-ERK1/2 signaling pathway.270 The presence of 
SOS1 in platelets has been described.267,268 ERK1/2, however, is also regulated downstream 
of PKC in platelets231 and this would also be disrupted in Grb2-deficient platelets through 
impaired PLCγ2 activation. Regardless of the mechanism, the exact function of MAPKs in 
platelets is controversially discussed, possibly due to off-target effects of MAPK inhibitors, 
but increasing evidence suggests a role in promoting thrombus formation.230 Interestingly, 
Mazharian et al. have previously shown that treatment of platelets with an ERK1/2 inhibitor 
results in decreased platelet adhesion to collagen under high shear flow.271 Based on this 
observation, it appears possible that the impaired adhesion and thrombus formation of Grb2-/- 
platelets may in part be a consequence of impaired ERK1/2 signaling. 
GPVI-deficient mice are protected from pathological thrombus formation, but display only 
very mildly prolonged bleeding times.223 In contrast, while LAT-deficiency is also protective in 
experimental thrombosis models it additionally causes a significant hemostatic defect.88 Here 
it was found that Grb2-/- mice, similar to Lat-/- mice,88 display highly variable and overall 
prolonged bleeding times, indicating that Grb2 has an important functional role downstream 
of GPVI and CLEC-2 in normal hemostasis (Figure 3-18). Very surprisingly, however, Grb2-
deficiency alone was not protective in models of arterial thrombosis (Figure 3-19), suggesting 
that other signaling pathways can fully compensate for the partial loss of (hem)ITAM 
signaling in this setting. Consistently, it was found that blocking TxA2 generation by ASA 
treatment (1 mg/kg) markedly reduced or delayed occlusive thrombus formation in Grb2-/- 
mice, whereas it had no significant effect in wt mice (Figure 3-22). This effect may be 
explained by different mechanisms: First, a previous study from our group has demonstrated 
that abolished GPVI signaling can be compensated for by an alternative pathway involving 
TxA2-mediated activation of integrin α2β1 via Gq/G13-induced signaling pathways, thereby 
enabling platelets to arrest on collagen and reinforce activation through outside-in 
signals.226,272 In addition, the residual signaling capacity of Grb2-/- platelets in response to 
GPVI stimulation may become relevant under in vivo conditions in the presence of 
costimulatory GPCR agonists. Indeed, despite CRP had only a minor effect on integrin 
αIIbβ3 activation when applied on Grb2-/- platelets alone, it dramatically elevated integrin 
activation in the presence of the GPCR agonists ADP and the TxA2 analogue U46619 in 
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vitro, resulting in a robust activation response (Figure 3-20). In accordance, aggregometry 
experiments with platelets from ASA treated mice confirmed a supportive role for TxA2 
production for aggregate formation of Grb2-deficient platelets in vitro (Figure 3-21). These 
observations are in line with a model in which the residual signaling capacity of Grb2-
deficient platelets may be sufficient to trigger a self-amplifying loop that allows arterial 
thrombus formation in vivo and that administration of ASA interferes with this process, 
thereby constraining occlusive thrombus formation. The difference to LAT-deficient animals, 
which are protected in a model of laser-induced injury,88 may consequently be a result of the 
weaker response of Lat-/- platelets to GPVI agonists (Figure 3-12) which has been shown to 
be accompanied by severely impaired or abolished release of second wave mediators.86,273 
Additionally, Lat-/- platelets displayed a much more pronounced impairment in the CLEC-2 
signaling pathway (Figure 3-12), that has been shown to contribute to thrombus formation in 
vivo.11,49 A completely different and quite speculative explanation for the lack of a protective 
phenotype of Grb2-deficient animals in thrombosis models would be that Grb2 has a function 
downstream of GPV, as the absence GPV can compensate for the loss of GPVI in different 
in vivo thrombosis models (David Stegner and Bernhard Nieswandt, personal 
communication). 
Taken together, the presented data demonstrated that Grb2 is dispensable for platelet 
formation, but plays an important role in platelet activation in hemostasis and thrombosis by 
coordinating and stabilizing the formation of the LAT signalosome after GPVI/CLEC-2 
receptor stimulation. This indicates that Grb2-dependent signaling in platelets may contribute 
to the pathogenesis of acute ischemic disease states. 
 
4.3 Dual regulation of platelet CD84 by ADAM10 and calpain 
Metalloproteinase-dependent cleavage of platelet receptors, shedding, is an established 
mechanism to regulate receptor surface expression and has been proposed to regulate 
platelet reactivity and cellular function, e.g. by modification of receptor signaling, adhesive 
properties of the platelet surface or the generation of bioactive fragments.38,189,274 A recent 
proteomic approach identified several novel proteins which are proteolytically cleaved from 
the platelet surface, among them the ITSM-bearing type I transmembrane protein CD84.194 
The data presented in this thesis clearly confirm this initial finding in human and mouse 
platelets and provide further details of CD84 proteolysis. Using transgenic mice, ADAM10 
was identified as the principal sheddase of CD84 in murine platelets and additionally calpain 
was found to cleave CD84 intracellularly. Thus, the data presented here reveal a dual 
regulation of CD84 by two distinct proteolytic mechanisms in platelets. 
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This study clearly established ADAM10 as the principal sheddase to mediate CD84 cleavage 
in mouse platelets in response to the GPCR agonist thrombin and the (hem)ITAM agonists 
rhodocytin, CVX and CRP, as well as upon platelet treatment with different shedding 
inducing agents. In contrast, ADAM17 plays no or only a very minor role in this process 
(Figure 3-31 and Figure 3-32). In this regard, CD84 seems to be unique, since prominent 
platelet receptors have been shown to be shed either exclusively by ADAM17 (GPIbα, 
semaphorin 4D)184,189 or by ADAM10 and ADAM17, depending on the shedding-inducing 
stimulus (GPV, GPVI).37,192 Importantly, ADAM10 also appears to be the only protease to 
mediate CD84 ectodomain shedding in clotting blood, as indicated by the unaltered sCD84 
levels in the serum as compared to plasma of Adam10-/- mice (Figure 3-33). This suggests 
that even under conditions of maximal agonist receptor stimulation no other protease can 
cleave the receptor, at least in mouse platelets.  
In contrast, Fong et al.194 observed a significant reduction of CD84 shedding (about 44%) in 
human platelets in the presence of a selective ADAM17 inhibitor, but it was not analyzed in 
detail whether ADAM10 activity was also affected by this inhibitor. In addition, this effect was 
measured after platelet treatment with PMA, which hardly induced any shedding of CD84 in 
mouse and only moderate shedding in human platelets (Figure 3-28). Of note, the PMA 
concentration used in the other study is about 100-fold higher than the one used here and 
the incubation time was also prolonged (1 h vs. 15 min). Treatment of murine platelets for 1 h 
with PMA resulted in increased metalloproteinase-dependent shedding of CD84, similar to 
the effect of CCCP (data not shown). However, flow cytometric analysis revealed severely 
altered FSC/SSC characteristics which may be indicative for platelet disruption. This effect 
was absent after only 15 min of incubation, which was, however, still sufficient to shed GPIbα 
in control experiments (data not shown). Thus, the high doses of PMA and extended 
incubation in the experiments of Fong et al. may have additional effects besides PKC-
mediated induction of metalloproteinase activity. It cannot be entirely excluded that minor 
differences in the substrate selectivity of ADAM family sheddases may exist between mouse 
and human. However, the comparable results between the species (Figure 3-28), including 
the moderate release of sCD84 by reagents acting mainly by activation of ADAM17 (PMA, 
CCCP) and the strong generation of sCD84 by reagents that activate both 
metalloproteinases (W7, NEM; see introduction), indicate that ADAM10 is also the dominant 
metalloproteinase for shedding of CD84 in human platelets. Additional studies are necessary 
to finally answer this question. 
In addition to receptor stimulation a recent study has demonstrated that pathological shear 
triggers shedding of GPVI by a mechanism that is independent of aggregation and 
intracellular signaling.275 Whether this also applies to CD84 remains to be elucidated. 
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Blocking of platelet aggregation by inhibition of integrin αIIbβ3 significantly reduced the 
release of sCD84 after platelet stimulation with CRP and thrombin. Similar observations have 
been made previously for CD40L shedding,191 but not for GPVI shedding.186 Interestingly, 
phosphorylation of CD84 in response to platelet activation is also markedly reduced by 
blocking platelet aggregation in human platelets.175 Therefore, it is tempting to speculate that 
the aggregation-induced phosphorylation of CD84 may facilitate shedding of the receptor, 
e.g. by changing its conformation or by binding or dissociation of molecules. One example 
how molecules associated to the cytoplasmic tail can influence shedding of a receptor is 
calmodulin. The GPIb/V/IX complex and GPVI bind to calmodulin,24,276 and its dissociation, 
e.g by treatment of platelets with the calmodulin inhibitor W7, induces receptor 
shedding.186,188,192 Whether calmodulin interacts with CD84 was not directly addressed in this 
study. However, the finding that treatment of platelets with W7 induced strong shedding and 
calpain-dependent degradation of the C-terminal part of CD84 (Figure 3-28 and Figure 3-29) 
indicate that CD84 is a calmodulin-binding protein.38,232 This is further supported by the 
presence of positively charged, membrane-proximal amino acid sequences in the human and 
mouse CD84 protein, similar to the calmodulin-binding sequences of GPVI and the 
GPIb/V/IX complex.24,276 
The analysis of CD84 shedding by Western blot identified a second proteolytic cleavage of 
the protein that was carried out by the cysteinyl-proteinase calpain. Calpain-mediated 
intracellular cleavage of receptors in platelets has been described for PECAM-1,198 the β3 
integrin subunit196 and for FcγRIIa, which becomes “de-ITAM-ized”.197 The predicted calpain 
cleavage site within CD84 is located between the two ITSMs and upstream of the tyrosine 
that becomes phosphorylated upon ligation of CD84 and during platelet aggregation (Figure 
3-30).175 Thus, the calpain-mediated intracellular cleavage of the C-terminus may attenuate 
or terminate signaling, but further experimental evidence is required to prove this.  
The data presented here show that CD84 is proteolytically cleaved by ADAM10 and calpain, 
which can operate simultaneously, but independently of each other (Figure 4-1). Calpain was 
able to cleave both the full length-protein and the C-terminal remnant which is generated by 
ADAM10 activity (Figure 3-29). It is well recognized that stimuli which induce extracellular 
shedding also have the potential to activate intracellular calpain cleavage.38 This is nicely 
exemplified by a study of Gardiner et al., investigating FcγRIIa and GPVI regulation in human 
platelets. Stimulation of either of these two receptors or treatment of platelets with W7 
resulted in simultaneous calpain-induced proteolysis of FcγRIIa and metalloproteinase-
mediated ectodomain shedding of GPVI.197 In case of CD84 these two distinct proteolytic 
mechanisms act on one single protein, which appears to be unique for the proteolytic 
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regulation of platelet receptors. It is currently unclear why one receptor is targeted by two 
distinct proteolytic mechanisms, however, two different explanations are intruding: First, 
cleavage of the receptor by either protease may not directly terminate, but rather modify 
CD84 function. For example, calpain cleavage has been recently shown to switch the 
functional outcome of β3 integrin signaling from cell spreading to retraction.199 Likewise, the 
shed extracellular domain of CD84 may be bioactive (see below). Second, ectodomain 
cleavage and intracellular calpain cleavage show different kinetics, with ectodomain 
shedding lagging behind (Figure 3-32). Therefore, CD84 cleavage maybe accelerated in 
certain settings, e.g. in the presence of CLEC-2 agonists, since the CLEC-2 agonist 
rhodocytin is the most powerful activator of calpain activity (Figure 3-32). 
 
Figure 4-1 Schematic representation of the regulation of CD84 by intra- and extracellular 
cleavage. In the absence of sheddase and calpain activity, CD84 is intact and both antibodies detect 
the full length protein (A). If intracellular cleavage occurs, the anti-CD84C-term antibody M-130 is unable 
to bind CD84 (B and C). In addition to intracellular cleavage, ectodomain shedding by a metallo-
proteinase may occur (B). In the absence of shedding (e.g. W7 + GM6001 treatment), calpain-
mediated cleavage can be visualized by detection of a shortened CD84 protein with the anti-CD84N-term 
antibody JER1 in Western blotting (C). If shedding occurs in the absence of calpain activity (e.g. NEM 
treatment) a C-terminal remnant can be detected with anti-CD84C-term antibody (D). Please note: the 
exact binding site of the anti-CD84C-term antibody is unknown, as are the cleavage sites for calpain and 
the sheddase; further degradation of the C-terminus may also occur. (Hofmann,* Vögtle* et al., 
J Thromb Haemost, 2012)202 
Low amounts of sCD84 were consistently detected in the supernatant of unstimulated wt, but 
not of Adam10-/- or GM6001-treated wt platelets. Additionally, CD84 plasma levels in wt mice 
were elevated as compared to Adam10-/- mice. These two findings strongly suggest that 
CD84 is continuously released from the platelet surface by ADAM10, similar to constitutively 
shedding of GPIb by ADAM17.37,184 The residual levels of sCD84 in Adam10-/- may originate 
from other cell types, such as leukocytes. Alternatively, cleavage may occur in trans with 
platelet CD84 being shed by ADAM10 present on other cell types, as it has been 
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demonstrated for ephrin cleavage in a heterologous cell system in vitro.277 The high basal 
sCD84 levels in the plasma of healthy wt mice, which are about 50% of the levels measured 
after blood clotting in the serum, indicate that its use as a marker of thrombotic or 
inflammatory activity may be limited. Additional sCD84, which might be locally generated 
upon platelet activation in vivo, e.g. during thrombotic events, is not expected to reach 
sufficient amounts to result in a significant elevation in the systemic plasma concentration 
above the basal level. Glycocalicin, the shed extracellular fragment of GPIbα is another 
platelet receptor fragment that has likewise been detected in considerable amounts in 
plasma of normal healthy mice,193 and is also not a sensitive marker of platelet activity. 
The function of CD84 in platelet physiology is not well-explored, but one study reported that 
its C-terminus becomes tyrosine phosphorylated in response to platelet aggregation and 
upon antibody-mediated CD84-crosslinking.175 Since the close proximity between platelets in 
aggregates enables contact-dependent signaling,278 and because of the ability of CD84 to 
undergo homophilic interactions,178 it has been suggested that CD84, similar to SLAM, may 
contribute to thrombus stability. Thus CD84 was proposed as a potential target for 
antithrombotic drug discovery.175,279 Indeed, a role for CD84 in mediating cell-cell contacts 
has been recently demonstrated for lymphocytes where it facilitates prolonged B cell:T cell 
contact required for optimal germinal center formation.180 Platelets can spread on the 
immobilized CD84 extracellular domain in a SAP-dependent manner, indicating a functional 
role of CD84,175 however, a signaling or adhesive function of CD84 in platelet activation and 
aggregation has not been shown to date. Initial studies on Cd84-/- mice in our laboratory 
showed that the lack of CD84 in platelets does not affect classical platelet functions such as 
integrin activation or aggregation in response to major agonists. Also tail bleeding times are 
not prolonged in these animals, indicating that CD84 may not serve an essential function in 
hemostatic/thrombotic processes (Sebastian Hofmann, unpublished data). Besides platelets 
also many immune cell types abundantly express CD84169,174,177 and the receptor undergoes 
homophilic interactions. Thus, CD84 may be of functional importance in mediating platelet-
immune cell rather than platelet-platelet interactions. Shedding of CD84 from the platelet 
membrane may represent a novel mechanism to regulate such interactions e.g. by limiting 
the number of molecules available for adhesive contacts, thereby promoting the passification 
of the platelet surface. This may be of relevance in certain settings like leukocyte migration 
through the thrombus280 or in the thrombo-inflammatory setting of ischemic stroke.281 Further 
studies on platelet and immune cells are required to better understand the role of CD84 and 
its proteolytic cleavage in thrombotic, inflammatory and/or immunologic processes.  
In addition, sCD84 may serve as a regulator of biological function, similar to the soluble 
fragments of CD40L and semaphorin 4D.189,274 As shown recently, CD84 stabilizes B cell:T 
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cell interaction.180 Therefore, it is tempting to speculate that sCD84 of platelet origin might 
have the potential to modulate immune cell interactions. This could be of relevance in distinct 
compartments where sCD84 can accumulate, e.g. in the joint fluid where platelet 
microparticles have been reported to contribute to disease progression of rheumatoid 
arthritis.282 A very recent study reported CD84 to be a survival factor for chronic lymphocytic 
leukemic (CLL) B cells. Interestingly, the recombinantly expressed CD84 extracellular 
domain inhibits CCL cell survival in vitro, presumably by blocking homophilic interactions 
between these cells.283 Whether and how sCD84 fragments also affect other cells, needs 
further investigation. 
In summary, it was shown that CD84 is tightly regulated by two distinct proteolytic 
mechanisms in mouse platelets: the extracellular cleavage by ADAM10 and intracellular 
cleavage by calpain. In addition, it was demonstrated that shedding of CD84 is a constitutive 
process occurring in vivo. 
 
4.4 Concluding remarks 
In this thesis different aspects of cell receptor signaling and regulation in cells of the 
hematopoietic system were investigated by the use of transgenic mouse models and 
biochemical approaches. The major findings are: 
Impact of the continuous Ca2+ influx on T cells: 
• NFAT resides in the nucleus in unstimulated Stim1Sax/+ T cells. 
• Upon stimulation of Stim1Sax/+ T cells, PLCγ1 shows an altered phosphorylation 
pattern in the presence, but not in the absence, of extracellular Ca2+. 
• Despite its aberrant phosphorylation, the enzymatic activity of PLCγ1 is not impaired. 
• Stim1Sax/+ T cells show a decreased production of Th2-type cytokines. 
 
Function of Grb2 in platelets: 
• Loss of Grb2 severely impairs (hem)ITAM signaling downstream of GPVI and 
CLEC-2. 
• Grb2 is dispensable for GPCR signaling, integrin outside-in signaling and platelet 
production. 
• The selective (hem)ITAM signaling defect impairs hemostasis, while thrombus 
formation in vivo can be compensated for by other signaling pathways. 
• Grb2 facilitates (hem)ITAM signaling by stabilizing the LAT signalosome. 
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Proteolytic regulation of CD84: 
• CD84 receptor levels on platelets are regulated by ADAM10-mediated ectodomain-
shedding and intracellular cleavage by calpain. 
• Both processes work simultaneously, but independently of each other. 
• Shedding is a constitutive process occurring in vivo and soluble CD84 can be 
measured in mouse plasma. 
 
4.5 Perspective 
The molecular mechanisms of how Stim1Sax/+ T cells maintain their function despite elevated 
[Ca2+]i are still poorly understood. Furthermore, it remains to be investigated how the 
alternative phosphorylation pattern of PLCγ1 is established and if other proteins and 
signaling pathways are also affected by constitutive Ca2+ influx. Additionally, the function of 
Stim1Sax/+ T cells in different mouse models of immunological disease has not yet been 
tested.  
Grb2 was established as a critical adapter protein of the LAT signalosome. However, 
questions regarding the functional redundancies of adapter proteins like Grb2 and Gads and 
the different requirements of adapter proteins in ITAM, hemITAM and integrin signaling, as 
well as between platelets and immune remain to be answered. Further studies with mice 
double-deficient for known adapter proteins and the identification of new adapter proteins 
may answer some of these questions. 
Owing to the limited knowledge about the function of CD84 in platelets, this study could not 
provide information about the physiological relevance of CD84 shedding and intracellular 
cleavage. Further studies on the function of CD84 in platelet and immune cells using Cd84-/- 
mice will help to better understand the role of this receptor in thrombotic, inflammatory, 
and/or immunologic processes and will ultimately provide novel insights into the significance 
of CD84 proteolysis on platelet function. In addition it remains to be elucidated whether or not 
CD84 can also be shed from cell types other than platelets. 
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6 Appendix 
6.1 Abbreviations  
aa amino acid 
ab antibody 
ASA acetylsalicylic acid 
ACK ammonium-chloride-potassium 
ADAM a disintegrin and metalloproteinase 
ADP adenosine diphosphate 
AP-1 activator protein 1 
ATP adenosine triphosphate 
BCR B cell receptor 
BMc bone marrow chimeric 
bp base pairs 
BSA bovine serum albumin 
Btk Bruton’s tyrosine kinase 
[Ca2+]i intracellular calcium level [Ca2+]i 
Ca2+ calcium 
CC coiled coil 
CCCP carbonyl cyanide m-chlorophenylhydrazone 
CD cluster of differentiation 
CLEC-2 C-type lectin-like receptor 2 
CRAC Ca2+-release-activated Ca2+ 
CRP collagen-related peptide 
CsA cyclosporin A 
CTLA-4 cytotoxic T lymphocyte antigen 4 
CVX convulxin 
DAG diacylglycerol 
DIC differential interference contrast 
DMEM Dulbecco’s modified Eagle's medium 
DMSO dimethyl sulfoxide 
Dok downstream of tyrosine kinase 
EAT-2 Ewing’s sarcoma activated transcript 2 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
ER endoplasmic reticulum  
ERK extracellular-signal-regulated kinase 
FACS fluorescence-activated cell sorting 
f.c. final concentration 
FcR Fc receptor 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FSC forward scatter 
Foxp3 forkhead box P3 
Gads Grb2-related adapter downstream of Shc 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
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GP glycoprotein 
GPCR G protein-coupled receptors 
Grb2 growth factor receptor-bound protein 2 
GTP guanosine trisphosphate 
h hour(s) 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP horseradish peroxidase 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IP immunoprecipitation 
IP3 inositol-1,4,5-trisphosphate 
ITAM immunoreceptor tyrosine-based activation motif  
ITIM immunoreceptor tyrosine-based inhibition motif  
Itk IL-2-induced tyrosine kinase 
ITSM immunoreceptor tyrosine-based switch motif 
JNK c-Jun N-terminal kinase 
kDa kilo Dalton 
LAT linker for activation of T cells 
M molar 
mAb monoclonal antibody 
MAP mitogen-activated protein 
MEK mitogen-activated protein kinase/ERK kinase 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
min minute(s) 
MK megakaryocyte 
MOPS  3-(N-morpholino) propanesulfonic acid 
MPV mean platelet volume 
NEM N-ethylmaleimide 
NFAT nuclear factor of activated T cells 
PCR polymerase chain reaction 
PECAM-1 platelet-endothelial cell adhesion molecule-1 
PE phycoerythrin 
PF4 platelet factor 4 
PGI2 prostacyclin 
PI3K phosphoinositide-3-kinase 
PIP2 phosphatidylinositol-4,5-bisphosphate 
PKC protein kinase C 
PLC phospholipase C 
PMA phorbol 12-myristate 13-acetate 
prp platelet-rich plasma 
PS phosphatidylserine 
PVDF polyvinylidene difluoride 
RasGRP Ras guanyl nucleotide-releasing protein 
RC rhodocytin 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute 
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RT room temperature 
SAM sterile α-motif 
s second(s) 
sCD84 soluble CD84 
SD standard deviation 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SERCA sarco/endoplasmic reticulum Ca2+-ATPase 
SH2 Src homology 2 
SHIP SH2 domain-containing inositol-5-phosphatase 
SHP SH2 domain-containing protein-tyrosine phosphatase 
SAP SLAM-associated protein 
SLAM signaling lymphocytic activation molecule 
SLP-76 SH2 domain-containing leukocyte protein of 76 kDa 
SOCE store-operated calcium entry 
Sos1 son of sevenless homolog 1 
SSC side scatter 
STIM stromal interaction molecule 
Syk spleen tyrosine kinase 
TAE TRIS acetate EDTA 
TBS TRIS-buffered saline 
TBS-T TRIS-buffered saline containing Tween 
TCR T cell receptor 
TF tissue factor 
TG thapsigargin 
TGF transforming growth factor 
Th T helper 
tMCAO transient middle cerebral artery occlusion 
TNF tumor necrosis factor 
Treg regulatory T cell 
TRIS tris(hydroxymethyl)aminomethane 
TRPC transient receptor potential channel 
TTC 2,3,5-triphenyltetrazolium chloride 
TxA2 thromboxane A2 
vWF von Willebrand factor 
w/o without 
wt wildtype 
XLP X-linked lymphoproliferative syndrome 
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